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Abstract 
The physicochemical properties of a drug affect to a large extent 
its subsequent biological absorption and bioavailability profile. 
Considerable pharmaceutical interest is therefore directed torwards the 
improvement of drug dissolution characteristics of drugs with low 
aqueous solubility. 
This thesis has considered the controlled modification of drug 
dissolution profiles by means of incorporating low concentrations of 
hydrophilic polymers by different processes into a host drug substance. 
In order to examine this approach and its potential use, the physico- 
chemical, solid state, stability and tableting properties of a poorly 
aqueous soluble drug, phenylbutazone, in alternative polymorphic form 
and containing low levels of two hydrophilic polymers - hydroxypropyl 
methylcellulose (H. P. M. C. ) and the surfactant poloxamer 188 - prepared by 
both conventional crystallisation and spray drying are reported. 
As an integral nart of the work attempts were mado to identify the 
different polymorphic forms of phenylbutazone. The 6-form, the cammerdiallý 
4- available stable ýorm and the a and s metastable forr. s (nomenclature after 
Huller, 1978).. were isolated. The a form was found to be unstable on 
storage. A .7 fold increase in intrinsic dissolution rate was observed for the metastable s-polymorph compared with the stable 6-polymorphic form. 
The effect of crystallisation rate on the formation of polymorphs of 
phenylbutazone was studied using a mini-spray dryer, and slower rates of 
crystallisation were found to favour polymorph formation. 
The hydrophilic polymers, H. P. M. C. and poloxamer 188 were incorporated 
by conventional crystallisation and spray drying into the drug crystal. 
Samples were subjected to a series of tests including differential 
scanning calorimetry, X-ray powder diffraction, scanning electron micro- 
scopy, and intrinsic dissolution and solubility. When prepared by 
conventional crystallisation H. P. M. C. was f8und to form a "high energy" 
complex with phenylbutazone which melted 10 C lower than the parent drug. 
When prepared by spray drying H. P. M. C. inhibited the formation of the 
metastable a-polymorph of phenylbutazone. A2 fold increase in intrinsic 
dissolution rate was observed for crystallised and spray dried samples 
containing 2% w/w or more added polymer. 
Poloxamer 188 did not form a complex witý phenylbutazone and unlike 
gation of the a-polymorph. For both H. P. M. C. did not inhibit thejgr 
fold increase in dissolution rate was crystallised and spray 0 
obtained at polymer levels oý 1% w/w or above. The increase in dissolution 
has been attributed to facilitated wetting by lowering of interfacial 
tension rather than through the formation of micelles. 
The stability of-selected phenylbutazone: polymer samples was tested at 
elevated temperatures. The stability was found to be affected both by the 
method of sample preparation and the type of additive. Large breakdowns 
occurring by a hydrolytic effect were identified for the crystallised phenyl- 
butazone samples containing poloxamer 188. 
The effects on compact. ion of phenylbu. tazone in alternative form 
and presence of polymeric additives were studied by compressing samples of 
similar particle sizes of phenylbutazone as supplied (67form), samples of 
(i i i) 
spray dried phenylbutazone (a-form) and samples containing different 
concentrations of H. P. M. C. prepared both by conventional crystallisation 
and spray drying. Compaction data were analysed according to the Heckel 
relationship and by force transmission ratio as well as from the tensile 
strengths of prepared tablets. 
The presence of H. P. M. C. up to 5% w/w concentration in phenylbutazone 
did not change the mean yield pressure for the crystallised or spray 
dried samples, although a difference in mean value was observed between 
the crystallised and spray dried materials, 93.22 MPa and 147.02 MPa 
respectively. Force transmission was found to be improved for samples 
containing H. P. M. C. prepared by both techniques and in general, the 
tablet tensile strengths for crystallised samples containing H. P. M. C. 
were approximately three times greater than for spray dried samples at 
equivalent tablet porosity. Differences are attributed to variation in 
solid state and particulate properties between samples. 
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CHAPTER 1 
1. General Introduction 
Gastrointestinal absorption and bioavailability of hydrophobic 
drugs are often limited by their poor aqueous solubility and low 
dissolution rate. This can result in undesirable effects since larger 
amounts of drug may be required to raise the amount of dissolved drug 
to the levels needed to achieve the desired therapeutic effects. Slow 
dissolution will also prolong the drug contact time with the gastric 
mucosa which might result in unwanted side effects such as irritation 
or risk of developing ulceration. Improving the solubility and 
dissolution rate generally increases the absorption and total bio- 
availability. 
With a view to improving these parameters, a great deal of research 
has been carried out using different procedures, all aiming to achieve 
higher'drug dissolution rates. These procedures include reducing the 
size of drug particles, as the dissolution rate increases with the 
associated increase in surface area of the drug exposed to the 
dissolution medium. Examples include the 50% reduction in the 
therapeutic dose of griseofulvin after micronisation of the drug 
(Atkinson et al. 1962) and the enhanced absorption of spironolactone 
following particle size reduction (Levy 1962). 
A second way of improvingýthe dissolution rate is to change the 
crystallographic nature of the substance i. e. using a different poly- 
morphic form such as a metastable polymorph. Metastable forms are at 
higher energy levels than stable polymorphs and generally exhibit 
higher dissolution rates. Many workers, including Twashi (1968), 
Matsuda et al. (1934), Hamlin et al. (1962), have used the phenomenon 
of polymorphism to increase the dissolution rate of studied materials. 
-2- 
Other attempts to increase dissolution rate include incorporating 
a hydrophilic polymer into the drug crystal, to form solid dispersions 
(Sekiguchi & Obi 1961, Tachibana & Nakamora 19E5). Different hydrophilic 
polymers have been introduced into the drug crystal, 
following different procedures which include a melting technique and 
solvent evaporation. Some workers have used a combination of 
techniques (Chiou & Riegelman 1971). 
An additional way of achieving an increase in the dissolution rate 
of sparingly water soluble drugs is to incorporate surfactant molecules 
into the drug host in an attempt to lower the solid/liquid interfacial 
tension which will lead to better wetting and as a result, increase the 
dissolution rate (e. 9-Naggar et al. 1980, Chiou'et al. 1976). 
Further studies are required to elucidate the mechanisms whereby 
dissolution rate is increased and the associated changes induced in 
crystallographic character of drug: additive combinations. 
The primary objective of this study is to incorporate polymeric 
additives at low levels into a model hydrophobic drug, phenylbutazone, 
using two preparation techniques - conventional crystallisation and 
spray drying - and examine the crystallographic and physicochemical 
characteristics dependent on polymer inclusion and explore relationships 
between monitored property changes. In addition the stability of the 
drug-polymer materials and processing performance, as reflected in 
tableting, are examined. Both stability and processing performance 
represent critically important aspects in the formulation and develop- 
ment of dosage forms containing the drug: polymer materials. 
It is now appropriate to consider briefly the general properties of 
crystals. 
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1.1 Properties of crystals and crystal habit 
The habit of a crystal may be defined as the description of the 
outer appearance of a crystal (Chopra & Dhall 1981). If the 
environment of a growing crystal affects the crystal shape without 
changing its internal structure a different habit is obtained 
(Haleblian 1975), generally resulting from different rates of growth 
of the various faces of the crystal. Under certain conditions of 
crystallisation one set 6f faces may be induced to grow faster than the 
other, and the growth of another set of faces may be retarded (Mullin 
1972). Crystal growth may also be retarded by adjacent crystals. As a 
result the regular surface of the crystal may be inhibited or an 
irregular-shaped crystal may occur since the latter crystal should 
occupy only the space left and it has to adjust its shape according to 
the available space. 
The degree of supersaturation may affect the crystal habit. The 
higher the supersaturation the tendency of the crystal to change from 
granular to needle-like shape (Mullin 1972) 
The interaction between solute and solvent has a great effect on 
the final shape of the crystal. For example, resorcinol crystallises 
from benzene into fine needles, whilst squat prisms are obtained when 
crystallised from butylacetate (Haleblian 1975). 
The presence of impurities in a system can have an important effect 
on the growth of a crystal. Some impurities may retard crystal growth, 
others may enhance growth, while others may exert a highly selective 
effect, acting only on certain crystall, ographic faces and thus modify 
crystal habit (Fairbrother & Grant 1978,1979 , Chow et al. 1984). 
-4- 
Impurities may influence the crystal growthin various ways, 
including changing the properties of the solution, or the equilibrium 
saturation concentration or by adsorbing to the crystal faces and 
exerting a blocking effect. Alternatively, they might interfere with 
the growth steps and thus disrupt the flow of growth layers across the 
faces (Mullin 1972). 
The internal structure of the crystal and the difference in the 
arrangement of the molecules is likely to be more important than 
changes in the crystal habit, and has a greater influence on changing 
the physicochemical properties of the material. Crystals can be 
broadly divided into two categories according to the internal structure 
of the crystal 
a. Crystalline 
b. Non-crystalline (amorphous) 
1 .1 .1 The crystalline state 
The true solid crystal comprises a rigid lattice of molecules, 
atoms or ions, the locations of which are characteristic for the 
substance. The regularity of the internal structure of this solid body 
results in the crystal having a characteristic shape (Mullin 1972). 
The crystalline state is that thermodynamically favoured for 
solids. It is characterised by the three-dimensional order of the 
molecules within its crystal lattice. The molecules are arranged in a 
pattern that minimises the total energy of the crystal, both kinetic 
and potential. This usually results in a minimum amount of void space- 
between the molecules. The packing arrangement for a compound will be 
a function of both its molecular shape and the chemical groups in, the 
molecule involved in the intermolecular bonding e. g. hydrogen bonding, 
dipole-dipole interaction and change transfer. 
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1.1.2 The amorphous state 
Under certain conditions it is possible to isolate solids in which 
the molecules do not have sufficient time to organise themselves into 
three-dimenional patterns or arrays. There is thus no regularity in 
the structure which influences the X-ray powder diffraction pattern. 
A pattern from a crystalline powder consists of many sharp 
diffraction maxima. In contrast the pattern for a non-crystalline 
powder may show only a few diffuse diffraction peaks at low angles. 
Amorphous compounds are thermodynamically unstable since they are the 
most energetic form so there will be a tendency to entropically drive 
these solids to a stable crystalline state. - The instability ofthese 
compounds makes their preparation and isolation difficult(Haleblian & 
McCrone 1969, Halebl ian 1975). 
1.1.2.1. Pharmaceutical applications of amorphousmaterial 
The thermodynamic instability of amorphous compounds has retarded 
their general use as they will revert to the stable form especially if 
the formulation is in aqueous suspension. Special treatment for the 
formulation is needed to retard reversion. 
Mullins & Macek (1960) showed that amorphous novobiocin was ten 
times more soluble than the crystalline form. These workers also 
demonstrated that the amorphous material was readily absorbed after 
oral administration while the crystalline was not bioavailable. 
Simonelli et al. (1976) showed that sulphathiazole could exist in an 
amorphous form. Moustafa. et al. (1971), when studying sulphamethoxazole 
and Gouda et al. (1977) with sulphapyrine showed both materials could 
form amorphous compounds, and these materials gave faster dissolution 
rate and higher solubility than the crystalline form. 
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1.1.3 Polymorphism 
Polymorphism is the ability of a substance to occur in several 
different molecular arrangements, which are known as polymorphs. The 
various polymorphs of an individual substance exhibit different 
physical properties such as density, optical properties, energy content, 
X-ray diffraction pattern, infrared spectrum, solubility and dissolution 
rate (Kuhnert-Bradstatter 1971). 
As a result of energy differences the polymorphic forms will 
transform from the metastable modifications which exist in higher energy 
levels to the stable form which is in a lower energy level. The trans- 
formation of one form into another is accompanied by the absorption or 
evolution of latent heat. If the transformation is reversible, i. e. one 
form can convert into the other and vice versa by altering the 
temperature or pressure, then the polymorphism is said to be enantio- 
tropic. If the transformation proceeds only in one direction from an 
unstable modification at all temperatures, then this type of poly- 
morphism is called monotropic (Hartshorne & Stuart 1970; Verma & 
Krishna 1966). 
The transformation rate of one polymorph to another depends on the 
mobility of the molecules in the solid, the type of structural change 
that takes place and environmental factors. If the transformation 
involves only a small degree of alteration in the intermolecular 
bonding, a rapid conversion of metastable form to the stable form 
occurs. When a substantial difference in the packing arrangement 
exists between the forms, the transformation can be extremely slow 
(Verma & Krishna 1966). When the metastable polymorphic form is 
placed in contact with dissolving solvent it will be rapidly converted 
to the more stable form as in solution polymorphism does not exist 
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(Carstensen 1980). The solubility of each form depends on the ability 
of molecules to leave the crystals to the solvent. The stable form 
possesses lowest free energy in a definite environment so it has the 
lowest solubility. 
Several techniques are widely used to study polymorphism. Optical 
microscopy shows the effect of polymorphism on the transmission of 
light in different directions through the crystal. Since the alternative 
polymorphic forms have different internal structure they have different 
refractive indices (Bile 196"). A hot stage attachment fitted to a polarising 
microscope enables the melting of the polymorph and the change in 
crystal associated with it to be followed (Koflers 1954). X-ray powder 
diffraction is a useful tool as the crystalline sections in powders 
give characteristic X-ray diffraction patterns which consist of peaks 
at certain positions of varying intensities. Each powder pattern of 
the crystal lattice is characteristic for a given polymorph due to 
differences in packing. Several workers have used this method to 
identify polymorphs (e. g. Bile 1963, Trivedi et al. 1959). 
Differential scanning calorimetry has been successfully used to 
demonstrate polymorphism in materials as the heat loss or gain 
resulting from physical or chemical changes occurring in samples is, 
recorded as a function of temperature as the substance is heated at 
uniform rate. Other techniques used include infrared spectroscopy, 
dissolution rate and solubility (Muller 1978, Ibrahim et al. 1977, 
Tuladhar et al. 1983, Guillory 1967). 
The phenomenon of polymorphism and its effect on physicochemical 
properties has attracted many workers to investigate different 
materials. For example, Perrin & Michel (1973a, b), Aguiar et'al. (1967), 
Aguiar & Zolmer (1969), Banerjee et al. (1971) studied the poly- 
mqrphism of chloramphenicol and its influence on dissolution rate and 
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absorption. Tawashi (1968), and Summers et al. (1970) reported the 
existence of aspirin in different polymorphic forms. 
Other examples of compounds reported to exist in different poly- 
morphic forms include phenylbutazone (Ibrahimet*al . 1977, Muller 
1978, 
Tuladhar et al. 1983 and Matsuda et al. 1984), methylchloromethane (Silver & 
Rudman 1970), mebrobamate (Clements 1973), barbiturates (Mesley & 
Clements 1968. -, Mesley et al. 1968), sulphonamides (Mesley & Houghton 1967) 
and cortisone acetate (Carless et al. 1966). 
1.1.3.1 Pharmaceutical applications of polymorphism 
Solubility and dissolution rate: 
The metastable polymorphic forms of sparingly soluble drugs can be 
used instead of the lower solubility stable form. Molecules in the 
higher energy forms will have more tendency to leave the crystal to go 
into solution and may enhance absorption and bioavailability. Many 
workers (e. g. Muller 1978, Matsudaet al. 1984, Tuladhar et al. 1983) used this 
phenomenon to study the dissolution rate of the different polymorphic 
forms of the same material in vitro in an attempt to predict in vivo 
bioavailability. However further work is required to confirm the 
prediction of in vivo bioavailability. 
Summers et al. (1973) found that the tensile strength of tablets 
formed from metastable polymorphs was weaker than those formed from the 
stable form. These workers related this observation to the strength of 
the particle-particle bond with the metastable polymorph forming weaker 
bonds. Some workers have studied polymorphic transmission during 
compression (Chan & Doelker 1984). 
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When metastable polymorphs are dissolved in suitable solvents, 
clear solutions are eventually obtained. However with time crystals can 
start appearing or the solubility of the stable. form may have been 
exceeded. The precipitated crystals can also form cakes making it 
di ffi cul t to di sperse (Carl ess et'al . 1966) . Clearly such changes in 
the formulation are unacceptable. 
1.2 Solid dispersions 
A further way of improving the dissolution rate of water insoluble 
drugs is to incorporate a hydrophilic material such as polymeror 
surfactant. One way of achieving this, which many workers have 
successfully used is by the formation of solid dispersions. 
The solid dispersion term is applied to those systems in which a 
drug is homogeneously distributed through a solid matrix. Depending on 
whether the matrix is water soluble ar not, dissolution of the drug can 
be increased or decreased. When attempting to enhance drug dissolution 
the matrix should be water soluble. 
Two basic procedures have been used to prepare solid dispersions - 
fusion or solvent evaporation. The fusion technique involves heating 
both the drug and the carrier to a temperature at which they melt. Then 
the molten liquor is left to cool in an attempt to entrap the drug 
molecules between the carrier molecules in a fine particulate form. 
The method was first used'by Sekiguchi & Obi (1961) and since that 
report, studies of solid dispersions have attracted many workers. These 
include Simonelli et aL (1969), Bates et al. '(1969), Goldberg et al. 
(1966), and Chiou & Riegelman (1969). Whilst this process has the 
advantage of being rapid it suffers from the disadvantage of risk of 
decomposition of the components or evaporation due to high temperatures 
used. 
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The solvent method uses a suitable volatile solvent which dissolves 
both the drug and the carrier. The solvent is then evaporated by means 
of vacuum or gentle heat. This method was first reported by Tachibana 
& Nakamura (1965) and the technique has subsequently been widely used 
(b. g. Myersohn et al. (1966), Malone et al. (1966), Hoelgaard & Moller 
(1975), Sekikawa et al. (1979), Anastasiadou (1982)). The main advantage 
of this technique is that it does not involve the risk of decomposition 
or evaporation of a component by heat due to the lower temperature 
required for the evaporation of the organic solvent. However incomplete 
solvent evaporation may result which might reduce the stability of the 
product. Difficulties can also be experienced in selecting a common 
solvent. 
Some workers (e. g. Chiou & Riegelman 1971) have used a combination 
of both the fusion and solvent techniques. The dissolution rate of the 
drug from the resulting products is markedly enhanced when the 
incorporated matrices were water soluble. Chiou & Riegelman (1971) 
listed the possible mechanisms involved: - 
1. decrease in drug particle size. 
2. possibility of solubilising the drug by the carrier. 
3. good separation of the drug particles from each other which prevents 
them aggregating or agglomerating, thereby increasing the exposed 
surface area of the drug to the solvent. 
4. better wettabilityand dispersibility due to the fact that the drug 
particles are encircled by the soluble carrier which can readily 
dissolve and enable water to contact and wet the drug particles. 
The main application of solid dispersions in pharmacy is in improving 
solubility and dissolution rate. Numerous workers have researched this 
field and used different hydrophilic carriers with different types of 
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hydrophobic drugs. 
Various additional explanations for observed increases in 
dissolution rate have been proposed, including glass solution formation 
(Chiou & Riegelman 1969), solid solution formation (Goldberg 1965), 
decrease in particle size (Gibaldi et al. 1968), eutectic mixture 
(Sekiguchi & Obi 1961) and higher energy compounds (Simonelli et al. 
1976). 
Direct crystallisation can also be used to add carrier to the drug. 
This technique involves flocculating a solution of the hydrophobic drug 
in an organic solvent (mainly alcohol) by the addition of an aqueous 
solution containing the required amount of carrier. This method is 
rapid, has no risk of decomposition of the component, but problems 
associated with removing the water and the solvent from the product can 
occur. This method has been used by Naggar et al. (1980) and Chiou. et al. 
(1976), and is employed in this study to incorporate hydrophilic polymer 
and surfactant molecules and will be discussed further in Chapters 4 and 
5 of this thesis. 
1.3 Spray drying 
, 
Spray drying can be defined as the transformation of the feed from a 
liquid state into dried particles by spraying them into a hot drying 
medium (Masters 1979). The feed is dispersed as fine droplets into the 
drying chamber which has a current of hot air or gas where the solvent 
evaporates rapidly forming dried often spherical particles before they reach 
the wall of the drying chamber (Lachman, Lieberman, Kanig 1970). The dried 
powder is carried by the airstream to the collection system and the 
gaseous solvent is expelled by the exhaust pipe to the air or where it 
could be recovered depending on the type of spraying process. 
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The process of spray drying can be illustrated diagrammatically' 
as described by Marshall (1954). 
Atomisation-] 
I 
Drying 
Separation and 
collection of 
products 
Atomisation 
Atomisation is the process of changing the feed tofine droplets. 
It is the most important part of the spray drying as it disintegrates 
the feed into fine droplets. The atomiser is usually placed inside the 
drying chamber to bring the droplet into contact with the hot drying air 
which could be flowing upwards, downwards or outwards 
to dry the feed before it reaches the wall of the chamber. The ideal 
atomiser is that which generates monosized droplets. 
Fig. 1.1 The various types of atomisation available for 
spray driers 
Atomisation 
Rotary Nozzle 
4, 
wheel disc pressure sonic pneumatic 
1.3.1.1 Rotary 
In this type of atomisation the feed is introduced to the centre of 
a rotating disc or wheel, which rotates at a high speed. The feed will 
distribute towards the edge of the disc by means of centrifugal force. 
When the feed reaches the edge of the disc it has to gain disc speed 
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before leaving the disc to the chamber. So the degree of atomisation 
depends upon peripheral speed, feed rate, liquid properties and atomiser 
design (Masters 1979, Friedman Ot al. 1952). There are two types of 
rotary atomiser - disc and wheel (see Fig. 1.1). 
There are two types of rotary disc, either smooth surface or with 
vanes. The smooth surface type has the disadvantage that at high speed 
the liquid feed might slip and would not form an intact film on the disc 
and this will affect the homogeneity of the droplet particle size. The 
problem of slipping in the. smooth disc can be overcome by increasing the 
friction between the feed and the disc. This could be achieved by 
fitting the disc upside down as an inverted plate or cup and introducing 
the feed onto the lower surface in the centre (Dombrowski et al. 1968, 
1974). By means of centrifugal force the feed will move outwards from 
the centre and will be pushed downward by the concave edge of the disc 
which will apply pressure on the liquid preventing slipping (Hinze & 
Milborn 1950, Frazer 1957, Masters 1979, Beuttener & Steiger 1956). 
The other type of discs are fitted with vanes which will control the 
spread of the feed film over the disc by confining it to the vanes 
surface, and at the periphery the maximum liquid release velocity 
possible is attained (Masters 1979, Marshall 1954, Tate 1965). 
The principle of the rotating wheel atomiser is similar to that of 
the rotating disc, except that no feed slippage occurs as the feed travels 
through radial vanes to the surface (Kurabyasi 1960). At low speeds and 
feed rates, viscous and surface tension forces predominate in droplet 
formation. For intermediate speed, the disintegration of the liquid 
ligaments at the edge of the vanes is by centrifugal forces and to a 
lesser extent by gravitational forces. At high liquid flow and high 
wheel speed the disintegration of the liquid occurs at the edge of the 
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vanes by frictional effect between the liquid and the air with the 
liquid emerging as a thin film from the vanes. 
This procedure, whilst not achieving a homogeneous spray, produces a 
spray of a small droplet size. Homogeneity of the spray can be 
improved by increasing the viscosity and the surface tension, but this 
will tend to increase droplet size (Masters 1979). 
1.3. -1.2 Nozzle 
The function of the nozzle atomiser is the acceleration and 
disintegration. of the bulk liquid flow, terminating with the dispersion 
of the resulting droplets to form a spray. A single orifice or ejector 
cannot be considered an atomiser. The liquid is disintegrated if the 
liquid jets are turbulent enough, but the droplets are not dispersed by 
the action of the nozzle (Masters 1979). There are three different 
types of nozzle atomiser - pressure, sonic and pneumatic (see Fig. 1.1). 
The principle of the pressure nozzle is the conversion of pressure 
energy with the liquid bulk into kinetic energy of thin moving liquid 
sheets. The sheet breaks up under the influence of the physical liquid 
properties or friction with the medium in which the sheet is discharged. 
Any change that causes fluctuations in the order of the sheet thickness 
promotesdisintegration. Centrifugal pressure nozzles are employed where 
the feeds are of low viscosity and contain no large solid particles in 
the suspension. With correct nozzle selection both fine and coarse 
sprays can be obtained. The pressure nozzle atomiser has the advantage 
of having low cost and ease of replacement. The main disadvantages are 
the need for high pressure pumps, and the restriction on the type of 
feed material which can be used without causing wear to the nozzle 
(Marshal 1954, Masters 1979). 
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In the pneumatic nozzle atomiser, the liquid feed is broken up into 
very fine droplets by impacting the liquid bulk with a high velocity 
gas Bradley 1973a, b). The principle of breakinq up the fluid can be 
considered to occur in two phases. The first phase involves tearing the 
liquid into large droplets or filaments. The second phase involves 
breaking these large filaments into smaller and smaller droplets. This 
process is influenced to a large extent by the viscosity, density and 
surface týnsion of the liquid and the gaseous flow. The spray produced 
by this procedure is characterised by high homogeneity. This type of 
atomiser is usually used to spray viscous liquids and to produce fine 
droplets, (frazer et al. 1963, Masters 19791. 
Sonic nozzle atomisers break up the liquid through sonic excitation, 
The need for such atomisers became necessary with the increasing number 
of Tiquids that cannot be atomised successfully by the ordinary atomisers. 
Such liquids include the non-Newtonian, highly viscous systems and have 
long chain molecular structure and need excessive pressure for 
effective atomisation in centrifugal pressure nozzles to increase drying 
rates (Katta & Gauyinl975, Masters . 
1979). 
1.3.2 Drying 
Drying is the process of removing the solvents (usually water) from 
the feed to leave the solid component of the feed in fine powder form. 
Drying takes place in two stages, the first stage occurring when the 
droplet leaves the atomiser, It will then be faced by the hot air in 
the chamber and so evaporation of the solvent will take place immediately 
from the surface of the droplet. At this stage there is enough solvent 
in the droplet to-maintain a solvent film at the surface of the droplet 
by diffusion of liquid from the interior of the droplet, When the 
critical point I's reached there is insufficient liquid in the droplet to 
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replace at an equiYalent rate the evaporating liquid and a solid shell 
will form around the droplet. The second stage of drying starts after 
shell formation. The eyaporation rate now depends on the rate of 
diffusion of the liquid through the shell, and the thickness of the 
shell will increase with time CM-asters 1979). 
Increasing the concentration of the solid in the feed will decrease 
the Yapour pressure of the liquid and hence reduce drying rate. Also 
drying rate will be i'ncreased when drying in a medium other than air if 
this medium has higher diffusivity and thermal conductivity. This can 
be seen when drying using light gases, such as hydrogen (Masters 1979). 
Charlesworth & Marshall C19601 illustrated the shape, composition and 
changes occurring duri, ng drying of spray dried particles. These authors 
divided the spray dried particles into two groups - those spray dried in 
drying air temperature above or below the boiling point of the liquid 
droplet (Fig. 1.2). 
From the diagram shown in Fig. 1.2 one can conclude that the 
properties of the solid part in the spray's feed play a major role in 
the final shape of the spray dried particles. For porous rigid materials 
fine intact spherical particles are generally produced while decreasing 
porosity increases the chance of imperfection. For the non-porous plastic 
material different shapes are produced with different possible imper- 
fections, but generally non-spherical with almost non-reproducible shape 
and size. Also the boiling point of droplet contributes when determining 
the final shape of the formed particle Csee Fig. 1.21. 
1.3.3 Collection 
Collection inyolyes separating the dried powder from the solvent and 
collecti, ng the product from the drier, The separation either takes place 
in one or two stages, In two stage separation, product is collected at 
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the drying chamber and the fine powder product is recovered in 
collecting equipment, while in single stage systems all the product is 
collected in the separation equipment, 
The separation should be very efficient and very close to 100% 
espectally ff the dried-material is harmful and also for efficiency in 
processing. For health reasons the level of any discharged particle 
through the exhaust should fulfil. the regulations of the country where 
the dryer is operating. The powder is separated from the solvent either 
by gravity in which the product parti, cles fall to the bottom of the 
chamber and are collected either by scrubber or an emptying valve. 
Also the separation can be obtained by a cyclone in which a centrifugal 
force applied on each particle will make the particles move away from 
the centre to the wall of the cyclone. Then the air flow is turned 
upward to the exhaust. The residence time of the air in the cyclone 
before leaving is important as It should be long enough for all the 
particles to-move to the wall of the cyclone otherwise they will be 
pushed outside with the air flow to the exhausts. CMasters 1979, 
Lachman, Lieberman & Kanig 1970).. - 
1.3.4 Pharmaceutical applications'of'spray drying 
The applications of spray drying are increasing and spray drying is 
used in many industries such as the food industry, for making milk 
products, and fruit, vegetable and plant extracts, coffee, etc. Also 
spray drying is finding application in the ceramic and plastic industries 
(. Masters 19791. 
Spray drying has found use in the pharmaceutical industry because of P, 
the rapidity of drying and the unique form of the final product. Spray 
dryi, ng can thus be used by the pharmaceutical industry for drying heat- 
sensitive pharmaceuticals i-ncluding many antiblotics, vitamins, enzymes, 
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yeasts, Yacci. nes and plasma derivatives (Pasters 1979). Recently 
interest has been concentrated on applying this technique to prepare 
powders wi-th controlled particulate properties as the resultinq 
particles are generally spherical in shape, possess a narrow size 
distribution,. hayý reduced bulk density and are hollow (Abdulrahman 
19731, As a result, they are generally free flowing (Robinson et al. 
1961) and dissolve rapidly (-Kawashema et al. 1975, Kawashema & Takenaka 
1974). Spray drying finds value in the modification of materials for 
use in tablet formulations by direct compression CRaff et al. 1961) to get 
different polymorphi, c forms of materials CV. atsuda 1984) or obtain 
anhydrous and amorphous forms (. ýorriqan 19821. 
Spray drying has also been successfully used to prepare micro- 
capsules which provide solid particles of liquid droplets with an 
individual coat thereby modifying their physical, chemical or physio- 
logical characteristics. Speiser'Ot*al. C19731 prepared microcapsules 
of barbituric acid by spray polycondensation and Voellmy (1977) 
prepared microcapsules of phenobarbital using a similar technique. 
Takenaka et al.. (1982) prepared solid particulates of 
theophylline-ethylenediamine complex (4minophylline) by spray drying. 
Kawashema et al. (1983) used a spray drying technique to prepare solid 
particulate of aminopyrine-barbital complex. Takenakaet al. (1981) 
studied the effect of cellulose acetate phthalate, colloidal silica and 
other excipients such as talc, on the polymorphism of spray dried micro- 
capsulated sulphamethoxazole while Takenaka et al. (1980) spray dried an 
enteric coatedmicrocapsule of sulphamethoxazole. 
Spray drying was chosen in this work as an alternative technique to 
incorporate hydrophilic polymer and surfactant molecules with phenyl- 
butazone and data will be presented and discussed i'n Chapters 3,4 and 5 
of this thesis, 
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1.4 Tableting 
The art of compressing discrete solid particulate matter into a 
cohesive-mass has been practised since the days of the ancient 
Egyptians. It was not until the mid nineteenth century however that 
medicinal use of this process was made when Brockedon (1843) took out 
a patent for shaping pills, lozenges and black leads by pressure in a 
die. In the U. S. A. McFerren (1874) and Dutton (1876) extended and 
improved on Brockedon's idea and obtained further patents for tablet 
compression machinery. Developments from this patent using the 
increasing amount of technology available now enables production rates 
in excess of 600,000 tablets per hour using the most modern machines. 
Initially the process was purely empirical, with little or no account 
being taken of the mechanisms involved, the only criterion for 
acceptability being production of a compact. 
Fundamental research began in the 1920's mainly in the field of 
powder metallurgy, but quickly spread to other disciplines as the 
implications became more widely realised. Generally speaking two 
broad lines of investigation may be distinguished. (i) Studies of 
the distribution of forces at die and punch walls, and within compacts 
during compression (Higuchi 1954, Shotton & Garderton 1960, Fuhrer 
1962, Shotton et al. 1963, Lewis & Shotton, 1965, Leigh et al. 1967, 
Knoechel et al. 1967, Goodhart 1968) and (ii) analysis of the relation- 
I 
ships between the applied pressure and the resulting density of compact 
(Heckel 1961a, b, Hersey & Rees 1970, Fell & Newton 1971, Cooper & 
Eaton 19621. 
The former approach has involved the use of instrumental tableting 
machines of both single punch Ce. g. Lewis & Shotton 1965, Shotton & 
Garderton 1960, Higuchi et'al.. 1954, Leigh'et'al. 1967 and Fuhrer 1962) 
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and multi-punch types (e. g. Shotton et al. 1963, Knoechel et al. 1967, 
Goodhart et al. 1968). The first published account of the 
instrumentation of a single punch tableting machine was given by 
Huguchi et al. 1954, who bonded a strain gauge onto the upper punch 
frame and a load cell onto the lower punch. 
Because of the non-linear relationship between frame distortions 
and applied force, Shotton A Ganderton (1964) bonded strain 
gauges directly onto the punches, recording the forces on a U. V. 
recorder. 
The force transmitted radially to the die wall was first measured 
by Nelson (1955) and Windheuser. et al. (1963) who cut away a section of 
the die wall and bonded strain gauges on it. They reached the 
conclusion that materials which permitted good conversion of axial to 
radial pressure tend to form better tablets. A residual die wall 
pressure, after removal of the upper punch, was found by Higuchi et al. 
(1965). Instrumentation of this type has been reported by several 
workers (e. g. Leigh et al. 1967, Long 1960) who used it to record the 
compaction profiles of several materials, some of which were of 
pharmaceutical interest. 
1.4.1 Mechanisms occurring during compaction 
The several stages occurring during compaction could be listed as: - 
i) filling thq die 
ii) densification by particles slippage 
iii) elastic and plastic deformation 
iy) cold welding with or without fragmentation (York 1978) 
When a loose powder bed is subjected to a constant pressure, the 
pressure transmitted through the bed will decrease uniformally with the 
distance from the source. However, when the powder is filled in a die 
there are force losses due to extra forces which the upper punch has to 
overcome. These forces include die wall friction which is dependent on 
powder properties, the state of compaction and the interfacial condition- 
between powder and die wall (see Fig. 1 . 3). 
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Fig. 1.3 Forces operating on a powder under compression 
Where 
Fu = The applied force by the upper punch 
FL = Force transmitted to the lower punch 
FR = Radial force 
FD = Die wall reaction as die wall friction force 
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In powders and particulate solidsfriction usually occurs between 
the powder and the die wall which will induce the radial force, FR. 
Thus, some of the applied force will be transmitted to the die wall 
CFD) to oyercome the radial force. Thus Fu = FL +-FD. 
For elastic -materials, the elastic strain induced by the application 
of a load can be recovered by unloading the-material. The change in 
dimension is generally attributed to the stretching of the atomic bonds 
and changes in the internal energy of the loaded and unloaded specimen 
(Stanley-Wood 19831. When a material undergoes a linear stress-strain 
relationship, the elastic characteri'stics of the material such as 
Young's modulus and Poisson's ratio can be calculated. 
plastic matertals are materials which have non-recoverable strain on 
unloading when loaded beyond the elastic li'mit. The process occurs 
mainly because of the sliding of atoms over each other (Stanley-Wood 1983). 
The plastic deformation of materials occurs non-homogeneously by means of 
lattice dislocation Within the crystal structure of materials (see 
Fig. 1.41. Some materials undergo fragmentation with increasing 
applied load. 
1.4.2 Pressurejvolume relationships 
Many equations have been proposed to account for pressure/volume 
relationships during compaction CKawakita & Ludde 1970,1971). However, 
the equation developed by Heckel*(1961a, 1961b) has been found 
particularly useful in numerous compaction studies (Hersey & Rees 1970, 
Hersey et al, 19-72, Fell & Newton 1971, York & Pilpel 1973, Esazobo cat 
Pilpel 1977, York 1978, De B-oer et'al, 1978, Rue & Rees 1978, Kurup & 
Ptlpel 1978, Ho & Hersey 1-980, Paronen & Juslin 1-9831, 
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Fi 1.4 Representation of (a) Elastic deformation, 
(b) Plastic deformation and (c) Fragmentation 
of model powder particles during compression 
low rearrangement 
load and packing 
high 
load 
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-AA, load 
removal 
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-26- 
The Heckel equation essentially describes a first order relation- 
ship for the change in pore volume with pressure. The relationship 
is giyen by equation 1.1 
1n1= KP +A1.1 
I-D 
Where D is the density of the compact relative to the 
absolute densi, ty of the-material being compacted 
P is the applied pressure CMpa). 
K'-1 where Y is the Yield pressure of the material 
Y, 
and A is a function of the original compact volume, 
Several workers have however, expressed caution when analysing data 
by the Heckel equation (Rees & Rue 1978, York 1978ý since the 
experimental conditions and method of measurement (e. g. within die or 
after removal following compaction) influence the numerical values of 
parameter derived from the analysis. Nevertheless, by standardising 
experiment procedures it is possible to use the datato 
compare the compaction behaviour of materials. 
Hersey & Rees (1970) described two types of powder compaction 
behaviour when analysed according to the Heckel relationship. Type A 
and type B (see Fig. 1.5). Type A was observed for particles whose 
bulk density was dependent on initial particle size. Then under 
pressure the densification was due to particle rearrangement or 
slippage, followed by plastic deformation. 
Type B was observed for materials that do not maintain the initial 
bulk density differencet due to particle size Yariation, have higher 
yield pressures and undergo consolidation by initial fragmentation to 
form a consistent packing followed by plastic deformation, 
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A third type of behaviour, type C was distinguished by York & 
Pilpel (1973), showing a very rapid approach to limiting density for 
materials with very low yield pressures (see Fig. 1.5). 
1.4. *3 Force transmission 
Early workers used the ratio of maximum lower to upper punch 
force or "R" value to study lubricant efficiency in tablet formulations 
(Nelson et al. 1954; Strickland 1959; Strickland et al. 1960) and 
axial pressure transmission across unlubricated beds (Shotton & 
Ganderton 1960; Shotton et al. 1963). The better the force trans- 
mission in an axial direction, the closer the "R" value approaches 
unity. 
Since 1960 when Long elucidated the significance of radial versus 
axial pressure cycles, these plots have found widespread use in the 
evaluation of compaction data (Obiorah & Shotton 1976; Summers et al. 
1976; Carless & Leigh 1974; Carstensen & Toure 1980; Carstensen et al. 
1981; Carless & Sheak 1976). Long (1960) for model materials 
extended measurements to cover the complete compression cycle, 
including the removal and dissipation of pressure. Leigh et al. (1967) 
investigated, pharmaceutical materials and suggested behaviour similar 
to three different types of theoretical compression patterns, namely 
an elastic body, a Mohr's body and a body with constant yield stress 
(see Fig-1.6 ). Further studies have attributed physical 
significance to each straight line of the pressure cycle plots 
showing differences between pharmaceutical powders (Carless & Leigh 
1974; Davis et al. 1977) and various crystal forms (Summer et al. 
1976). 
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1.4.4 Stress relaxation 
Stress relaxation is the decrease in the applied force which 
occurs when a compact is under static compression, due to plastic 
deformation of tfie compressed material into interstitial spaces. 
Various workers (Cole et al. 1975; Hiestand et al. 1977; Rees & Rue 
1977) have used stress relaxation curves to compare the plastic 
flow of pharmaceutical powders under pressure. David & Augsberger 
(1977) derived the relationship: - 
In AF = In F 0- 
K"t 
where &F is the amount of force left in the viscoelastic region at 
time t; AFO is the total magnitude of this force at t=0 and K 
11 
is the viscoelasticslope. By using the viscoelastic slope, K 
11 
1 
these workers were able to quantifýy the degree of plastic flow. 
They found that materials with a higher viscoelastic slope exhibited 
a higher degree of plastic flow under compression and would form 
stronger compacts. 
1.4.5 lablet property evaluation 
In terms of tablet property evaluation, several groups of workers 
have plotted tablet crushing force against mean compression pressure 
(Shotton & Ganderton 1960,1961, Hersey et al. 1967, Rees & Hersey 
1972, Shotton & Obiorah 1973), where the mean compaction pressure 
(Pm) is given by: - 
Pm - 
Pa+Pb 
r- 1.2 
and Pa and Pb are the maximum applied and transmitted pressures to the 
upper and lower punches respectively. A comparison Of the relative 
slopes of crushing force against compression pressure plots has been 
used to give a qualitative indication of the tendency of materials to 
produce strong tablets (Krycer et al. 1982). 
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Rudnick'et al. (1963) and Fell & Newton (1970), when describing 
the stress distributions within tablets subjected to diametrical, 
compression tests, haVe shown that when suitable padding material is 
positioned between the tablet and the upper and lower plates, the 
tensile strength of the tablet can, be calculated. It is essential 
to achieve such conditions when using this-test as otherwise line 
loading may cause failure by compressive or shearing stresses. 
By observation of the specimen after failure, three types of 
fracture have been reported (Rudnick'et al. 1963; Fell & Newton 1970). 
They are shown diagrammatically in Fig. 1.7 and are termed: - 
i) compression or shear failure (producing irregular 
fragments) 
normal tensile failure Ctablet fractures along 
loaded diameter into two halves) 
iii) triple cleft failure (symmetrical split into 
four pieces). 
A tensile break can therefore be confirmed by observing the failure 
pattern and such breaks could be calculated by the following equation: - 
Tt = 
2P 1.3 
lru-ý 
where Tt = tablet tensile strength 
is the load applied 
D= tablet diameter 
tj = tablet thickness 
Fell & Newton C1970) have however shown that measured tensile strength 
differs when padding material is used compared with data obtained 
without padding, suggested that this causes doubt as to which value 
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Fig 1.7 
FRACTURED TABLETS AFTER DIAMETRICAL COMPRESSION 
Shear and Compressive Failure 
Zý: 
ýý53 
ýp 
1---ý> 
Normal Tensile Failure 
Triple Cleft Failure 
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represent the true tensile strength. Rudnick'et al. (1963) had 
previously commented that the tensile strength value is controlled 
by the test conditions and is true for each test. Thus, for 
comparison of different values and parameters, the test should be 
performed under the same conditions. 
1.4.6 Tableting of modified materials 
Several compaction studies have compared similar materials with 
various modifications. Varsano & Lachman (1966) found that potassium 
chloride crystals and granules behaved differently at lower compression 
loads than those of potassium citrate. They attributed this to 
inherent material properties rather than changes in particle size. 
York & Pilpel (1973) recognised a decrease in tablet tensile strength 
as the melting point of the fatty acid increased which was attributed 
to different amounts of interparticle bonding. Fell & Newton (1971), 
when studying spray dried and crystalline lactose, found that particle 
rearrangement was greater for smaller size fractions and that the 
yield pressure for spray dried samples was lower than that for 
crystalline materials. Summers et al. C1977) reported that the 
tensile strength of tablets prepared from metastable polymorphs of 
aspirin, barbitol and sulphathiazole was lower than for the stable 
form. This was attributed to the higher potential energy state of 
the metastable polymorph and weaker bonding, so the particle-particle 
bonds produced'for the metastable were less than that for the stable 
f orm. 
Since the physicochemical properties of materials can be 
advantageously modified by incorporating additiyesý it is appropriate 
to consider the further processing of these materials by tableting 
which is a widely used pharmaceutical operation. Thus the objective 
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of this part of the work was to examine the effect of incorporating 
small amounts of polymer into phenylbutazone on its compaction 
behaviour and tablet tensile strength together with a study of the 
effect of different material preparatio. n techniques - direct 
crystallisation or spray drying - on these properties. The results, 
analysis and discussion of these experiments are presented in 
Chapter 7 of this thesis. 
1.5 Materials selected for study 
For this study phenylbutazone (PbZ) was chosen as a representative 
water insoluble drug. It was selected because: - 
a) it exhibits an extremely low aqueous solubility 
b) it is reported to exist in different polymorphic 
foms 
c) it is thermally stable after melting which enables 
quantitative thermalanalyses to be performed. 
II Hydroxypropylmethylcellulose (H. P. MoC. ) 
This polymer was selected to be used as a carrier in this study 
because: - 
a) it is a widely used hydrophilic polymer 
b) it is approved for oral human use 
c) it has not been used to our knowledge in previous 
solid dispersion studies 
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III Poloxamers 
Poloxamers are a group of non-ionic surfactants having the 
general structure: - 
H(O-CH2-CH24 (0-CH-CH2)b (0-CH2-CH2)a OH 
I 
CH3 
They were selected for use in this study because: - 
a) they are non-ionic surfactants, so they would not have 
irritating effects when taken orally 
b) a wide range of hydrophilic-libophilic balance is 
available within the group of compounds, due to 
differences in the polyoxypropylene-polyoxyethylene 
ratio. 
The following chapters of the thesis present details of a study 
of the effects of incorporating polymeric additives into phenyl- 
butazone using crystallisation and spray drying technique. Chapter 2 
defines the materials used in the work and the experimental 
procedures followed. 
Chapter 3 consists of three parts which present an evaluation of 
the spray dryer used, a study on the reported phenylbutazone poly- 
morphs and a study on the effect of crystallisation rate on the 
polymorphism of phenylbutazone. The effects of presence of 
different amounts of H. P. M. C. and poloxamer on the physicochemical 
properties of phenylbutazone are presented in Chapters 4 and 5 
respectively. 
In Chapter 6a study of the stability of the prepared powder 
samples stored under controlled conditions is reported and Chapter 7 
reports on examination of the tableting properties of both spray dried 
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and crystallised samples of phenylbutazone: hydroxypropyl 
methylcellulose systems. 
Whilst detailed discussions are provided in Chapters 3 to 7 
inclusive, a general discussion of the results is provided in 
Chapter 8, and general conclusions and suggestions for future work. 
CHAPTER 2 
-37- 
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2.1 Materi als 
Phenylbutazone powder (BP), Approved Prescription Services Ltd., 
Cleckheaton. Batch No. 109173. 
The degradation products of phenylbutazone: 
4 hydroxyphenylbutazone 
a carboxy-N-caproylhydrazobenzene 
N caproylhydrazobenzene 
. 
a carboxy-a-hydroxy-N-caproylhydrazobenzene 
N (a-ketocaproyl)-hydrazobenzene 
a-hydroxy-N-caproylhydrazobenzene 
All supplied by Ciba-Geigy, Basel, Switzerland. 
(G 28 455) 
(GP 40 588) 
(G 30 184) 
(G 28 454) 
(GP 46 060) 
(GP 46 062) 
n-Heptane, analar grade, BDH Chemicals Ltd., Poole, England. 
Batch No. 10363. 
2-Propanol, analar grade, BDH Chemicals Ltd.. Poole, England. 
Batch No. 10224. 
Absolute alcohol (BP), James Burrough, England, claim 99.86% minimum. 
Butan-2-01, analar grade, BDH Chemicals Ltd., Poole, England. 
Batch No. 10316. 
Cyclohexane, analar grade, BDH Chemicals Ltd., Poole, England. 
Methanol, H. P. L. C. grade, Rathburn Chemicals Ltd., Scotland. 
Potassium dihydrogen orthophosphate, analar grade, BDH Chemicals 
Ltd., Poole, England. 
Acetonitrile, H. P. L. C. grade, Rathburn Chemicals Ltd., Scotland. 
Salicylic acid, analar grade, BDH Chemicals Ltd., Poole, England. 
Batch No. 10226. 
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Acetone analar grade, BDH Chemicals Ltd., Poole, England. 
Hydroxypropyl methylcellulose (H. P. M. C. )U. S. P. 
pha rmacoat 603 (CPS 3) lot no - 57- 022 
pharmacoat 606 (CPS 6) lot no-57-035 
pharmacoat 615 (CPS 15) lot no-57-712 
All supplied by Shin-Etsu Chemical Co. Ltd., Japan. 
Polyoxyethylene-polyoxypropylene glycols poloxamer surfactants 
poloxamer 188 lot no. C 12/CC 
poloxamer 407 lot no. H Ol/L5 
i)oloxamer 338 lot no. H 23/L5 
poloxamer 184 lot no. C 66/CC 
poloxamer 181 lot no. H 97/L5 
poloxamer 101 lot no. C 64/CC 
All supplied by ugine Kuhlmann, Manchester. 
Silica gel self indicating BDH Chemicals Ltd., Poole, England. 
All other reagents are laboratory grade unless otherwise stated and 
all water used'was double distilled from an all-glass still. 
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2.2 Methods 
2.2.1 Assay of phenylbutazone 
The B. P (1980) assay procedure was used to assay the purity of 
phenylbutazone powder. 0.5gm accurately weighed of phenylbutazone 
powder was dissolved in 25 mls of acetone then titrated against 0.1 N 
sodium hydroxide using 0.5 ml of bromethymol blue as indicator until 
a blue colour was obtained which persisted for fifteen seconds. Blank 
tests were carried out using the same procedure omitting the phenyl- 
butazone powder. This assay was also used to estimate the amount of 
phenylbutazone in samples after recrystallising with H. P. M. C. and 
poloxamer surfactants. All tests were carried out at least in duplicate. 
2.2.2 Ultraviolet spectrophotometer calibration curve 
A scanning U. V. spectrophotometer (SP 800 Unicam, Cambridge) was 
used to check the wavelength of maximum absorbence. A calibration curve 
of U. V. absorbence against known concentrations of phenylbutazone in 
0.01N sodium hydroxide was prepared using solutions containing between 
0.0002 to 0.002 mg % of phenylbutazone, and the absorfibence E, of each 
concentration was measured using a second U. V. spectrophotometer 
(Cecil Instruments CE 292, Cambridge). Maximum absorbence E was 
observed at 264 nm and a graph of E at 264 nm was plotted against 
concentration (see Fig. 2.1). 
2.2.3 Buffer solution 
For solubility and dissolution experiments a buffer medium 
consisting of 0.68% w/v dihydrogen orthophosphate'at pH 7.5 (adjusted 
using 1N sodium hydroxide), was used. 
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2.2.4 Solubility and intrinsic dissolution 
The determination of the equilibrium dynamic solubility of 
samples was carried out in a shaking water bath (Gallenkamp, England) 
at 37 OC±o. JOC using phosphate buffer. An excess amount of the powder (1 gm) 
was placed in 100 ml of the buffer solution in a 250 ml stoppered 
conical flask which was then placed in the shaking water bath. 
Sampling was carried out at definite times by taking 1 ml of the 
solution with a1 ml glass grade A syringe and filtering through a 
membrane filter (Millipore size 0.45 mm, Millipore). The volume 
was then completed to 100 ml using 0.01N sodium hydroxide. The U. V. 
absorbence of resulting solutions was measured at wavelength 264 nm. 
The equilibrium dynamic solubility was measured using the same 
procedure at 200,370,500 and 600C, so that the data could be 
analysed by the Van't Hoff equation (Florence & Attwood 1981) to 
obtain AHs , the enthalpy of solution. 
Log K=- -AH s 2.1 2-. 3U7R-7 
Where K= solubility (mg/100 ml) 
gas constant 
T= absolute temperature (OK) 
-AH sf rom Plots of log K against 
1 
gave straight lines with slope T. 03 
which AH s was obtained. 
To overcome the problems of particle size and surface changes during 
powder dissolution, intrinsic dissolution was carried out for the supplied 
phenylbutazone and all the prepared samples using a Wood's apparatus 
(see Fig. 2.2). This is designed to maintain constant surface area of 
1.57 cm2 of compressed powder during dissolution. Samples for 
dissolution were prepared by placing the die on a smooth surfaced 
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Fig. 2.2 Intrinsic dissolution testing apparatus 
thread and 
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hardened stainless steel plate, then 300 mg of the powder previously 
sieved through a 200jim sieve was carefully layered into the hole in 
the die. The punch was then added and pressed using a manually 
operated hydraulic press (Apex PMQ in a controlled manner to defined 
values of applied forces. The whole punch and die unit was attached 
to a rotating motor CHieldolph RZPL, Germany) and placed in a constant positil 
in the dissolution medium which consisted of 600 mls of buffer solution in 
a one litre round-bottomed beaker at 370C. Samples (10 ml) were taken 
at fixed time intervals and filtered using a membrane filter 
(Millipore size 0.45 mm). After each sampling, 10 ml of buffer at 370C 
was added to keep the volume of the dissolution medium constant through- 
out the experiment. 
- The sample was then diluted to 100 ml using MIN sodium hydroxide 
and the concentration of drug released was measured using U. V. 
absorbence at 264 mM. 
The dissolution rate of diffusion controlled process can be 
represented by the Noyes-Whitney equation (Florence & Attwood 1981) 
which may be written: - 
dm = K. A (CS-C0) 2.2 it- 
dm 
where Ff = the rate of increase in the amount of material in solution 
A= the area of the solvated tablet exposed to the 
dissolution'medium 
the intrinsic dissolml-, ion rate constant 
Cs= the maximum solubility 
Co = concentration of drug in solution at time t. 
By having large receptor volume in comparison with the donor phase 
and ensuring "Co', does not rise above approximately 10% of Cs, sink 
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conditions are achieved. In this situation the equation can be 
simplified to: - 
dm % a -t K. A C 2.3 
Since M=V Co where M= amount of material in solution and V 
volume, the equation (2.3) can be written as 
V Co = K. A Cst 2.4 
and 
Ký. A is the slope of the graphical representation of drug v 
released against time. 
For these experiments -A, the constant surface area, could be 
calculated 
A= 2-ff 2 
2 1= 27 (0.5) 1.57 cm2 
Thus the intrinsic dissolution constant (ý) from compressed discs of 
prepared samples can be calculated using the expression: - 
Slope = 
ý. A 
v 
2.5 
However, for graphs of total drug released versus time this equation 
reducesto: - 
Slope = Ký. A 
Initial experiments with compressed discs of as supplied phenyl- 
butazone were carried out using speeds of rotation 60,100 and 150 r. p. m. 
and compression force 175 KN. A second set of experiments using 
compression forces of 105 and 245 KN and rotation 100 r. p. m. was 
performed. Subsequent experiments were carried out at 100 r. p. m. and 175 KN. 
2.2.5 Crystallisation of phenylbutazone 
2.2.5.1 Preparation of polymornhism of phenylbutazone 
Muller C1978) when preparing the a-polymorphic form of phenylbutazone 
(which, as supplied, Oxistsin the stable a form) , added water to a 2- 
propanol solution of phenylbutazone until the cloud point was reached. 
The solution was then warmed and allowed to cool rapidly. This procedure 
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was followed in this work and the 'resulting crystals were filtered 
using a sintered glass funnel and dried at 50C under vacuum. 
For the preparation of $-form, as reported by Muller (1978), 
samples were recrystallised by flocculating an ethanolic or 
n-heptane solution of phenylbutazone in water stirred at high speed. 
Muller (1978) reported that the-y-form was prepared by heating 
the a-form to about 96 0C then cooling down to 800C, then reheating. 
An endothermic transition was observed on the D. S. C. thermogram at 
105 0 C. Attempts were made using equivalent conditions in this work 
to isolate the y-form of phenylbutazone. 
2.2.5.2 CrZstallising phenylbutazone*with hydroxZpropyl 
methylcellulose (H. P. M. C-. ).. 
a. Preparation of H. P. M. C. dispersion 
The required amount of H. P. M. C. was added to one third of the 
total volume of water, preheated to 900C and stirred with a glass rod 
until all the particles were wetted, then the remaining water was 
added cold with stirring. The warm solution was allowed to cool 
slowly to room temperature and a clear solution of required 
concentration was obtained. 
b. Crystallising phenylbutazone with H. P. M. C. 
The samples were prepared by dissolving 6 gms o. f phenylbutazone in 100 mlsl 
absolute alcohol at 600C. The drug solution was then added to aqueous 
H. P. M. C. solutions containing H. P. M. C. concentrations of 0.01,0.1,1, 
2 and 5% w/v. The formed crystals were left for one hodr before 
collecting on a sintered glass filter and allowed to dry at room 
temperature under vacuum over self-indicating silica gel. 
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2.2.5.3 Castalliting'phenylbutazoe with polZoxyethylene- 
poly6xypr6pylehe'glycols (poloxamers. ) 
The samples were prepared following the same procedure used to 
crystallise phenylbutazone with H. P. M. C. However, since the poloxamers 
are aqueous soluble they were dissolved directly in the water with 
simple stirring. 
2.2.0 Crystal*characterisation and polyýorphic studies 
2.2.6.1 Differential scanning calorirnetU'(D. S. C. -) 
Samples were analysed by thermal analysis using D. S. C. (DuPont 
1090 thermal analyser and 910 differential scanning calorimeter, 
DuPont, Stew nage) (see Fig. 2.3). 
The procedure involves heating the sample contained in an 
aluminium pan and a similar empty reference pan at a predetermined rate 
and over a predetermined temperature range. If a related change takes 
place in the sample the temperature of the sample lags (endotherm) or 
leads (exotherm) the reference pan temperature. The temperature 
difference between the sample and the reference is represented graph- 
ically in relation to the differential heat flow. 
Heating rate is a very important factor affecting the melting point 
as well as the observation of polymorphic endothermic transitions. A 
series of different heating rates of 2.5,10,20 and 50OC/min was 
examined to identify the appropriate heating rate to be used for this 
study. (In this study the peak of melting endotherm was considered as 
the melting point of the tested sample). From this preliminary work, 
subsequent D. S. C. analyses were carried out using a standard heating 
rate of 10 0 C/min and sample weight between 3-8mg over the temperature 
range 30-1300C under nitrogen flow (10 ml/min) in a crimped aluminium 
pan with a pierced lid. The results were analysed using the DuPont 
. -47- 
 SI IA 
Sampl e 
Pan 
Thermal 
Radiati 
Shield 
F 
Rubber 
0 Ring 
Purge Gas Coolant Vacuum 
:e Pan 
Block 
intan 
noelectric 
Cel 1 Base 
Plate 
Fig. 2.3 Cross section of differential scanning calorimeter 
II 
-48-. 
interactive D. S. C. V. 2 program to integrate the melting endotherms. 
2.2.6.2 Determination'of thermodynamic activation energX of 
the ý-polXmorph of phenylbutazone 
The activation energy, Ea, of the transition endotherm for 
a-polymorph was calculated using the relationship after Kissenger (1975) 
d log -z 
Tm -Ea 2.6 T. -3-0-31T 
Tm 
from the endothermic peak maximum temperature (Tm) observed after 
following different heating rates (0) of 2,5,10,15 and 20 0 C/min. The 
01 -Ea plot of log -7 against Tm gave a straight line with slope = T=. R Tm 
from which Ea was calculated. R is the universal gas constant. 
2.2-6.3 Thermogravimetg 
The formation of solvates, and samples expected to form solvates 
or retain solvent, was investigated using a themogravimetric analyser 
(DuPont 951 thermogravimetric analyser, DuPont, Stevenage). This 
consists of a microbalance with a sensitivity of ±1 x 10-2 mg. Samples 
(5-10 mg), loaded in the platinum cradle at one end of the microbalance 
arm, were heated at a programmed heating rate over a definite temperature 
range. Any weight losses, such as that due to the evolution of solvent, 
were recorded on the thermogram. 
2.2-6.4 Powder X-raX diffraction 
Samples for examination on an X-ray powder diffraction instrument 
(Philips PW 1120/00 with proportional detector probe, Holland) were 
prepared by filling powder into the cavity in the sample holder, then 
smoothing with a glass slide. The sample was then subjected to an 
X-ray radiation stream from a copper potassium-a electrode with 
wavelength of X=1.54059 A. The pattern was monitored on an attached 
-49- 
recorder (Philips, Holland) at a chart speed of 10 mm/min. 
2.2.6.5 Infrared spectroscopX 
The I. R. spectra of the samples were recorded on an infrared 
spectrophotometer (Pye Unicam SP 200, Cambridge) using nujol mulls. 
2.2.6.6 Microscopy 
a., Scanning electron microsqqp 
Photomicrographs were obtained using a scanning electron microscope 
(Stereoscan 600, Cambridge Instruments, Cambridge) fitted with a back- 
scattered electron detector (K. E. Developments, Cambridge). All the 
0 
samples were coated with gold (of thickness -500A) using a direct 
coating technique under vacuum (2 x 10- 
4 torr). 
b. Optical microscope and particle sizing 
An optical microscope with Olympus OM2 camera attachment was used 
to obtain photographs of the spray dried and crystallised phenylbutazone 
samples. The microscope was also used for sizing the spray dried 
samples using a calibrated linear graticule technique for measuring a 
linear dimension of particles in a constant direction. 600 particles 
were counted for each analysis. 
c. Hot stage microscope 
A zoom stereoscope microscope (Kyow, Tokyo) fitted with a hot stage 
attachment linked to a control Onit (UTP. Stanton Redcroft, 
Lo-ndon) ýAs u§ed to view the samples over a 
programmed temperature range to observe and record the melting point of 
the samples, and to monitor the physical changes occurring at any poly- 
morphic trans. ition. Samples were placed on a glass microscope cover slip, 
to minimise the heat difference between the sample and the heating plate. 
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All the samples were heated at 10 C/min. 
2.7 Spray'drying 
Spray drying of phenylbutazone was carried out using a BUchi 190 
mini-spray dryer (BUchi Laboratory Techniques Ltd., Switzerland) - see 
Fig. 2.4 - which operates on the principle of nozzle spraying with 
parallel flow i. e. the sprayed product and the drying air flow in the 
same direction. 
The spray drying process was carried out by feeding the sample by 
means of a pump fixed on the top of the spray dryer, into the drying 
chamber in a very fine droplet form by means of an atomising air flow 
11 which was supplied from an air compressor. When the atomised small 
droplet was exposed to the hot temperature of the drying chamber (inlet 
temperature) the solvent evaporated rapidly leaving the dried powder. 
The powder and the solvent were transported to the cyclone separator 
by means of an aspiration force, and the solvent was separated from the 
dried product which collected in the sample collector. The solvent 
vapours were eliminated through the exhaust pipe. 
2-7.1 Solvent used for spraX dryiM - 
Aqueous ethanol was used as the spray drying solvent because 
phenylbutazone is virtually insoluble in water. A preliminary 
experiment to determine the solubility of phenylbutazone in aqueous 
ethanol and aqueous 2-propanol was carried out (see Fig. 2.5 ). The 
graphs show an increase in drug solubility with increasing alcohol 
component in the solvent system. From these results the concentration 
of 2% w/v phenylbutazone in 75% v/v ethanol in water was, chosen for all 
spray drying processes. 
F ig2 4ý 
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2.7.2 Spray drying of'phenylbutazone 
Solutions containing 2% w/v phenylbutzone in 75% v/v ethanol/water 
were spray dried using the Bi6chi mini-spray dryer. A full factorial 
analysis was carried out to assess the effect of the four monitored 
variables in the spray dryer (inlet temperature, pump rate, flow rate 
and aspiration rate) on the properties of spray-dried 
products such as particle size, per cent efficiency of process 
(wt product (i. e. kwt phenyTFItazone used)x 100Z) and number of peaks on 
the D. S. C. 
thermogram of prepared samples. Three levels of each variable were 
selected. For pumping rate 4 ml/min, 8 ml/min and 16 ml/min were 
employed and for flow rate 200,400 and 600 I/h were selected. 
Aspiration rates (measured using an anemometer (Airflow Developments 
Ltd., High Wycombe, TA 3000))were 0.00823 M3 /sec, 0.00903 m 
3/sec 
and 
0.01060 m3 /sec. 100,125 and 1450C were the three inlet temperatures 
selected. In each run 200ml of 2% w/v phenylbutazone solution was 
spray dried and the outlet temperature (which is the temperature of the 
airstream containing the solid particles before entering the cyclone) 
was monitored. Efficiency of process as well as the particle size of 
the product were measured, and each run was carried out at least in 
duplicate. 
2.8 High pressure liquid chromatography (H. P. L. C. ) 
2.8.1 Calibration curve for phenylbutazone-. 
_a_n_d-'its 
degradation compounds 
A high pressure liquid chromatograph with variable wavelength U. V. 
detector (Pye Unicam L. C. U. V. detector) was used. A 20pl sample 
was injected via a microsyringe (S. G. E. Type A-RN) to a Particil-lo ODS 
reversed phase column 25 cm x 4.6 mm internal diameter, packed by the 
pressurised slurry method in methanol. 
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Initially an attempt to reproduce the system reported by Fabre (19ý2) 
was made using an equivalent column. The mobile phase consisted of a 
degased 60: 40 mixture of 0.1 M trimethomine citrate buffer (pH 5.25): 
acetonitrile. However this proved generally unsatisfactory since the 
column repeatedly blocked. One possible explanation is that the 
citric acid in the buffer which was used to adjust the pH crystallised 
inside the column causing blockage. 
After screening other systems it was found that two solvent systems 
were required to resolve all seven materials (six breakdown products 
and phenylbutazone) (see Table 6.1). The first system usedwas 
methanol H. P. L. C. grade 58% v/v and double distilled water 42% v/v, for 
resolving, identifying and quantifying degradation products No. 11fivv, 
and vt -The second system was 42'/1,0 v/v methanol and 58% v/v water which 
resolved phenylbutazone and degradation product! No-41 - Degradation 
No. I'- was excluded because it was found to change slowly to No. 111 on 
dissolving in the solvent. In all cases analar grade salicylic acid 
was used as an internal standard. To obtain the calibration curve each 
of the degradation products and phenylbutazone was run at four 
concentrations 25jig, 12.5pg, 6.25lig and 3.125jig together with 10pg of 
internal standard in all samples at a flow rate of 2 ml/min, pressure 
188t2 bars, detector sensitivity 0.08, and chart speed 10 mm/min. The 
absorbence was measured at 237jim and calibration curves were plotted 
see Figs. (2.6,2.7,2.8). 
2.8.2 Testing thespray-dried samples 
A number of spray-dried samples were selected to be tested by 
H. P. L. C. for presence of decomposition products. These samples were 
chosen to represent those prepared under the extreme conditions that 
phenylbutazone was exposed to during spray drying. These samples were 
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analysed using the same conditions as those listed for calibration 
curve preparation. 
2.9 Stability'-testinQ 
Five samples were subjected to a stability testing programme. 
2.9.1 Materials 
the original as supplied phenylbutazone 
phenylbutazone crystallised from'20, lo w/v HPMC solution (PHS4) 
phenylbutazone spray dried from 2% w/v HPMC solution (PHR4) 
phenylbutazone crystallised from 1% w/v poloxamer 188 solution (PPR3) 
phenylbutazone spray dried from 1% w/v poloxamer 188 solution (PPS3) 
2.9.2 Method 
Portions (3 gms) of theseýsamples were each stored under four 
conditions - 200C, 370C and 500C in sealed containers and also in open 
containers at 200C and 40%±5% RH. The samples were tested for any degradatio I 
or change inthermal behaviour using H. P. L. C. and D. S. C. initially and 
after 3 and 6 months to check any change in D. S. C. thermograms and 
H. P. L. C. profiles. 
2.10 Tableting 
'I True density-measurement 2.100 
1 
The true density of the powder samples was measured using an air 
comparison pycnometer (Model 930, Beckman). By placing a known 
weight of powder in a sample bottle of known volume previously 
determined, the true density can be determined. 
2.10.2 Instrunlen'ted tablet machine 
Tableting was performed using a single punch tablet machine 
(Manesty Type E) fitted with J" flat faced punches instrumented with 
load cells (Kistler Type 901 ) see Fig. 2.9a,, b. The charge induced in the 
Fi g. 2.9 
I 
B 
D 
Instrumented tablet machine lower punch assembly 
C 
A- Piezo-electric load transducer D- Lower punch 
B- Force distributing washer E-P. T. F. E. insulating sleeve 
C-P. T. F. E. insulating plug F- Lower punch holder 
-60 
Fig. 9b 
A 
i 
Instrumented -tablet machine un , per punch assembly 
A Piezo-electric load transducer D- Upper punch 
B Force distributing washer E-P. T. F. E. insulating sleeve 
C-P. T. F. E. insulating plug F- Upper punch holder 
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load cells which were positioned above the upper and below the lower 
punch during a compression gave signals proportional to the load, 
which were then amplified through the charge amplifiers (Kistler, Type 
5006) and fed to a CP100 micro-computer (Comart Ltd., Winlingdon, 
England). The micro-computer has two floppy disc drives, each with 
a capacity of 390K bytes, which uses the CP/M operating system for the 
8080 micro-processor Thecomputer was connected to a visual display 
unit, V. D. U., (Model 910, Teletype). 
The voltage outputs from the charge amplifier connected to the load 
washers could. not be fed and analysed directly by the computer as they 
must be converted to digital pulses. For this a Model-12 analogue to 
digital converter, ADC ýuel System Control, Cerforation, USA) was 
used (see Fi 9-2.10). The output f rom the 1 oad cel 1s coul d then be f ed and 
stored in the computer which enabled interpretation of the maximal 
force applied to upper punch and the maximal force transmitted to the 
lower punch. Together with knowledge of the tablet weightand material 
density, the tablet volume, porosity and Heckel function could be 
calculated. 
Calibration of the load washers involved using a third load washer 
independently mounted (Type 903A, Kistler) which was calibrated againsta 
universal testing machine, T42 Orion calibrated to grade A standard. 
The upper punch load washer was then calibrated by applying the punch 
face against the calibrated load washer. The lower punch washer was 
subsequently calibrated against the upper punch washer by inverting a 
cylindrical stainless steel plug (diameter = 10m, height = 10MM). in 
the die and applying force via the upper punch. The relevant 
calibration curves are illustrated in Figs. (2.11,2.12,2.1ý- 
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To prep are tablets the powders were sieved through a 200um sieve. 
The lower punch was lowered to its lowest position and 400 mg of the 
powder sample was carefully placed in the unlubricated die. The upper 
punch was positioned at its maximal height. The tableting machine was 
switched on for a single tablet press, then switched off immediately 
the upper punch had emerged from the die. After removal of each 
tablet, the punches and die were cleaned and wiped carefully by 
mechanical rubbing with a tissue. The thickness and diameter of the 
tablet were measured via a micrometer Type 130J5 (Mercer, England) to 
±0.01 mm after ejection. The tablets were then left for 5 days under 
controlled environmental conditions, (200C and 40±5% RH). Then tablet 
thickness and diameter were remeasured. A minimum of five tablets 
were prepared at each compression force examined for all samples. 
2.10 .3 Tablet tensile strength 
After storage for 5 days the crushing strengths of the tablets 
were measured using a Hebelein tester (Mod. 2E/205 - Switzerland). 
When the tablets were observed to break into two semi-circular 
sections after failure i. e. tensile failure, equation 2.7 was applied 
to estimate the tensile strength. 
Tensile strength = 
2xcrushinq forcex9.81xlo-6 MPa 2.7 
7xraa'iusjm)xthickness(m) 
A minimum of five tablets for each sample were examined. 
CHAPTER 3 
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CHAPTER 3- Spray drying of nhenylbu tazone and study of 
phenylbutazone polymorphism 
3.1 The Buchi mini spray 
3.1.1 Introduction 
Spray drying is a useful technique for incorporating additives 
to drugs ( Takenaka et al . 1980,1981 ). As mentioned previously spray 
drying was used in this work as an alternative method of incorporating 
hydrophilic polymers with phenylbutazone. For this purpose the 
BUchi mini-spray dryer was used. The spray dryer has a number of 
operation variables. It was thought useful initially to study the 
effect of each variable on the performance of the spray dryer and to 
study the polymorphic-transitions which might occur during spray 
drying, and the effect of spray drying on the stability of the product. 
3.1.2 Evaluation of spray dryer 
In an attempt to provide understanding of the effect of the 
operating variables on the performance of the spray dryer, a full 
factorial experiment was carried out at three levels of inlet 
temperature, pump rate, aspiration rate and two levels of flow rate 
(see Table 3.1). Experiments were carried out as given in Chapter 2. 
3.1.2.1 Process efficiency 
The process efficiency was defined as the percentage w/w of dried 
product recovered to the total amount of solid spray dried. 
Analysis of the efficiency of the process data and calculation of 
the variance of the factorial experiments was carried out. However 
when the F-test (Moroney 1980) was applied to consider the inter- 
action of the variables the F-figures were significant at all levels 
and further examination was not attempted (Moroney 1980). However when 
the results in Table 3.2 of each single variance were considered as a 
-68- 
Table 3.1 Efficiency of process and particle size of 
product unde r differ ent conditions of 
spray drying process 
Median 
Inlet Aspiration Pump Flow Outlet Efficiency Run Particle 
Temperature rate rate rate temp. of process No. size in 3 (m /sec) (ml/min) (L/hr) C/ io W/w ýIm 
4 400 61 OC 17 .5 1", 28 17.0 
600 560C 20.4% 1 28.5 
0.008232 8 400 51 0C 0.5% 27 23.0 
600 50 0C 26,5% 29 21.6 
18 400 38 0C 12.3% 30 22.0 
600 36 0C 16.0% 31 16.5 
4, 400 62 0C 32.5% 32 17.5 
600 600C 22.5% 33 16 .0 
100 0CO. OG903 Ei 400 550 C 11.0% 34 18.0 
600 530C 12.5% 35 14.5 
16 400 39 0C 15.0% 38 17 .0 
600 380C 17.5% 39 12.8 
4 400 640C 321 .0 */10 41 16.5 
600 630C 21.0% 36 10.2 
0.0106 8 400 60 0C 11.0% 43 20.0 
600 580C 12.5% 44 16.0 
16' 400 480C 1.5% 42 18.5 
600 460 C 31.0% 37 14.5 
cont 
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Table 3.1 cont 
Me dian 
Inlet Aspiration Pump Flow Outlet Efficiency Run Particle 
Temperature rate rate rate temp. of process No. size in 
(m 3 /sec) (ml/min) (L/hr) % W/W vM 
4 400 65 
0C 0.00/ 1Q /0 4 27.5 
600 620C 16 . 0,., 2 26.5 
0.008232 8 400 600C 13.50AI, 45 25.5 
600 590C 13. O, il, 46 14.0 
16 400 530C 3.0',, 47 18.0 
600 400C 13.0'% 48 14.0 
4 400 720C 1.3% 49 16.5 
600 670C 21.01o 50 19.0 
1250C 0.00903 8 400 660C 20.50.1, 40 14.5 
600 630C 10.010 57 15.0 
16. 400 540C 8.5% 57 18.0 
600 5o'C 9.. O"Il 56 16.0 
4 400 790C 19.5% 14 19.0 
600 - 780C 22.5% 52 17.0 
0.0106 8 400 740C 23.5% 53 21.0 
600 700C 26.0% 54 19.0 
16 400 520C 4.0% 55 2 1.0 
600 600C 20.0% 51 16.5 
cont 
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Table 3.1 cont 
Median 
Inlet Aspiration Pump Flow Outlet Efficiency Run Particle 
Temperature rate rate rate temp. of process. No. size in 
(m 3/sec) (ml/mi n)(L/hr) /0 W/w Pm 
4 400 830C 20.0% 13 17.0 
600 81 0C 23.0% 5 16 .0 
0.008232 8 400 740C 10.0011, 15 39 .0 
600 720C 16.0% 18 22 .0 
16 400 860C 5.0% 8 33.5 
600 620C 23.00.1 7 24.0 
4 400 860C 0.5% 23 20 .0 
600 850C 21 . 5% 19 17 .0 
1450C 0.00903 8 400 82 0C 20.5% 58 27 .0 
600 0 74 C of 18.3, o 11 17 .0 
16 400 690C 2.5% 24 25.0 
600 630C 5.0% 20 22.0 
4 400 970C 0.5% 21 40.0 
600 90 0C 13.0% 26 28.0 
0.0106 8 400 850C 2.0', - 16 24.0 
600 81 oc 22.0'% 25 21.0 
16 400 730C 9.5% 22 31.0 
600 720C 8.5% 19 21.0 
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Table 3.2 Analysis of variance of process efficiency 
using factorial experiment results 
Nature of Effect 
Main factors 
Interaction 
between pairs 
of factors 
Interaction 
between 
triplets of 
factors 
Interaction of 
all factors 
Replication 
Total 
Source 
T 
A 
R 
F 
T. A 
T. R 
T. F 
A. R 
A. F 
R. F 
T. A. R 
T. A. F 
T. R. F 
A. R. F 
T. A. R. F 
Residual 
Sum of 
squares 
5.5 
0.18 
1-1.75 
7.8 
4.6 
8 
1.5 
1.25 
2.5 
0.8 
4.76 
2.28 
- 2.98 
3 
12.2 
7.05 
76.2 
f. 
2 
2 
8 
54 
107 
Variance 
estimate 
2.775 
0.09 
5.875 
7.8 
1.15 
2 
0.75 
0.33125 
1.25 
0.4 
0.595 
0.57 
0.745 
0.75 
1.525 
Key: 
T= inlet temperature 
A= aspiration rate 
R= pump rate 
F= air flow 
0.13 
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guideline for the effect on each processing variable, the pump and 
flow rates appear to have a more significant effect on the process 
efficiency as they show higher variance figures. This agrees with 
the practical point that increasing the pump rate increased the amount 
of feed per unit time. Increasing the flow rate will decrease the 
size of the droplet which needs a shorter time to dry. Thus the 
chance of the product not drying completely and sticking to the wall 
of the chamber in&eases, thereby reducing the process efficiency. 
The relatively low percentages of solid recovered are attributed to 
the small amounts used in these preliminary experiments and the fact 
that when spray drying the products tended to attach to the corners 
and wall of the glassware of the spray dryer. When larger batches of 
material were dried, efficiency figures increased. 
3.1.2.2 Particle size of Droduct 
AnalYsis of the particle size data from the factorial experiments 
and application of the F-test produced significant results at all 
levels indicating that all four processing variables have an effect on 
the particle size of the product. However from Table 3.3 a rank order 
of variable influence on particle size emerges - aspiration rate>inlet 
temperature>flow rate>pump rate. Optical microscope analysis and 
photographs indicated that increasing the inlet temperature in general 
increases the size of the spray dried-particles (Fig. 3.1). 
At the highest temperature used, particles do not exhibit 
conventional spherical shape, but branch irregularly. This appearance 
can be attributed to very rapid solvent evaporation from the sprayed 
droplets in the hot drying chamber causing irregular rupture of the 
droplet (flash drying) because there is a need for a very rapid solvent 
dissipation. This might be the same principle as in the case of rapid 
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Table 3.3 Analysis of variance of particle size using 
factorial experiment results 
Nature of Effect Source Sum of d. f. Variance 
squares estimate 
Main factors T 83.2 2 41.6 
A 123.7 2 61.85 
R 3 2 1.5 
F 21.4 1 21.4 
Interaction T. A 264 4 66 
between pairs T. R 9 120 4 30.225 
of factors . 
T. F 57.4 2 28.7 
A. R 98.7 4 24.675 
A. F 91.6 2 45.8 
R. F 87.9 2 43.95 
Interaction T. A. R 166.2 8 20.775 
between A. F T 99.4 4 24.85 triplets of . 
factors T. R. F 14.3 4 3.575 
A. R. F 38.3 4 9.575 
Interaction of T. A. R. F 136.4 8 17.05 
all factors 
Replication Residual 208.03 54 3.85 
Total 1625.11 107 
Key: 
T= inlet temperature 
A= aspiration rate 
R=R pump rate 
F= air flow 
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Fi g. 3.1 
Size distribution curves for samples of phenylbutazow? s7ra.,, 
dried under different conditions. 
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cooling crystallisation. There is need for a fast rate of heat 
dissipation and the elongated crystals provide a high surface area which 
is suitable for this purpose (Mullen 1972). 
The flow rate plays a major role in controlling the particle size. 
In general increasing the flow rate decreases the particle size. The 
aspiration rate evacuates the drying chamber and therefore for a constant 
feeding rate there will be increased volume per droplet at higher 
aspiration rates, i. e. the chance for fine droplets to form bigger 
droplets by collision is reduced. Also at higher aspiration rates the 
time allowed for crystal growth is shorter resulting in smaller crystals. 
3.1.3 Outlet temperature 
Statistical analysis of the outlet temperature data resulted in 
large values of variance, and F-values. Thqs all four operating 
variables contribute in determining the final outlet temperature. These 
results, presented graphically in Figure 3.2 indicate that: - 
a) outlet temperature increases with increasing inlet temperature, 
aspiration rate and decreasing flow and pump rates, 
b) increasing the pump rate increases the difference between 
inlet and outlet temperature, 
C) the effect of pump rate on outlet temperature is more marked 
when aspiration rate is low and flow rate is high. 
Figure 3.3 shows that there is a relationship between the outlet 
temperature and the thermal behaviour of the spray-dried phenylbutazone sample 
as indicated by the number of peaks on the D. S. C. thermograms. These 
transitions are attributed to the presence of polymorphic forms and 
will be discussed later in Section 3.2. It can be seen however that 
the additional transitions decrease with increasing outlet temperature. 
-76- 
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3.1.4 Validation of the spray drying process 
Figure 3.4 shows scanning electron photomicrographs of spray-dried 
sodium sulphite and shows regular spherical particles. This product 
was obtained using similar operation conditions to those used for spray 
drying phenylbutazone. The scanning photomicrographs show that the 
morphology of the spray-dried phenylbutazone samples (see Fig. 3.10) 
were not identical to the typical spherical spray-dried particles 
seen for sodium sulphite. The difference in particle morphology of the 
phenylbutazone is thus related to the specific features of phenylbutazone 
rather than the operation of the spray dryer or the procedure used. 
3.1.5 Stability of phenylbutazone products after spray drying 
Selected samples of spray-dried phenylbutazone (Table 3.4) were 
analysed by HPLC. For all samples a single peak corresponding to 
that of untreated phenylbutazone was observed. Thus spray drying 
phenylbutazone over the range of operating variables used in this study 
did not cause chemical degradation. 
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Table 3.4 Preparation conditions for spray dried phenylbutazone 
samples examined by H. P. L. C. 
Sample No. Inlet Outlet Fl ow Pump Aspiration 
t%perature t%perature rate rate pte 
(Q ( C) (L/h) (ml/min) (m /sec) 
1 100 38 600 16 0.00903 
2 100 46 600 16 0.01060 
3 100 63 600 4 0.01060 
4 125 40 600 16 0.00823 
5 125 60 600 16 0.01060 
6 125 79 400 4 0.01060 
7 145 63 600 16 0.00903 
8 145 74 600 8 0.00903 
9 145 90 400 4 0.01060 
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3.2 Polymorphism of phenylbutazone 
3.2.1 Introduction 
Phenylbutazone has been reported to exist in different polymorphic 
states. However there is confusion in the literature about the number 
of these polymorphs (see Table 3.5). Matsunaga et al. (1976) reported 
the existance of three polymorphic forms. Form I with a melting point 
of1030C, Form II melting point at 930C solidifying immediately to 
remelt at 1030C, and Form III which melts at 930C. Ibrahim et al. 
(1977) reported that phenylbutazone exists in four polymorphic forms - 
Form I prepared from isobutylalcohol melting at 800C9 Form II prepared 
from cyclohexane melting at 900C, Form III which could be prepared from 
n-heptane and melted at 930C. and Form IV melting at 1050C prepared 
from 2-propanol. Muller (1978) reported that Forms I and II mentioned 
by Ibrahim et al. were solvates (pseudopolymorphs) and also reported 
the existance of two new polymorphs. He obtained one of the new 
polymorphs, a form melting point at 950C, by adding water to ethanolic 
solution of phenylbutazone and also by melting and recrystallising the 
commercial phenylbutazone. Muller reported that the other new polymorph 
Y form could not be isolated. 
Tuladhar et al. (1983) reported that phenylbutazone can exist in 
five polymorphic forms. Form A prepared from 2-propanol has a melting 
point of 1050C. Form B, melting point 1030C, was obtained by dissolving 
5 gm of phenylbutazone in 100 ml of n-heptane and the solution was 
heated in a water bath at 900C then the solution was allowed to stand for 
2-3 hours and filtered. Form C, melting point 960C, was obtained by 
dissolving 5 gm of phenylbutazone in 550. ml n.,,! heptane and heating the 
solution in a water bath at 700C. The solution was then filtered and 
allowed to cool at room temperature for 2-3 hours. Form D. melting 
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Table 3.5 Reported melting points (OC) of phenylbutazone 
polymorphic forms 
Matsunaga et al 
( 19 7Tý- 
Form 1j. P. 
Cjc) 
1 103 
I1 93,103 
111 93 
Ibrahim et al. Muller Tuladhar et al. 
(1 977T- (1978) (19837- 
Form %. P. Form N,. P. Form 
( C) rc) 
1 80 CL 93 A 105 
I1 90 5 95 B 103 
111 93 y 105 c 96 
IV 103 6 107 D 94 
E 92.5 
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point 940C, was prepared by allowing the filtered solution in C to 
cool at room temperature for 24 hours then filtering. Form E, melting 
point 92.50C, was prepared by allowing the filtered solution of C form 
to cool in an ice bath for 2-3 hours then filtering. All the samples 
were allowed to dry under vacuum at room temperature. 
The objective of this part of the work was to attempt to prepare 
the reported phenylbutazone polymorphs following procedures reported in 
the literature and to develop an understanding of the polymorphism of 
phenylbutazone which will assist in interpreting the changes occurring 
when preparing phenylbutazone samples containing polymeric additives by 
crystallisation and spray drying. 
3.2.2 Experimental 
3.2.2.1 Materials 
The materials used were listed in Section 2.1. 
3.2.2.2 Method 
The commercial phenylbutazone (6 form) and the prepared polymorphs 
and $-were subjected to the following tests: D. S. C.,, SEk, X-ray 
diffraction, solubility and dissolution rate, all according to the 
methods described in Chapter 2. 
3.2.3 Results and discussion 
The discrepancies in the number of polymorphic forms observed 
between workers could possibly be caused by different experimental 
techniques. In all previous works with. D. S. C. different heating rates 
were used. Howeyer by heating samples of phenylbutazone at different 
heating rates (Fig. 3.5), different shapes of endotherms were obtained. 
For a fast heating rate of 500CImin a broad endothem is obtained, but 
as the heating rate was reduced the peak became sharper. In addition 
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since thermal lag increases as heating rate increases, different peak 
melting points are found for different rates. Fast heating rates can 
also mask solid-solid transitions in polymorphic materials. In this 
study a standardised D. S. C. technique with heating rate of 100CImin 
using samples in crimped pierced aluminium pans under an atmosphere of 
nitrogen was selected. 
3.2.4 Characterisation of polymorphs 
3.2.4.1 Differential scanning calorimetry (D. S. C. ) 
The D. S. C. thermograms of the prepared samples of phenylbutazone 
show that the stable form 6 (the commercial. form) exhibited one single 
endothermic peak at 1070C. The thermogram for the sample obtained by 
adding water to the 2-propanol solution of phenylbutazone until the 
cloud point then allowing the solution to cool (Ibrahim et al.. 1977, Muller 
1978) showed a small endothermic peak at 930C on the D. S. C. thermogram 
followed by an exotherm at 950C and remelt at 1070C (see Fig. 3.6). 
The first endothermic peak at 930C, possibly the a form, was found to 
be very unstable on storage. The presence and magnitude of the 
endotherm at 930C was found to be dependent upon preparative conditions 
such as the amount of water. Flocculating the n-heptane solution of 
phenylbutazone by adding water produced a sample with a melting point 
of 950C and was termed the s form (Fig. 3.6). 
The method of Kissinger (1957) was used to calculate the energy of 
activation from maximum peak temperature (Tm) for the transition of B 
polymorph to 6 at different heating rates (0). From the plot of log 
0. 
1 EA I'm 
against Tm- a straight line was obtained with slope equal to 2.303R 
(Fig. 3.7) 
from which the heat of transition of a polymorph was estimated to be 
796.6 KJ]mol which is in close agreement with the figure obtained by 
Muller (1978) (850 KJ]mol). 
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3.2.4.2 Scanning electron microscope 
There were little observed differences in the morphology Of the 
crystal of the different forms from scanning electron photomicrographs. 
All samples were shown to be needle-like with reduced length-to-width 
aspect ratio for the a form(Fig3.7b)- 
3.2.4.3 Powder X-ray diffraction 
The powder X-ray diffraction patterns for the a polymorph and the 
stable form 6 are illustrated in Fig. Ma. Differences can be 
qualitatively characterised by the position of three main peaks in the 
diagram. The small differences between the results obtained and those 
in the literature (Table 3.6) raight be due to the difference in 
packing of the powder bed. 
The differences in X-ray patterns between the polymorphs are due to 
differences in the crystal spacing resulting from differences in 
molecular packing arrangement taking place during crystallisation. 
3.2.4.4 Infrared spectrum 
Only very minor changes at high wavelength regions in the i. r. 
spectra between the different forms were identified. Similar 
observations for the polymorphs of phenylbutazone have been reported by 
Muller (1978) and Ibrahim et al. (1977). 
3.2.4.5 Solubility 
The dynamic solubility of the isolated polymorphs was tested in 
buffer solution of pH 7.5 in a shaking water bath at 370C. There was 
a major difference in the solubility between the metastable ý polymorph 
and the 6 stable form. The 6 form showed an increase in concentration 
in solution with time until a maximum equilibrium concentration was 
reached after 48 hours (see Fig. 3.8). The a form exhibited a faster 
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Fig. 3.7a Powder X-ray diffraction patterns of phenylbutazone 
as supplied and samples spray dried at different 
crystallisation rates. 
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Table 3.6 X. -ray diffraction patterns of the main peaks 
of phenylbutazone 6 and ý polymorphs 
Polymorph 29 Muller 1978 
Found Report 1/10 
8.1 7.9 100 
20.9 20.7 60 
6.95 7.05 9 
8.9 8.35 100 
20.9 20.2 60 
7.1 7.05 40 
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increase in solubility, with a peak solubility value occurring after 
4 hours which was 1.8 fold higher than the maximal solubility shown 
by the stable 6 form. The solubility profile then started to decrease 
with time until the equilibrium concentration exhibited by the 6 form 
was reached after 48 hours. This peaking in solubility is a feature of 
metastable polymorphs Carstensten 1980) which exhibit higher initial 
solubility than the stable form. This is due to higher free energy of 
the metastable polymorphs compared with the stable form . The 
solubility of each form depends on the ability of molecules to escape 
from the crystal to the solvent which is controlled by the free energy 
content of the crystal. The stable form possesses the lower free 
energy at a particular temperature and pressure, and therefore has the 
lower solubility or escaping tendency. However in solution polymorphism 
does not exist ýarstensten 1980), so the solution will be super- 
saturated with respect to the equilibrium dynamic solubility of phenyl- 
butazone. As a result, excess solute molecules crystallise out of 
solution until the solution level of the stable form is reached. 
3.2.4.6 Dissolution rate 
The dissolution ratEsof the polymorphic forms were studied by 
determining their intrinsic dissolution rates using a Woods apparatus 
with constant surface area compressed discs. Since it was reported by 
Ibrahim et al. (1977) and Matsunaga et al. (1976) that polymorphic forms 
show some transition into the stable 6 during compression, a study of 
the thermal behaviour of the compressed metastable $ polymorph powder 
using the D. S. C. was done by compressing a disc of powder and taking 
samples of three parts of that disc (1) the inner face adjacent to the 
surface, (2) the outer face which will be in contact with the 
dissolution medium, (3) from the middle of the compact. The percentage 
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of transition to 6 form taking place during compression, using the 
uncompressed powder as reference was then estimated from D. S. C. 
thermograms. It was found that the transition was higher at the inner 
face of(53%)and decreased towards the outer face in which the transition was 
found to be snall (about 5.3', 12). Since the outer face was that 
exposed during dissolution tests, this transition effect was considered 
small enough to be disregarded for this test. 
Figure 3.9 illustrates the dissolution rate curves obtained. The 
metastable ý polymorph showed a 1.5-fold increase in dissolution rate 
compared with the stable 6 form. As discussed above the metastable 
polymorph is at a higher energy level so molecules are expected to 
be able to leave the tablet surface to the solution more readily than 
the stable form. No peaking value in dissolution rate testing are 
observed because the dissolved amounts were only small fractions of the 
maximum solution levels of phenylbutazone in the dissolution medium. 
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3.3 The effect of crystallisation rate on the polymorphism 
and dissolution rate of spray dried phenylbutazone 
3.3.1 Introduction 
The polymorphism of water insoluble drugs can be used in 
formulations to modify the physicochemical properties of the drugs 
(Muller 1978; Ibrahim'et al. 1977). When preparing polymorphs by 
crystallisation procedure, the nature of the solvent and the rate of 
crystallisation are critically important, with most studies 
concentrating on the former variable (Ibrahim et al. 1977, Muller 
1978). In this study the effect of crystallisation rate on the poly- 
morphism and dissolution rate of spray dried phenylbutazone has been 
examined. 
As mentioned in Chapter 1, phenylbutazone was chosen as a 
model drug because: - 
a) it has low aqueous solubility., 
b) it exists in several polymorphic forms (see Section 3.2). 
c) it is suitable for crystallographic studies using thermal 
analysis techniques and does not decompose after melting. 
Different crystallisation rates using a BUchi mini-spray dryer were 
achieved by varying the inlet temperature, pumping rate, aspiration 
rate and air flow rate. As described in Section. 3.1.2.1 a factorial 
experiment was performed to assess the effect of different levels of 
the four variables on the outlet temperature and thermal behaviour of 
the product which is an indication of the number and type of poly- 
morphs present in the examined sample. 
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3.3.2 Experimental 
3.3.2.1 Materials 
The materials used were listed in Chapter 2, 
3.3.2.2. Method 
T 1he samples prepared under different spray drying conditions (see Table3.1 
were examined by D. S. C., SEM, powder X-ray diffraction, hot stage 
microscopy, and solubility and dissolution rates were measured, all 
according to the methods described in Chapter 2. 
3.3.3 Results and discussion 
It was found earlier in this work that the outlet temperature, 
which corresponds to the drying temperature at the surface of the 
drying particles, is influenced by all four operating variables. For 
fast crystallisation rates, the outlet temperature is therefore high, 
and as the crystallisation rates become slower, the outlet temperature 
drops. From Fig. 3.3 Section 3.1, the effect of outlet temperature on 
the thermal behaviour of the spray-dried samples, represented by the 
number of peaks, can be divided into five regions. For the outlet 
temperature range 780C to 96 0 C, the spray-dried samples exhibited a 
single endothermic peak at 107 0C which corresponds with the endothem 
obtained for the stable 6 form of phenylbutazone. These samples were 
prepared at the highest outlet temperature and the fastest crystall- 
isation rate. 
As the outlet temperature decreased a small shoulder appeared on 
the melting endotherm. This effect was observed for the range of 
outlet temperature from 670C to 780C. As the outlet temperature and 
the crystallisation rate decreased, a second shoulder appeared on the 
endotherm widening the total peak. This effect was noticed for the 
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region of outlet temperature from 62 0C to 66 0 C. 
For the region of outlet temperature from 560C to 61 0C an extra 
discrete endothermic peak appeared at 950C followed by an exothermic 
peak, which corresponds to that previously obtained for the a poly- 
morphic form. For the lowest outlet temperature region of 36 0C to 
560C, two additional endothermic peaks appeared on the thermogram at 
940C and 990C each followed by an exotherm. This suggests the 
presence of at least two polymorphic forms in the sample. 
Four samples from different regions were chosen for further 
investigations (see Table 3.7). 
3.3.4 Characterisation of the samples 
3.3.4.1 Scanning electron microscope 
Figure 3.10 shows scanning electrophotomicrographs of the supplied 
phenylbutazone and the four samples selected for further study. The 
morphology of the spray-dried samples can be seen to be totally 
different from the original supplied phenylbutazone samples with the 
crystal shape changing from needle-like to irregular shapes. For 
sample PS1 branched and large particles were obtained and this 
appearance is attributed to droplet coalescence and rapid drying of 
the particles. As spray drying conditions became less severe the 
particle size of the product gradually became smaller and the 
particle shape became closer to the typical spherical spray-dried 
particles. This is evident in samples PS2, PS3, PS4 (see Fig. 3.10). 
3.3.4.2 Hot stage microscope 
The hot stage microscope was used to observe the changes during 
polymorphic transformation and the melting behaviour of the samples. 
Partial melt inside the crystal was detected for the sample PS3. 
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Table 3.7 Preparation conditions for spray dried 
samples PSl-PS4 
Sample Aspiration Pump Rate Flow Rate 
Rate (m 3 /sec) (ml/min) 
. 
(L/hr) 
Psi 0.01060 16 400 
PS2 0.01000 8 400 
PS3 0.00903 4 600 
PS4 0.01060 16 600 
Inlet temperature 
0c 
145 
125 
100 
100 
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Fig. 3.10 Scanjq I yron microscope photomicrographs 
of samples PSI, PS2, PS3 and PS4 
Psi 
20 Fm 
PS2 
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Fig. 3.10 Scanning electron microscope photomicrographs 
of sanfieg Sýb PS2, PS3 and PS4 
PS4 
20 pM 
,, S3 
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This effect was. noticed at 950C at a heating rate of lo/min. The 
same effect was noticed for sample PS4, but for a wider temperature 
range (95-1000C) possibly -due' to overlapping of the melting of two 
polymorphs.. 
3.3.4.3 Differential scanning calorimetry 
Figure 3.11 shows the D. S. C. thermograms of commercial phenyl- 
butazone (6 form) and the four spray-dried samples. Original phenyl- 
butazone and sample PSI exhibited one single endothermic peak at 107 0 C. ) 
whi lst sample PS2 showed a minor deviation at 950C and small shoulder 
at 103 0C on the endotherm. Sample PS3 gave an extra endothermic peak 
at 95 0C followed by an exotherm at 970C. This indicates the presence 
of a polymorph and corresponds to the ý form. Sample PS4 exhibited 
two extra endothermic peaks at 950C and 990C each followed by an 
exothermic peak at 97 0C and 1010C respectively indicating the presence 
of at least two polymorphs in this sample. Both samples PS3 and'PS4 also 
gave the major endotherm at 1070C as observed in the original phenyl- 
butazone and samples PSI and PS2. Thus the D. S. C. thermograms show 
that at fast crystallisation rates metastable polymorphic forms were 
not formed, and the product has the same thermal behaviour as the 
stable commercial 6 form. As the crystallisation rate decreased the 
number of metastable polymorphics formed increased. 
3.3.4.4 Powder X-ray diffraction 
The powder X-ray diffraction pattern for the stable 6 form of 
phenylbutazone and the four spray dried samples are illustrated in 
Fig. 3.7a. Sample PS4 showed a totally different pattern from 
phenylbutazone 6 form and the $ polymorph with multi peaks at 6.4,10, 
14.6,16,19 and 24 degree of 28. This sample also gave two extra peaks 
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on the D. S. C. thermogram which were thought to indicate the presence 
of two polymorphs. Sample PS3 gave an X-ray diffraction pattern 
similar to that shown by crystallised ý polymorph which also showed 
on the D. S. C. thermogram an extra peak at 950C. For sample PS2 only 
minor differences from the original X-ray pattern for phenylbutazone 
were observed. This sample exhibited a minor difference in the D. S. C. 
thermogram with a small shoulder on the melting endotherm. Sample PSI 
was essentially the same as that observed for phenylbutazone 6 form 
and had a very similar D. S. C. thermogram with a single endotherm at 
1070C. 
3.3.4.5 Solubility 
The dynamic equilibrium solubility of the representative spray 
dried samples was examined in buffer phosphate of pH 7.5 at 37 0 C. 
Peak solubility was observed after 4 hours for all the spray-dried 
samples, followed by lower equilibrium values after 48 hours (see 
Fig. 3.13), and the height of the peak increased as the crystallisation 
rate reduced. This effect is attributed to the presence of polymorphic 
forms which initially showed metastable solubility prior to conversion 
to the stable form in solution. This is supported by the fact that the 
thermal behaviour of the samples observed by D. S. C. showed that as the 
crystallisation rate decreases the number of polymorphic forms present 
increased. The peak solubility figures agree with those reported by 
Matsuda et al. (1984). These workers tested the solubility of the 
spray-dried samples only for 5 hours. Matsuda et al. (1984) claimed 
that this peak values represent the limiting solubility of the samples 
and that the apparent equilibrium solubilities of $ and aforms were 
not affected by time suggesting that they were not converted to 6 form. 
This conclusion opposes the generally accepted mechanism of polymorphic 
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solubilify behaviour, in that the metastable forms exhibit peaking 
solubility followed by conversion to the stable form and associated 
crystallisation from the super-saturated solution to the equilibrium 
solution of the stable form ýarstensten, 1980). 
3.3.4.6 Dissolution rate 
Dissolution rate data were obtained for compressed discs using 
a Woods apparatus to provide constant 
surface area in phosphate buffer pH 7.5 at 370C (Fig. 3.14). 
Increases in dissolution rate over the supplied phenylbutazone were 
observed in the same sequence as that seen for solubility increases, 
i. e. samples PS4>PS3>PS2>PS1. The reason no peaking value was observed 
for dissolution rate data is attributed to the fact that the dissolved 
material had not reached the concentration level required for super- 
saturation with respect to the ý form. 
It is interesting to note that samplepsishowed an increase in 
dissolution as well as peaking effect in solubility curves, whilst the 
D. S. C. thermogram and X-ray diffraction pattern were similar to the 
original phenylbutazone a form. By integrating the area under the 
melting endotherm curve, the latent heat of fusion can bequantified 
It was found that the latent heat of fusion (-see Table 3.8) was 10% 
lower than that for 6 form phenylbutazone. This change might be due 
to the change in particle morphology andjor the presence of some 
amorphous drug after spray drying (Corrigan 1982). 
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Table 3.8 Heat of fusion for phenylbutazone as 
supplied and sample PS1 
Heat of fusion All f 
Sample K3/mol 
Pbz 27.00 
Psi 24.31 
-111- 
3.4 Conclusions 
1. The four spray dryer variables inlet temperature, pump rate, 
aspiration rate and flow rate were all found to contribute in 
controlling the spray dryer performance. Of the four variables 
examined, the inlet temperature and pumping rate had the largest 
effect on particle size and number of polymorphs in the product. 
2. Three polymorphic forms of phenylbutazone were prepared and 
identified6 , the commercially available form, a form which was 
found to be very unstable, and the a form. 
3. Dissolution rate of phenylbutazone e-polymorph exhibited 1.5 
increase in dissolution*rate compared with the original 6-form. 
4. The rate of crystallisation was found to be important in 
influencing the'number of polymorphs present in the spray-dried 
product. As the rate of crystallisation decreased the number of 
polymorphs formed increased. 
5. No degradation of phenylbutazone occurred during spray drying. 
CHAPTER 4 
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CHAPTER 4 
4.1 The effect of H. P. M. C. on the physicochemical properties 
of phenylbutazone. Samples prepared by crystallisation and 
spray drXing 
4.1.1 Introduction 
The use of hydrophilic polymers in the formulation of water 
insoluble drugs to enhance their dissolution rate has been widely 
studied (see Chiou 1969, Simonelli 1969, Gibaldi 1983). There are many 
ways of preparing the drug-polymer complex, including solid dispersion 
(Sekiguchi & Obi 1961),, flocculating from alcoholic solutions (Naggar 
1980) or spray drying (Takenaka et al. 1982). 
Solid dispersions, the most popular technique used to make the 
drug-polymer complex, have been defined by Chiou & Riegelman (1971) as 
dispersion in the particular or molecular state of one or more very 
slightly soluble active ingredients in one or more water soluble inert 
excipient. 
Solid dispersions can be obtained by two major procedures - melting 
or solvent evaporation (Anastasiadou 1982). Sekiguchi & Obi (1961) 
first used solid dispersions prepared by the melt method to increase the 
solubility of sparingly soluble drugs. They proposed the formation of 
eutectic mixture of-a sparingly water soluble drug with hydrophilic 
carrier by melting the physical mixture of the drug and the carrier then 
cooling it to room temperature (Chiou 1969). Gibaldi (1968) showed that 
the magnitude of the increase in dissolution rate was a function of the 
ratio of the carrier to drug in the eutectic-miiture; maximum rates were 
observed for the fusion mixtures containing very high proportions of 
carrier. 
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The solvent method was first reported by Tachibana & Nakamura 
(1965). This consists basically of dissolving the drug and the carrier 
in an organic solvent and evaporating the solvent. Numerous reports 
have subsequently been presented to explain the increase in dissolution 
rate of the treated drugs. Workers have suggested that the increase in 
dissolution rate is due to the decrease in particle size (Gibaldi 1968), 
eutectic mixture formation (Sekiguchi & Obi 1961), presence of glass 
transition (Chiou 1969), or the formation of high energy compounds 
(Simonelli 1969). 
The main disadvantagesof the solid dispersion method are the risk of 
decomposition of the drug and the possible evaporation of the components 
of the product by heat (Anastasiadou 1982). The method of flocculating 
the alcoholic solution of the drug in an aqueous solution of the polymer 
(Chiou 1976, Naggar 1980) was used in this study to reduce any 
possibility of decomposing the drug. This technique is thought to either 
coat each drug crystal with a film of polymer (Simonelli 1969) or create 
a complex with the drug via nucleophilic oxygen which is present in many 
polymers (Martin 1973). 
Spray drying has also been successfully used to prepare microcapsules 
and provide solid particles or liquid droplets with an individual hydro- 
philic coat thereby modifying their physical, chemical or physiological 
characteristics. Speiser et al. (1973) prepared microcapsules of 
barbituric acid by spray polycondensation and Voellmy (1973) prepared 
microcapsules of phenobarbital using a similar technique. ThenTakenaka 
& Kawashima Cl 982) prepared sol id parti cul ates of theophyl 1i ne-ethyl ene- 
diamine complex (aminophylline) by spray drying and Kawashima (1983) 
reported a spray drying technique to prepare a solid particulate 
preparation of an aminopyrine-barbital complex. Takenaka & Kawashima 
(1981) studied the effect of cellulose acetate phthalate and colloidal 
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silica, and other excipients such as talc, on the polymorphism of spray 
dried microencapsulated sulphamethoxazole, while Takenaka. et al. (1980) 
spray dried enteric coated microcapsules of sulphamethoxazole. 
The objectives of this section of the work were: (1) to examine the 
effect of incorporating a hydrophilic polymer H. P. M. C., by crystallis- 
ation and spray drying, in phenylbutazone on the crystallographic 
and physicochemical properties of the resulting materials; and (2) to 
examine the influence of preparation process on the properties of the 
resulting products. 
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4.2 Experimental 
4.2.1 Materials 
The details of the materials used are listed in Chapter 2. 
4.2.2 Methods 
4.2.2.1 Crystallisation 
The polymer was added to the drug by flocculating 100 ml of an 
ethanolic 6% w/v solution of the drug in 100 ml of an aqueous medium 
containing different concentrations of H. P. M. C. ranging from 0.01 to 5% 
w/v H. P. M. C. as reported in Section 2.2.6.2b. The dried crystals were 
crushed gently in a mortar and sieved through a 200pm sieve, then 
stored in a vacuum desiccator over self-indicating silica gel for the 
period of testing. 
4.2.2.2 Spray drying 
The amount of H. P. M. C. needed to produce the required H. P. M. C. 
level was dissolved in the aqueous part of the feed solution. Phenyl- 
butazone was dissolved in absolute alcohol to give a 2% w/v solution. 
The two solutions were mixed and fed into the mini spray dryer operated 
under conditions previously found to produce a a-polymorph of phenyl- 
butazone (i. e. inlet temperature 1000C, pump rate 4 ml/min-, 
aspiration rate 0.00903 m3/sec and flow rate 600 L/hr). 
The materials prepared by crystallisation and spray drying were 
examined using the following techniques - D. S. C., SEM, powder X-ray 
diffraction, solubility and dissolution rates all according to the 
methods described in Chapter 2. 
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4.3 Results and discussion 
4.3.1 Incorporation of H. P. M. C. by direct crystallisation 
H. P. M. C. was chosen in this study as it is a hydrophilic polymer, 
physiologically inert and suitable for human use. Also it is used in 
a wide range of coating formulations in film coating and controlled 
release preparations (e. g. Okhamafe 1983). However, it does not 
appear to have been used previously to prepare solid dispersions with 
water insoluble drugs to modify drug dissolution characteristics. 
Assay of phenylbutazone - H. P. M. C. samples 
An attempt to use HPLC to assay the two components in the phenyl- 
butazone-polymer samples was made, but the procedure was not successful 
due to lack of reproducibility. The assay procedure subsequently used 
was that given in the B. P. (1980) to measure the phenylbutazone content 
in the drug-polymer sample. The untreated supplied drug containing 
99.3% w/v phenylbutazone was used as the standard and other samples 
were related to it. The assay results (see Table 4.1) correspond 
approximately to the concentrations of H. P. M. C. used in the crystall- 
isation liquor. 
4.3.1.2 Differential scanning calorimetU 
The prepared samples were tested by D. S. C. using aluminium crimped 
pans with pierced lids at a heating rate of IOOC/min under a flow of 
nitrogen gas of 10 mljmin. The D. S. C. thermogram of phenylbutazone 
(Fig. 4.1) crystallised without polymer exhibited-a single endothermic 
peak at 1070C, which corresponds to that of the untreated phenyl- 
butazone. For the sample prepared from 0.01% w/v H. P. M. C. solution 
there is an extra small endothermic peak at 970C in addition to the 
endotherm at 1070C. The area of the new peak at 970C increased with 
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Table 4.1 Assay ýesUlts of phenylbutazone and samples 
crystallised with H. P. M. C. containing solutions 
Sample Concentration of HPMC % w/w of phenylbutazone Estimated 
Code (% w/v in final in product % w/w of HPMC 
crystallisation solvent) in samples 
PH 0.0 99.30 0.00 
PHRI 0.01 99.25 0.05 
PHR2 0.1 99.10 0.20 
PHR3 1.0 98.21 1.09 
PHR4 2.0 97.10 2.20 
PHR5 5.0 93.50 5.80 
* Figures represent the arithmetic mean of three results 
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increasing H. P. M. C. concentration. Concurrent with the increase in 
the new peak at 970C, the original endotherm at 1070C diminished up to 
H. P. M. C. concentration of appr6ximately 2% w/w (see Fig. 4.1) when the 
endotherm at 1070C is completely absent. The peak at 970C is not 
thought to be due to polymorphic transitions as: - 
(a) the D. S. C. thermogram showed no exotherm between the two 
endothermic peaks at 970C and 1070C even when scanned at 
lower rates. If the endotherm was due to a polymorphic 
transition an exothermic peak after the 970C endotherm 
due to liquid recrystallisation would be expected. 
(b) for sample PHR4 the peak at 1070C was completely 
absent. If it was due to a polymorphic transition the 
endotherm at 1070C should be present. 
(c) no peaking values were observed in the dynamic solubility 
curves of the samples. 
Previous data (Section 3.2 P. 94 ) showed the existance 
of peaking values in the dynamic solubility curves of 
polymorphic materials. 
Table 4.2 shows the latent heat of fusion for the integrated 
endothermic peaks at 970C and 1070C for all the samples. The latent 
heat of fusion at 970C for sample PHR4 was 15% lower-'than that for 
phenylbutazone without H. P. M. C. 
This, together with the 100C shift in melting point, suggests the 
formation of a complex between the drug and the polymer possibly by 
hydrogen bonding9which could be called a 'high energy complex' 
(Simonelli et al. 19691, The major change in latent heat of fusion 
for the 1070C endotherm occurred'between samples PHRI and PHR2j 
whilst the major change in dissolution rate took place at the 1.09% 
vi/w polymer level (see Fig. 4.4) 
. 
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Table 4.2 The latent heat of fusion (AH ) of the two 
endothemic'peaks at 970 and 1070C'on the D. S. C. 
endotherm of phenyl butazone and crystal Ii sed sampl e 
containing H. P. M. C. 
Sample Concentration of HPMC ' &Hffor original AHffor new endotherm 
Code Estimated (-% w/w) of OC endotherm at 107 at 970C 
HPMC in samples (. KJJmol (KJJmol) 
PbZ 0.00 27.00 0.00 
PHR1 0.05 26.60 0.32 
PHR2 0.20 9.71 18.90 
PHR3 1.09 4.90 20.90 
PHR4 2.20 0.00 23.30 
PHR5 5.80 0.18 22.30 
I 
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Fi(l. 4.2 Scanning electýpjj npicroscope photomicroaraphs 
of samples PHRI, PHR2, PHR3, PHR4 and PHR5 
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Fig. 4.2 Scannýnq electron microscope photomicrographs 
Ig 4.2 
of samples PHR1, PHR2, PHR3, PHR4 and PHR5 
phenylbutazone crystallised with HPMC 
PHR 
--4 
20 PM 
PHR 5 
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This might suggest that the change in dissolution rate was not 
primarily due to the change in crystal energy associated with-the shift 
in melting point from 1070C to 970C. Higher percentages of H. P. M. C. 
may be required to facilitate wetting of drug crystal surface prior to 
dissolution. 
4.3.1.3 Scanning electron microscope 
Samples were examined with the SEM for any change in particle 
I 
morphology. The scanning electrophotomicrographs (Fig-4.2 ) indicate 
that the crystals retain their needle-like appearance, but the crystal 
length is reduced as the polymer concentration is increased. This 
observation is in agreement with Simonelli (. 1970) who reported that 
the rate of crystal growth is controlled by the polymer concentration. 
As the polymer concentration is raised the inhibition of crystal 
growth is increased. The observed decrease in crystal size is not 
thought to have influenced the increase in dissolution rate as 
postulated by Gibaldi (1968). This is because the decrease in crystal 
size increases with rising H. P. M. C. concentration whilst maximum 
increase in dissolution rate occurs at the 2.2% w/w H. P. M. C. level rather 
than the highest H. P. M. C. level studied, although other factors, such 
as changing viscosity of the diffusing layer, may be affecting observed 
dissolution rates. 
4.3.1.4 Powder X-ray diffraction 
Powder X-ray patterns were obtained (fig. 4.3) by irradiating 
I 
beds of the powder samples with a beam of Y-ray radiations using a 
diffractometer. All the crystallised samples containing H. P. M. C. 
showed peaks in the trace of 29 versus IjIo indicating that the 
samples had some degree of crystallinity and were not amorphous. The 
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X-ray pattern for H. P. M. C. powder alone was obtained to establish that 
there were no peaks in the absorbing region for phenylbutazone. All 
the samples showed the same X-ray pattern except for the sample 
prepared from 0.01% w/v H. P. M. C. which was very similar to that of the 
original phenylbutazone. The major difference occurred in the region 
of 20 between 16 and 240 Csee Fig. 4.3) in which the main peak at 220 
had reduced in size and divided into two peaks with the new peak at 28 
of 180. Small changes in the minor peaks could be attributed to the 
difference in packing during powder bed preparation. 
However the X-ray diffraction traces indicate that all the samples 
are crystalline and not amorphous. The change in X-ray pattern, 
especially the peak at 29 of 180, might be due to the presence of a 
phenylbutazone-H. P. M. C. complex. 
4.3.1.5 Solubility 
The results of the solubility experiments are listed in Appendix 2, Table 
11. The equilibrium dynamic solubility was measured using a shaking 
water bath at 370C in phosphate buffer. There was a small increase of 
1.2 fold in dynamic solubility for sample PHR4 compared with the original 
phenylbutazone with successive smaller increases in dynamic solubility 
with decreaS4ng concentration of H. P. M. C. in the samples (see Table 4.3). 
The increase in solubility is attributed to the presence of high*energy, 
compounds in which phenylbutazone molecules require less energy to 
escape from the crystal' lattice to go into solution than for those at 
lower energy levels. 
4.3.1.6 Dissolution rate 
Results from the dissolution rate experiments are listed in 
Appendix 2, Table 1-5 . The dissolution rate for the samples was 
examined using Wood's apparatus in phosphate buffer. There was an 
increase in dissolution rate for samples crystallised with H. P. M. C. 
TEXT CUT 
OFF IN 
ORIGINAL 
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Fig. 4.3 Powder X-ray diffraction patterns of phenylbutazone 
alone and samples crystallised from H. P. M. C. solutions. 
Original P 
P 
PHRI 
29 
PHF 
PHI 
vv 
30 24 16 10 
2e 
30 24 16 10 4 
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Table 4.3 The dynamic equilibrium solubility and intrinsic, 
. 
dissolution rate constant, 
and samples crystallised from solutions 
containing different concentrations of H. P. M. C. 
Sampl e 
Sample Estimated % w/w of Solubility 2 i / m code H. P. M. C. in samples (mgm/100 ml) (mg/m n c 
PbZ 0.00 390 0.188 
PHR1 0.05 400 0.250 
PHR2 0.20 410 0.270 
PHR3 1.09 430 0.290 
PHR4 2.20 450 0.360 
PHR5 5.80 440 0.410 
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compared with phenylbutazone alone (see Fig-4.4 ). Maximum increases 
occurred for sample PHR4, which contained 2.2% w/w H. P. M. C. Whilst 
samples prepared from the 5% w/v H. P. M. C. solution w-ere shovin in 
Section 4.3.1.2 to be composed completely of the hich Pnergy 
material, a decrease in dissolution rate is observed at this polymer 
level. This can be attributed to the polymer content in the sample 
reaching a limiting concentration such that the diffusion coefficient 
of the dissoluting tablet is modified which reduces the dissolution 
rate (Florence & Attwood, 1981). Alternatively, the polymer might 
modify the bulk viscosity of the dissolution medium reducing the 
dissolution rate (Braun & Parrott 1972, Kellaway & Najib 1983). 
However, when the amounts of V. P. M. C. dissolved in the dissolution media 
are calculated,, the effect of bUlk viscosity can be regarded as minimal. 
The mechanism by which hydrophilic polymers work to increase 
dissolution rate is not well understood 
but one possibility is that they reduce the hydrophobic barrier at the 
surface of the tablet by lowering the surface tension of the tablet 
which results in better wetting of the powder. Simonelli (1969) 
proposed that the polymer can act to improve the dissolution rate. He 
suggested that the dissolution of a complex can occur either by 
dissolving the intact complex in the dissolution medium with the drug 
then released from the complex, or by dissolving the bound drug from 
the surface by solvent interaction. 
The increase in dissolution rate of phenylbutazone crystallised with 
H. P. M. C. is attributed to the formation of a high energy drug: polymer 
complex via hydrogen bonding. Thus the drug molecules require less 
energy to dissolve and the presence of the hydrophilic polymer could 
facilitate wetting. Simonelli'(1969) suggested that coprecipitated 
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sulphathiazole-polyvinylpyrrolidone formed high energy compounds. 
These high energy compounds were shown to be amorphous compounds due 
to distribution of the drug in a very fine crystal form through the 
drug: polymer complex. For phenylbutazone-H. P. M. C. complex the 
situation appears to be different. 
Compounds melting 100C lower than the parent drug are formed and 
an increase in dissolution is associated with their presence, but they 
are crystalline in nature (. see Fig. 4.3). However, a crystallographic 
change took place during crystallisation with the polymer as the 
compounds exhibited different X-ray diffraction patterns from the 
original 6 form of phenylbutazone. All the samples containing H. P. M. C. 
exhibited the same X-ray diffraction pattern except for the sample at 
the lowest H. P. M. C. concentration. 
If it is assumed that the complex is created by hydrogen bonding 
only and that a single hydrogen bond is created between one phenyl- 
butazone molecule and one repeating unit in the H. P. M. C. polymer chain, 
then the mole fraction of each component in the complex would be 50% 
when maximally bonded and totally formed. The mole fractions of the 
components can be calculated accordirr_to the following equations: - 
n, 
nl+n2 
4.1 
X2 n2 - 4.2 
n1 +n2 
where X, the mole fraction of constituent 1 
x the mole fraction of constituent 2 
and n, and n2 are the number of moles of the constituent I and 2. 
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At 2.2% w/w H. P. M. C. concentration, when the 6 form appears to be 
completely lost, the mole fractions of the components of the product are: - 
moles of H. p. M. c. repeating unit = 
2.2 
- 0.008302 
moles of phenylbutazone = 
97.1 0.314851 TOT7. 
mole fraction of H. P. M. C. per 
repeating unit 
0.008302 0.0257 0.008302+UY4--851 
2.57% 
mole fraction of phenylbutazone = 
0.3 
- 
14851 0.97431 000302-ý0314851 
= 97.43% 
The calculated fraction of H. P. M. C. required to cause the original 6 
form to be absent in the product is thus approximately twenty times 
smaller than the theoretical amount of 50%. The resulting structure 
would also be amorphous since periodicity of the phenylbutazone would 
be totally absent. Thus, since crystallinity is observed and much 
lower percentages of H. P. M. C. are required, additional interactions 
Must be contributing to the proposed complex structuring. 
It is also possible that the H. P. M. C. interferes within the 
arrangement of the phenylbutazone molecules in the lattice changing 
the angles of the crystals causing alteration of some phenylbutazone 
patterns e. g. the appearance of new peak on the X-ray diffraction 
pattern of 2 Bat 180. 
4.3.2 Incorporation of H. P. M. C. by spray drying 
It was mentioned previously that when phenylbutazone was 
crystallised in the presence of H. P. M. C., a complex was formed. This 
crystalline complex was demonstrated to exist at a higher energy level 
than 6 form phenylbutazone. Following on from this study it was of 
interest to examine whether phenylbutazone-H. P. M. C. complexes formed 
during spray drying which by comparison involves Yery rapid 
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crystallisation rates. 
The operating conditions chosen for spray drying were those which 
produced a B-polymorph of phenylbutazone. Additional factors involved 
in selecting these conditions were: - 
(a) the product obtained by spray drying under these conditions 
was of uniform particle size, 
(b) the shape of the particles was the closest to the typical 
spherical spray-dried particles - observed in preliminary 
studies, 
(c) these conditions produced a single polymorphic form, i. e. 
a-polymorph. Thus the effect of H. P. M. C. on the poly- 
morphism of phenylbutazone during spray drying, could 
readily be monitored. 
The product was assayed for phenylbutazone content in the drug: 
polymer samples using the procedure given in the B. P. (1980). The 
untreated supplied drug containing 99.3% w/w-phenylbutazone was used 
as the standard and other samples were related to it. The assay 
results (see Table 4.4) indicate that the concentrations of H. P. M. C. 
in the products correspond closely to the amounts used in the feed 
solution to the spray dryer. 
4.3.2.1 Differential scanning calorimetry 
The D. S. C. thermograms of the products (see Fig. 4.5) were obtained 
by heating the samples in aluminium crimped pans with pierced lids, 
under nitrogen atmosphere, over the temperature range of 30-1300C at a 
heating rate of 100CJmin. For a sample of phenylbutazone spray dried 
alone, the thermogram exhibited an endothermic peak at 950C which 
corresponds to the B-polymorph, followed immediately by an exotherm 
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Table 4.4 Assay results of phenylbutazone and samples 
spray'dried with H. P. M. C. containing s6lutions 
Sample Concentration of HPMC % w/w of phenylbutazone Estimated 
Code (% w/w) in the feed in product % wjw of HPMC 
in samples 
PbZ 0.0 99.30 0.00 
PHSI 0.01 99.30 0.00 
PHS2 0.1 99.21 0.09 
PHS3 1.0 98.20 1.10 
PHS4 2.0 97.40 1.90 
PHS5 5.0 94.51 4.79 
Figures represent the arithmetic mean of three results 
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and the original phenylbutazone endotherm at 1070C (see Section 3.3 
page105). Samples PHS1 and PHS2, containing the lowest two levels of 
H. P. M. C., exhibited the same thermograms as phenylbutazone spray dried 
alone, and no change was noticed on the D. S. C. thermogram. 
For sample PHS3 in addition to the a-polymorph endotherm and 
exotherm, a small shoulder appeared at 1020C on the main melting 
endotherm. This shoulder became more distinct with increasing H. P. M. C. 
conceniration until at the 4.79', ol w/w H. P. M. C. level (sample PHS5) it 
predominated over the endotherm at 1070C. Associated with the increase 
in shoulder at 1020C was a decrease in the endothem at 95 OC. 
The presence of H. P. M. C. during the spray drying thus appears to 
have a two-fold effect on the thermogram. First, an extra and new 
endotherm starts to appear at 1020C which, for sample PHS5 dominates 
over the endotherm at 1070C. Second, H. P. M. C. appears to mask the 
formation of a-polymorph with the reduction in the endotherm at 95 oc 
as the concentration of H. P. M. C. increases above 1% w/w. This latter 
observation is in contrast to that of Takenaka et al. (1981) who 
reported that spray drying sulphamethoxazole with cellulose acetate 
increased the polymorphism of sulphamethoxazole. 
The endotherm at 1020C is thought to represent the melting of a 
drug: polymer complex as the X-ray diffraction pattern for these 
samples exhibited the new peak of 29 at 180 which was shown by the 
complex prepared by conventional crystallisation (see Section 4-3) 
The difference in melting point and therefore structure of the complex 
prepared by spray drying compared with that obtained previously might 
be due to differences in preparation conditions, especially the rate 
of crystallisation, 
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4.3.2.2 Scanning electron microscope 
Since all the samples were spray dried under the same conditions, 
samples were expected to have the same morphological shape and 
appearance. This was in fact observed and little change was noticed in 
the morphology of the product particles (see Fig-4.6 ). 
4.3.2.3 Powder X-ray diffraction 
Powder X..! ray diffraction data for the samples showed that samples 
PHS1, PHs2 and PHS3 containing approximately 0.01%, 0.1% and 1% w1w 
H. P. M. C. gave the same X-ray diffraction pattern, which was very 
similar to that shown by the phenylbutazone spray dried alone, i. e. 
s-polymorph, with an additional new peak in the region of 29 at 180. 
This peak was considered to be associated with the formation of a 
complex between the drug and the polymer (see Fig. 4.7 ) and be 
consistent with the interpretation of D. S. C. thermograms in Section 
4.3.2.1. 
For higher concentrations of H. P. M. C. the patterns changed, 
particularly in the area of 29 between 24 and 300. The peak at 240 
decreased in size with increasing H. P. M. C. concentrations. Also the 
minor peaks in the area between 25-300 diminished with increasing 
H. P. M. C. concentration. These observations support the suggestion 
that H. P. M. C. above 1% w/w concentration masked the formation of 
ý-polymorph of phenylbutazone on spray drying. 
The modified X-ray diffraction patterns also indicated that all 
the samples were crystalline in nature. Takenaka et al. (1981) 
reported that the reduced intensities of the Y-ray diffraction 
patterns of the products with a high cellulose acetate phthalate 
concentration indicated increased amorphous nature. This is in 
contrast to the H. P. M. C.: phenylbutazone products as the intensity of 
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Fig. 4.6 Scanning electron microoraphs of samples PHS1, 
PHS2, PHS3, ýWAark PHS5 
phenylbutazone spray dried with HPMC 
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Fig. 4.6 Scanninq electron micrographs of samples PHS1, 
PHS2, PHS3, PHS4 and PHS5 
phenylbutazone spray dried with HPMC 
PHS4 
0 20 pM 
PHS5 
Fig. 4.7 The powder X-ray diffraction patterns of phenylbutazone alone 
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all the peaks below 29 of 240 remained the same with only the minor 
peaks above 24 0 reduced in intensity with increasing H. P. M. C. 
concentration. 
4.3.2.4 Solubility 
The resultsof solubility experiments are listed in Appendix 2 
Tabl e'l 2. 
The dynamic solubility of the samples was measured by placing 
excess of the powder in contact with buffer in a shaking water bath, 
as described in Chapter 2. As discussed in Chapter 3 
polymorphic materials can be assigned two solubility values, peaking 
and equilibrium values. 
Only small increases in maximal equilibrium solubility were 
observed for samples containing H. P. M. C. (see Table 4.5). An 
interesting change, however, -occurred in the peaking solubility values. 
The spray-dried phenylbutazonewithout H. P. M. C. exhibited a peaking 
solubility value after 4 hours whilst for samples containing H. P. M. C. 
the time to reach peaking value was delayed and was achieved after 8 
hours. 
This observation is in agreement with Simonelli (1969) who 
suggested that the presence of polymer delays the conversion of 
metastable polymorph to the stable form. In addition the value of the 
peaking solubility decreased with increasing H. P. M. C. concentration in 
the samples, supporting the conclusion obtained from the D. S. C. 
thermograms that the presence of H. P. M. C. masks the formation of 
0-polymorph. The peaking value, which demonstrates the solubility of 
the metastable form, was reduced. Also the reduction in peaking value 
gives some support to the suggestion-that the endotherm at 1020C on 
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Table 4.5 The dynamic peakinq and equilibrium solubility, and 
intrinsic dissolution rate constant, ý', of phenyl- 
butazone and samples spray dried with solution 
containing different concentrations of H. P. M. C. 
Sample Estimated % w/w of Solubility (mgm/100ml) ,2 
Code H. P. M. C. in sample Peak Equilibrium (mg/min/cm 
PbZ 0.00 580 385 0.27 
PHS1 0.00 560 400 0.28 
PHS2 0.09 550 410 0.29 
PHS3 1.10 540 415 0.33 
PHS4 1.90 520 440 0.35 
PHS5 4.79 500 435 0.37 
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the D. S. C. thermogram is not due to a pQlymorphic transition, but is 
associated with a phenylbutazone: H. P. M. C. complex. 
The enthalpies of solution of the spray dried phenylbutazone-InIC sample 
were estimated by determining the dynamic equilibrium solubility of 
the samples at different temperatures, applying equation (2.3), and 
plotting log solubility against T. Typical Vadt Hoff plots (see 
Fig. 4-8,4.9)gave linear graphs. Enthalpies of solution, AHS, were then 
calculated from the slopes (see Table 4.6). The endothermic enthalpy 
of solution (, &Hs) decreased with increasing H. P. M. C. concentration, 
which is an indication that the samples containing higher H. P. M. C. 
concentrations require less energy input to dissolve and are therefore 
less ordered. Also the fact that the endothermic value of enthalpy 
for the spray dried samples are less than those for samples 
recrystallised with H. P. M. C. (see Table 4.6) is an indication 
that the systems prepared by spray drying are generally, less ordered 
than those made by conventional -crystallisation. This is partly 
expected since the a-polymorphic form is present in the spray dried 
sampl'es. 
4.3.2.5 Dissolution rate 
The results of the dissolution rate experiments are listed in 
Appendix 2, Table 6-10. 
The dissolution ratesof the spray dried phenylbutazone with 
H. P. M. C. were determflned using Wood's apparatus in buffer solution at 
370C and sampling intervals of 30 minutes. It was shown previously 
(see Section 4.21 that when phenylbutazone was crystallised from a 
2% w/v H. P. M. C. solution, the dissolution rate of the product was 
doubled Csee Fig. 4.10and Table 4.3). This was explained by the 
formation of a high energy complex between the drug and the polymers 
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phenylbutazone crystallised with HPMC 
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Fig. 4.8 Van't Hoff plots of the solubilities of the different 
forms of phenylbutazone alone and samples crystallised 
from solutions containing different concentrations of 
H. P. M. C. 
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0 
Table 4.6 The enthalpý of solution (AHJ for phenylbutazone 
'a 
drysWlised and spray dried'alon&, 'and samples 
containing H. P. M. C. prepared by crystallisation 
and spray drying 
Sample AH (Jjmol)of Sample &H (Jjmol)of spray 
Code cryitallised samples Code drIed samples 
PbZ 14.36 PbZ 12.46 
PHR1 13.88 PHSI 11.96 
PHR2 13.40 PHS2 11.00 
PHR3 12.45 PHS3 10.53 
PHR4 11.45 PHS4 9.85 
PHR5 11.4 PHS5 9.80 
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the presence of the hydrophilic polymer also facilitating wetting. 
When phenylbutazone was spray dried from solutions containing the 
same concentrations of H. P. M. C. the optimal increase in dissolution 
rate was similar to that achieved by samples prepared by conventional 
crystallisation with approximately 2% w/w H. P. M. C. level exhibiting 
the highest dissolution rate. But for samples containing lower 
concentrations of H. P. M. C. the dissolution rate for equivalent 
samples prepared by spray drying was higher than for samples prepared 
by conventional crystallisation due to the presence of $-polymorph in 
the spray-dried samples. The similarity in dissolution for samples 
containing higher levels of H. P. M. C. adds support to the proposed 
mechanisms of effect of the polymer in that increases in dissolution 
rate can be attributed not only to the formation of high energy 
compounds, but also to the fact that the complexes or the presence of 
H. P. M. C., lowers the surface tension of the dissolving tablet, 
resulting in better wetting of the crystal surfaces. For sample PHS5 
the dissolution rate was reduced as a result of changing the 
dissolution conditions either by modifying the diffusion coefficient 
at the surface of the dissolving tablet (Florence & Attwood 1981) or 
by increasing the bulk viscosity of the medium (Kellaway & Najib, 1983). 
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4.4 Conclusions 
1. Phenylbutazone samples were prepared by conventional crystall- 
isation and spray drying to contain H. P. M. C., which resulted in 
changes in the physicochemical and crystallographic properties of 
the drug. 
2. Analysis of data from D. S. C. and X-ray diffraction indicated 
that a crystalline complex formed between the drug and H. P. M. C. in 
crystallised samples, the complex exhibiting a 10 0C lowering of melting 
point than the parent drua and producing an extra peak on the powder 
X-ray diffraction pattern of 29 at 180 compared with phenylbutazone. 
The drug: polymer complex produced a two-fold increase. in dissolution 
rate which optimised at approximately 2% w/w H. P. M. C. level. 
3. Spray-dried samples, prepared under conditions to form the ý-polymorph, 
similarly demonstrated the formation of a complex between drug and 
H. P. M. C. with a melting point of 1020C and an increase in dissolution 
rate of 100% was observed for samples containing 2% wjw H. P. M. C. The 
presence of H. P. M. C. also appeared to inhibit the formation of the 
0-polymorph. 
4. The endothermic enthalpy of solution (AH s) was 
found to be higher 
for the crystallised materials than the spray-dried indicating that 
the state of crystallographic order in two series of compounds was 
different with the spray-dried samples showing greater crystallographic 
disorder. 
CHAPTER 5 
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CHAPTER 5 The effect of Poloxamer on the 
physicbchemical properties of phenylbutazone 
prepared by crystallisation and spray drying 
5.1 Introduction 
The activity and physiological properties of water insoluble drugs 
can be modified by increasing their solubility and dissolution rate. 
Many trials have attempted to add a hydrophilic material to the 
formulation to increase its hydrophilicity. Materials, which include 
hydrophilic polymers (Simonelli et al. 1976) (see Chapter 4) and 
surfactants (Naggar et al. 1980, Elworthy & Lipscomb 1968) which are 
often referred to as surface active agents, are in general compounds 
which whilst soluble in a given liquid, tend to accumulate or be 
positively adsorbed at interfaces with air,, another liquid, or a solid 
(Dittert 1974). The use of surfactants as solubilising agents to 
increase the solubility of sparingly water soluble drugs has been the 
subject of many studies in the last century (Attwood & Florence 1983). 
Surfactants are thought to affect the dissolution rate of water 
insoluble drugs. One hypothesis states that by lowering the inter- 
facial energy barrier between the drug and the dissolution medium, the 
drug is more readily wetted (Weintraub & Gibaldi 1969). This can take 
place by replacing the solid-air interface by a solid-liquid interface 
thereby increasing the available surface area for micellisation. Two 
factors should be considered when predicting the effect of the 
surfactant on the solid-liquid interface - the nature of the charge on 
the solid and the surfactant ion adsorbed by Van der Waal's forces. 
Thus when the surfactant is adsorbed to a non-polar solid, the 
surfactant is orientated with the hydrophilic group towards the aqueous 
solution thereby increasing the wettability. However when adsorption 
-149- 
takes place by charge interaction between the surfactant and the solid, 
e. g. by ion-exchange or ion-pairing, the surfactant will orient with 
the hydrophobic group toward the solution making it less wettable 
(Attwood & Florence 1981, Swarbrick 1965). 
Another mechanism by which surfactants influence the solubility of 
water insoluble drugs is by micellisation. Micelles are aggregates of 
surfactant-molecules in the bulk of the solution. These aggregates 
form when the surfactant molecules in the solution are in excess 
concentration to that required to form a closely packed monolayer at 
the water-air interface. The surfactant molecules are not accommodated 
in the monolayer and aggregate to form micelles, which can be of 
various structures especially spherical (. Dittert 1974). The lowest 
concentration at which micelles first appear is called the critical 
micelle concentration (CMC). The micelles are thought to form with the 
hydrocarbon portion inside the core (hydrophobic) and the hydrophilic 
portion towards the solvent. In the mechanism of entrapment of water 
insoluble drug molecules, the surfactant molecules accumulate in the 
interfaces between water and the drug. Then the hydrocarbon chains 
penetrate the interface to form weak bonds (adsorption) with the drug 
molecule and other surfactant molecules accumulate around the drug 
molecule to form micelles. This results in a marked increase in the 
apparent solubility of the drug in the medium thereby increasing the 
dissolution rate. 
Most studies in this field have explained the influence of 
surfactant on dissolution rate by micellisation mechanisms. Schott 
et al. (1982) found that when octoxynol was added to the dissolution 
medium an increase in dissolution rate of prednisolone tablets was 
obtained, which was attributed to micellar solubilisation. Tusti et al. 
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(1982) also attributed the increase in dissolution rate of a-lactam 
antibiotics to drug-micelle complexes. Rees & Scott (1974) studied 
the solubility of salicylic acid in micellar solutions of polysorbate 
20. All these workers used concentrations of surfactant above CMC and 
observed increases in solubility and dissolution rate were explained by 
micellar solubilisation. 
Other workers have used concentrations of surfactants below CMC. 
Weintraub & Gibaldi (1969) studied the effect of premicellar surfactant 
concentration in the dissolution medium on the dissolution rate of 
aspirin tablets and observed a significant increase in dissolution 
rate. This effect, attributed to wetting, was found to increase as the 
concentration of the surfactant approached CMC. Taylor & Wurster (1965) 
found a significant increase in solubility and dissolution rate of 
prednisolone in sodium lauryl sulphate solutions, related to co-operative 
phenomena which facilitated the dissolution rate. 
Several studies have examined the effect of the presence of 
surfactant by incorporating surfactant molecules into the drug crystals 
by recrystallising the poorly water soluble drug in an aqueous 
surfactant solution. Chiou et al. (1976) and Naggar et al. (1980), 
using this procedure, obtained an increase in dissolution rate, whilst 
increases were very small. The increases in dissolution rate were 
explained by lowering of the interfacial tension by the incorporated 
surfactant molecules which facilitated wetting. Levy & Gumtow (1963) 
used surfactants to counter the hydrophobic effect of tablet lubricants, 
such as magnesium stearate and a significant increase in dissolution 
rate was noticed. 
Spray drying has also been used to incorporate surfactants into 
hydrophobic drugs CMatsuda et'al. 19821. 
-151- 
This chapter reports a study of the physicochemical and 
dissolution properties of phenylbutazone samples prepared by 
conventional crystallisation and spray drying to contain different 
concentrations of non-ionic surfactants to examine the effects of the 
incorporated surfactant molecules. Since similar concentrations of 
surfactant (0.01%-5% wb-i) and preparation techniques are used compared 
with those for H. P. M. C. in Chapter 4, a comparison between surfactant 
and hydrophilic polymer effects can be made. For this purpose an 
interesting class of non-ionic polyoxyethylene-polyoxypropylene block 
co-polymeric surfactants, or poloxamers, sold under the trade name of 
Pluronic were used. 
The ability of the poloxaners to form micelles still remains 
the source of debate in the literature (Attwood & Florence 1983, 
Prasad et al. 1979). Mankowich (1954) concluded from light-scattering 
studies that polyoxyethylene co-polymer does not form micelles and 
Dwiggins et al. (1960) reached the same conclusion using ultra- 
centrifugation technique. Bell (1959) similarly reported that these 
co-polymer do not form micelles. However, Becher (1959) was the first 
to propose that ethylene oxide can form a CMC. Ross & Oliver (1959). 
when exami ni ng pol oxamer 182 , cal cul ated the CMC to be 2.4%, whi 1 st 
Sckmolka & Raymod (1965) reported a CMC of 0.0014% for the co-polymer 
of lowest HLB and 0.0037% for that of highest HLB. The discrepancy 
between workers concerning the existance and value of CMC's can be 
attributed to the different techniques used to prepare and assess the 
materials. 
The objective of this study was to examine the effect of 
incorporating pol. oxamers on the physicochemical properties of phenyl- 
butazone in particular the crystallographic structure, solubility and 
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dissolution rate. Since the technique of incorporating the poloxamer 
into the drug crystals was thought to have an effect on the products, 
the samples were prepared by both conventional crystallisation and 
spray-drying techniques. The spray-drying conditions employed have 
been shown in Chapter 3 Section 1 to produce the s-polymorph of phenyl- 
butazone and thus it was also of interest to study the effect of 
poloxamer surfactant on the formation of the a-polymorph of phenyl- 
butazone. 
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5.2 Experimental 
5.2.1 Materials 
Poloxamer 188 was used to study the influence of surfactant on 
the solubility and dissolution rate of phenylbutazone. Polox. amers 
338,188,184,181 and 101 were used to study the effect of changing 
the surfactant chain length on dissolution rate. All the poloxamers 
were used as received. The other materials used are listed in Chapter 2. 
5.2.2 Method 
5.2.2.1 Crystallisation 
The crystals were prepared by flocculating a solution of phenyl- 
butazone (6 gms) in 100 mls of absolute alcohol, with 100 mls of 
distilled water containing the required surfactant concentration. The 
resulting crystals were dried in a vacuum desiccator over silica gel 
for 72 hours. The dried crystals were gently triturated in a mortar 
then sieved through a 20OPm sieve and kept in the vacuum desiccator 
over silica gel over the period of testing. 
5.2.2.2 Spray drying 
The feed solution was prepared by dissolving phenylbutazone and 
the required poloxamer- concentrations (0.01-5% w/w) with respect to 
the amount of phenylbutazone, in aqueous alcohol (75% w/v) solvent, 
and spray dried as mentioned in Chapter 3 Section 3. using conditions 
which gave ý-polymorph of phenylbutazone when spray dried alone (as 
for sample PS3). 
The resulting samples were tested by D. S. C., powder X-ray 
diffraction, SEM and for solubility and dissolution rate, all according 
to the methods described in Chapter 2. 
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Table 5.1 The assay results of phenylbutazone samples 
recrystallised with noloxamer 188 
1 
Sample Concentration of HPMC % w/wt of phenyl- Estimated % w/w 
Code (% w/v) in final butazone in Poloxamer 188 
crystallisation solvent product in product 
PbZ 0.00 99.30 0.00 
PPRl 0.01 99.29 0.01 
PPR2 0.1 99.21 0.09 
PPR3 1 98.24 1.06 
PPR4 2 97.30 2.00 
PPR5 5 93.56 5.74 
Figures represent the arithmetic mean of 
at least three determinations. 
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Fia. 5.1 Scanning electwon. photomicrographs of samples 
PPRI, PPR2, PPR3, PPR4 and PPR5 
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Fig. 5.1 Scanning electron photomicrographs of samples 
PPR1, 
W, WR3, PPR4 and PPR5 
phenylbutazone crystallised with poloxamer 
-p 
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5.3 Results and discussion 
5.3.1 Incorporating surfactant by*direct crystallisation 
5.3.1 .1 Assay of the samples 
It was mentioned in Section 4.4, that it proved difficult 
to estimate the amount of H. P. M. C. present in the samples directly, 
and H. P. M. C. concentrations were calculated by difference after 
assaying the amount of phenylbutazone content of samples using the 
B. P. (1980) assay. The same procedure was used to determine the 
amount of poloxamer 188 in the samples (see Table 5.1). The assay 
results show that the uptake of poloxamer by the drug was similar 
to the concentration present in the crystallisation medium with the' 
exception of the 5Z w1v level, where a higher concentration appeared 
to be taken up by the sample PPR5. This might be due to preferential 
and enhanced adsorption at higher concentration levels of poloxamer. 
5.3.1.2 Scanning electron microscope 
Microphotographs of the crystallised phenylbutazone from 
poloxamer 188 solutions (see Fig. 5.1) indicate that whilst slight 
thinning of the crystals needles can be seen, no major change occurred 
in the morphology of the crystals when compared with recrystallised 
phenylbutazone. 
5.3.1.3 Differential scanninq calorimetrv 
The thermograms of the samples of, phenylbutazone crystallised in 
the presence of poloxamer 188 were obtained by D. S. C. using crimped 
aluminium pans with pierced lids under nitrogen flow. All the samples 
exhibited a single endothermic peak at 1070C (see Fig. 5-2). This 
suggests the presence of surfactant during the crystallisation process 
did not result in different polymorphic forms or complex formation. 
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Table 5.2 Melting point and heat of fusion of 
phenylbutazone crystallised with different 
concentrations of poloxamer 188 
Sample Estimated (% w/vj) Melting Point 
Code concentration of 0 C) 
poloxamer 188 in 
samp Ie 
Heat of 
fusion 
AH F (KJ/mol) 
Pbz 0.00 107 , 27.00 
PPR1 0.01 106.3 26.8 
PPR2 0.09 105.8 - 26.0 
PPR3 1.06 105.5 24.6 
PPR4 2.00 105.3 22.6 
PPR5 5.74 103 15.8 
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Fig. 5.3 The powder X-ray diffraction patterns for phenylbutazone 
crystallised from solutions cont 
30 24 16 8 
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This observation agrees with that reported by Chiou (1976) for 
sulphathiazole, prednisone and chloramphenicol crystallised with 
polysorbate 80. 
The latent heat of fusion (AHf) of the samples decreased with 
increasing surfactant concentration, and was accompanied by a small 
decrease in melting point of the samples (see Table 5., -). These data suggest 
that the surfactant molecules are taken into the drug crystals in a manner 
which does not result in a major change in the crystal form. Blaine(1982) 
(DuPont publications) reported that the higher the concentration of 
impurities in the sample, the lower its melting point and the broader 
its melting range and this trend is observed in Table 5.2. The 
surfactant molecules thus appear to act as impurities, possibly forming 
a solid-solU'tions system at low levels of incorporation. 
5.3.1.4 Powder X-ray diffraction 
The powder X-ray diffraction data for the samples of phenylbutazone 
crystallised in the presence of poloxamer and the poloxamer 188 
flakes alone (see Fig. 5.3) were obtained by bombarding prepared powder 
beds. The poloxamer 188 flakes alone exhibited two peaks in the 
region of 29 at 16.4 and 21.20, the same region where phenylbutazone 
peaks were expected (see Chapter 3. P92 ). The X-ray pattern of the 
crystallised phenylbutazone with different concentrations of poloxamer 
188 showed no major change in the number and positions of the main 
peaks exhibited by phenylbutazone alone, except for the emergence of 
two new peaks at 29,16.4 and 21.20. The size of these two peaks 
increased with increasing poloxamer 188 concentration and correspond 
to the peaks obseryed for poloxamer alone, The similarity in the 
powder X-ray diffraction traces between the samples and the original 
phenylbutazone supports the suggestion proposed from analysis of D. S. C. 
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data that when phenylbutazone is crystallised in the presence of 
polyoxamer, physical adsorption andjor solid solution formation were 
the dominant mechanisms and major changes in crystal form or complex 
formation were absent, 
5.3.1.5 Solubility 
Data for solubility experiments are listed in Appendix 3 Table 16. 
The equilibrium dynamic solubility of the phenylbutazone- 
polyoxamer samples were measured by placing excess of the powder (1 gm) 
in contact with 100 ml of buffer solution of pH 7.5 in a shaking water 
bath at 370C. The presence of the surfactant in the crystallised 
samples of phenylbutazone did not appear to have a great effect on the 
maximal solubility compared with the control sample of pure drug as 
the maximum increase obtained was 1.2 fold. This increase in 
solubility rose with increasing surfactant concentration until the 1% 
w/w level was reached: beyond this level no further increase was 
observed (see Table 5.3). (Maximum increase in dissolution rate was 
also obtained at the 1% w1w ý poloxamer level. ) 
A small increase in solubility has been reported by Finholt & 
Solvage (1968) when studying the influence of polysorbate 80 on the 
solubility of phenacetin (1.26 fold). Also Naggar et al. (1980) 
observed small changes in solubility of phenylbutazone crystallised 
with polysorbate 80. Both groups of workers also noticed major 
increases in dissolution rate, and concluded that the increase in 
dissolution rate was due to a small extent on its solubilising powder 
(Finholt & Solvage 1968). The small increase in solubility with 
increasing surfactant concentration indicates that poloxamer do not 
solubilise phenylbutazone in micelles which tends to support the 
conclusion of Mankowich (1954) that the polyoxyethylene copolymers 
do not form micelles, and that the increase in solubility and 
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Table 5.3 The dynamic equilibrium solubility and intrinsic 
dissolution rate constant, 1ý, of Dhen, %llbutazone 
and samoles crystallised from solutions 
containing different concentrations of poloxamer 188 
Sample Concentration of HPMC 
Code (% w/v) in final 
crystallisation solvent 
PbZ 
PPR1 
PPR2 
PPR3 
PPR4 
0.00 
0.01 
0.1 
1 
2 
PPR5 5 
Estimated % w/v Sample 
poloxamer in solubility 2 
sample mgm/100ml * (mg/min/cm 
I 
0.00 380 0.188 
0.01 405 0.364 
0.09 435 0.478 
1.06 460 0.569 
2.00 458 0.569 
5.74 460 0.569 
Figures represent the arithmetic mean of 
at least two determinations. 
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dissolution rate is due to facilitating wetting and lowering of the 
interfacial tension. 
5.3.1.6 Dissolution rate 
Data from the dissolution rate experiments are listed in 
Appendix 3 Table 1-5. 
The dissolution rate of phenylbutazone-poloxamer'samples was 
determined using a Woods apparatus. An increase in dissolution rate 
with increasing concentration of surfactant added during the 
crystallisation process was observed up to an optimal concentration 
of 1% w/v surfactant which gave the highest dissolution rate. Higher 
surfactant concentrations had no further effect on the dissolution 
rate (see Fig. 5.4 & Table 5.3). 
Although poloxamers have been widely studied, considerable 
confusion exists in the literature over the exact nature of their 
colloidal behaviour and in particular whether micelles are formed 
(Attwood & Florence 1983, Prasad et al. 1979). Whilst some workers 
suggest that micelles are not formed (Mankowich 1954, Dwiggins 1960) 
or only formed at high surfactant'concentration (Ross & Oliver 1959) 
others proposed that micelles are produced (Becher 1959, Prasad 1979). 
The influence of surface active agents on the dissolution rate 
of relatively water insoluble drug may involve several mechanisms. 
The surfactant decreases the interfacial energy barrier between the 
drug and dissolution medium allowing the drug to be wetted more 
completely and readily thereby effectively increasing the available 
surface of the solid for dissolution. Alternatively, when the 
concentration of the surfactant increases above the critical micellar 
concentration (CMC) the apparent solubility of the drug in the medium 
may markedly increase by means of micellar solubilisation thereby 
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effecting an increase in dissolution rate (Weintroub & Gibaldi 1969). 
Any change in solubility due to micellar solubilisation causes an 
increase in the difference between the saturation solubility (Cs) and 
solubility of the given time (Co) i. e. (Cs-Co) and any change in this 
ratio will lead to an increase in the dissolution rate (Parrott & 
Shama 1967, Bates et al. 1966). 
Whilst no significant change in dynamic equilibrium solubility 
was achieved for these samples, a 3-fold increase in dissolution rate 
was observed which is attributed to a facilitated wetting process 
rather than solubilisation. The increase in wetting is achieved by 
lowering the interfacial tension between the substance and dissolution 
medium which results in a low contact angle (Matsuda et al. 1982). 
It is also possible that the surfactant might increase the solubility 
of the drug in the diffusion layer during dissolution (Naggar et al. 
1980). The same suggestion was raised by Chiou (1976) who reported 
that the presence of the'surfactant inside and/or outside the crystals 
might enhance the solubility of the drug in the diffusion layer during 
the dissolution process. Also Levy & Gumtow (1963) found that sodium 
lauryl sulphate increased the dissolution rate of a compressed tablet 
of salicylic acid and they attributed this increase to improved 
wetting which was achieved by lowering the interfacial tension of the 
tablet by the surfactant. In the present work the limiting increase 
in dissolution rate at 1% w/v poloxamer level might correspond to the 
concentration which produces optimal wetting possibly achieved by 
adsorbing poloxamer to the drug crystal. Additional surfactant 
molecules would not provide a further effect with respect to 
dissolution rate. 
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Parrott & Sharma (1967) studied the dissolution rate of 
benzoic acid in the presence of different surface active agents in 
the dissolution medium and found that the dissolution rate increased 
with increasing surfactant concentration until a maximum rate was 
obtained. The maximum was followed by a decrease in dissolution rate 
with higher surfactant concentrations. A similar observation was 
reported by Elworth & Lipscomb (1968), when studying the dissolution 
rate of gri seof ul vi n, and by Naggar et a1. (1980), who studied 
phenylbutazone dissolution in the presence of polysorbate 80. All 
these workers attributed the decrease in dissolution rate following 
the maximum to changes in dissolution medium viscosity by the 
surfactant causing increase in the diffusion layer thickness and 
thus reducing the dissolution rate. However, Finholt & Solvage 
(1968) observed that at a certain level, addition of more polysorbate 
80 has very little effect on the dissolution rate of phenacetin, but 
no explanation for this effect was given. Collett & Tobin (1977, 
1979), in a study of solubilisation of poloxamer systems, found that 
the poloxamer solubilising power depends on the structure of the 
solubilisate for less hydrophobic drugs, the solubility increasing 
with increasing oxyethylene content. For the more hydrophobic the 
solubility decreases with increasing oxyethylene content. 
In the present work for phenylbutazone-poloxamer systems, the 
limiting dissolution rate is attributed to optimal wetting ability 
at 1% w/w level. The levelling at 1% w/w poloxamer concentration 
could be attributed to adsorption of poloxamer molecules to-'th'e drug 
crystals, surface. Addition of more poloxamer beyond 1% w/w did not 
result in adsorbing further surfactant molecules to the drug crystals. 
The physical adsorption hypothesis is supported by data from D. S. C. 
-168- 
POLOXAMER 338 
407 
188 
184 
181 
101 
/0-N 
co 
E 
0 0 0 
\E/ 
0 cn CD a- in 
0 
E 
50. 
10 
Z-ß 
30 60 9b lio 160 1ý0 2iO 
Time ( mins 
) 
Fig. '5.5 Dissolution curves for samples of phenylbutazone crystallised 
from solutions containing 1% w/v of poloxamer - 338,407, 
188,134,131 -ind . 1101 
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and X-ray diffraction studies, while the viscosity effect in this 
case is unlikely since a reduction in the dissolution rate was not 
observed. 
To examine the effect of oxyethylene and oxypropylene content 
of poloxamer on dissolution rate, a series of six different poloxamers 
was examined. Three of the surfactants were selected to have the 
same oxypropylene content with the amount of oxyethylene content 
varying forall the selected poloxamer i. e. in increasing HLB sequence. 
The samples of phenylbutazone with the different type of poloxamer 
were prepared by the same crystallisation procedure used before and 
the amount of poloxamer added each time kept constant at 1% W/V 
level in the crystallising liquor. The dissolution rate data for 
these samples (see Fig. 5.5) showed an increase in dissolution rate 
with increasing oxyethylene concentration in the sample. The rank 
order of poloxamer in increasing the dissolution rate was 330V>407> 
180>184>181>101. This observation is consistant with the conclusions 
drawn by Attwood & Florence (1983) that the solubility of the hydro- 
phobic drug 4-hydroxyocetanilide increased in aqueous poloxamer 
solutions with increasing oxyethylene content-of the polymer. 
5.3.2 Incorporation of poloxamer by spray drying 
5.3.2.1 Assay of spray dried phenylbutazone-poloxamer samples 
Table 5.4 shows the results for the spray dried phenylbutazone- 
poloxamer samples obtained by the B. P. assay procedure for phenyl- 
butazone. The poloxamer content was obtained by subtracting from 
the pure drug assay figure, and the assay results indicate that the 
spray dried samples contain amounts reasonably close to the 
theoretical concentrations of Poloxamer 188 used. 
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Table 5.4 Assay results of phenylbutazone samples spray 
dried from feed solutions containing poloxamer 188 
Sample Concentration of poloxamer % wjw of phenyl- Estimated % 
Code (% wjv) in final crystallisation butazone in w/w Poloxamer 
solvent with respect to phenyl- product in sample 
butazone concentration) 
PH 0.00 99.30 0.00 
PPSI 0.01 99.30 0.00 
PPS2 0.1 99.22 0.08 
PPS3 1.0 98.25 1.05 
PPS4 2.0 97.56 1.94 
PPS5 5.0 94.69 4.61 
Results are the arithmetic mean of 
at least three individual assays. 
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Fig. 5.6 Scanning electron nhotoriicrographs of samples 
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5.3.2.2 Scanning electron microscope 
The scanning electron photomicrographs were obtained for the 
spray-dried samples using the Steroscan 600 electron microscope. 
The photomicrographs showed no change in the'morphology of the spray- 
dried samples in the presence or varying the amount of poloxamer 
added (see Fig. 5.6). This was expected as all the samples were 
spray dried under the same spray drying conditions. Matsuda et al. 
(1982) used scanning electron photomicrographs to trace the location 
of surfactant added during the spray drying process and claimed that 
the micrographs indicate that the surfactant formed a thin layer 
over the crystal surface. No such feature can be seen in Fig-5.6- 
5.3.2.3 Differential scanning calorimetry 
The samples were tested for thermal behaviour using differential 
scanning calorimetry in crimped aluminium pans with pierced lids 
under nitrogen flow at a heating rate 10OC/min over the heating range 
20 to 1300C. The thermogram of the spray dried samples containing 
phenylbutazone only exhibited two melting endotherms, the first 
endotherm at 950C which corresponds to a-form and the second at 1070C 
which is the original melting endotherm for 6 phenylbutazone (see 
Fig. 5.7). This was expected, since as mentioned previously the 
spray drying conditions chosen were those which produced the 
polymorph. 
All the spray-dried samples containing phenylbutazone and 
different concentrations of poloxamer188 gave endotherms which are 
similar to the endotherms shown by the samples containing a-polymorph. 
This result leads to the suggestion that the presence of poloxamer188 
within polymorphic materials does not prevent the formation of 
polymorphic forms when the conditions are selected to form the poly- 
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Fig. 5.7 D. S. C. endotherm for samples PS, PPS1, PPS2, PPS3, PPS4 
and PPS5 (heating rate 10OC/min sample size 5-9 mg and 
under nitrogen flow) 
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morphs. Also, as concluded in Section 5.1.3. th" 
presence of poloxamer 188 does not appear to initiate the 
formation of alternative polymorphs, which is in agreement with 
Chiou's (1976) observation. This finding i. e. the lack of inter- 
ference with polymorphic formation, supports the suggestion that 
poloxamers when incorporated into the samples, are adsorbed 
physically onto the surface of the crystals. This is in contrast 
to the effect of H. P. M. C. on phenylbutazone, where a complex was 
thought to form between the polymer and phenylbutazone. 
5.3.2.4 Powder X-ray diffraction 
Powder X-ray diffraction scans were obtained by bombarding a 
bed of powder samples with X-ray radiation. The resulting X-ray 
diffraction patterns for all the samples were very similar to that 
obtained for the $ phenylbutazone polymorph, with the main peaks at 
29 of 100,16.209 230 and 24.20 (see Fig. 5.8). At higher concentrations 
Of poloxamer 188, a small peak at 29 23.2 
0 appeared which is an 
indication of the poloxamer peak, whilst the second poloxamer peak 
at 29,24. -20 appeared to overlap with the phenylbutazone peak at 29 
of 24.20. The similarity between X-ray patterns for all the samples 
, containing poloxamer agrees with the previous suggestion that 
poloxamer does not interfere with polymorphic formations, or form a 
complex with phenylbutazone. 
5.3.2.5 Solubility 
The result of the solubility experiments are listed in Appendix 3 
Table 17. 
The solubilit. y of the spray-dried samples of phenylbutazone- 
poloxamer 138 .,., ere tested by placing an excess weight of 
the samples 
(lam) in 100 nl of buffer of p1l 7.5 in a shaking water bath at 37 
0 C. 
The solubility showed a peaking value after 4 .0 
hours followed by a steady decline towards an equilibrium value (see 
Table 5.5 
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Table 5.5 The peak and equilibrium solubility and intrinsic 
dissolution rate constant, C, of phenZlbutazone 
and samples spray dried with different 
concentrations of poloxamer 188, at 37 0C 
Sample Estimated % w/w Peaking Samples equilibrium 
Code poloxamer in solubility solubility values 1ý 2 
sample values (mg/100 ml) 
1 
(mg/min/cm 
(mg/100 ml) 
PbZ 0.00 580 390 0.364 
PPS1 0.00 580 440 0.469 
PPS2 0.08 574 440 0.532 
PPS3 1.05 578 460 0.569 
PPS4 1.94 580 456 0.569 
PPS5 4.61 578 460 0.569 
4 
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The peaking value was similar for all the samples tested 
indicating that all the samples have similar a-polymorphic content. 
This further supports the conclusion reached from the D. S. C. 
thermograms and powder X-ray diffraction studies that the presence 
of poloxamer does not interfere with or change the ý polymorphic 
formation. 
Maximal or peaking solubility is attributed to the super- 
saturated solution at peaking metastable solubility subsequently 
recrystallising to the stable 6 form. The presence of poloxamer 
molecules do not affect the peaking time in contrast to the presence 
of H. P. M. C. When the metastable polymorph starts to convert to the 
stable form, the solubility started to decline to an equilibrium 
value. This showed a slight increase over the value obtained for 
the $-polymorph of phenylbutazone, with the increase reaching a 
plateau at concentrations of approximately 1.0% w/w and above (see 
Table 5-r) 1 
5.3.2.6 Dissolution rate 
The dissolution rate data of the spray-dried samples of phenyl- 
butazone-poloxamer were obtained for a compressed disc of the powder 
using a Woods apparatus in phosphate buffer. -at 370C and are listed in 
Appendix 3 Table 5-10. 
The dissolution rates of the spray-dried samples were very 
similar to the samples prepared by crystallisation i. e. there was an 
increase in dissolution rate up to 1% w/w poloxamer concentration 
(see Fig. 5.9 & Table 5.5). Incorporating polyoxamer above 1% w/w 
has negligible effect on the dissolution rate. This is attributed 
to improved wetting in the presence of poloxamer and the limitation 
at 1% w/w could be attributed to the same reasons mentioned in 
Section 5.3.1.6. 
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It is interesting to note that the samples prepared by 
spray drying which are ý polymorph and samples prepared by 
conventional crystallisation gave the same limiting value of 
dissolution rate at the same poloxamer concentration despite the 
difference in the crystal state of the samples (ý and6) and the 
difference in preparative conditions-Thus the optimal wetting 
effect exerted by poloxamer dominates over any effeC 4L 
obtained by the change in crystal polymorph. 
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5.4 Conclusions 
1. When poloxamerl88 was incorporated into phenylbutazone 
crystals a 3-fold increase in dissolution rate for both crystallised 
and spray-drieo samples was obtained, with optimal increases 
obtained at approximately l11o w/w poloxamer concent'ration. 
2. The increase in dissolution rate was thought to be obtained by 
facilitating wetting through lowering the interfacial tension, as 
the increase in solubility was relatively small. 
3. No complex appeared to form between the surfactant and the drug 
molecules and the poloxamer 188 molecules were thought to be primarily 
physically adsorbed to the crystal surface. 
4. The presence of poloxamer did not inhibit or initiate the 
formation of polymorphism. 
CHAPTER 6 
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CHAPTER 6 Stability'testing_of phenylbutazone samples 
containing'polymeric additives 
6.1 Introduction 
The life of a pharmaceutical product is the maximal length of 
time expected to pass between the manufacture and the last sale of 
the preparation. This time or shelf life, is usually calculated by 
the manufacturers and enables an expiry date to be listed on the 
container (Carstenston 1980). Shelf life can be defined as the time 
required for the drug level in a product stored at room temperature 
(250C) to degrade to 90% of its labelled potency (Ditter 1974). 
Degradation can result from many factors, but the major problems are 
environmental parameters such as temperature, light, oxygen and 
moisture (Florence & Attwood 1981). These factors cause either 
physical or chemical degradation through different reactions. A 
particular problem is hydrolysis which is the reaction of water with 
ions of weak acids and weak bases, and solid dosage forms are usually 
very susceptible to the moisture content of the atmosphere in the 
containers in which they are stored (Florence & Attwood 1981). 
Oxidation, which is the result of removal. of an electron from the 
molecule, is not easy to assess during storage, but its effect could 
be eliminated by adding antioxidant. The effect of temperature is 
important and Useful, as increasing the temperature generally 
accelerates degradation. The effect of temperature on the rate of 
decomposition may be described by an empirical equation proposed 
Arrhenius (Floren'ce & Attwood 1981). 
Log e= log Aý _ 
ra 
6.1 TTOTRT 
where 1ý is the degradation rate 
A is the frequency factor 
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is the degradation activation energy a 
T is the absolute temperature 
R is the universal gas constant. 
A plot of log e as a function of reciprocal temperature 
should be linear with a slope of -Eý/2.303R from which E" aa 
may be calculated (Florence & Attwood 1981). 
The degradation rate constant at any storage temperature may be 
extrapolated from measurement at a series of elevated temperatures 
where the reaction was accelerated by elevating the temperature. 
This finding is very useful in predicting the shelf life of a 
product. 
Several groups of workers have studied the effect of aging on 
the physicochemical properties of compressed tablets. Ewe (1934) 
used the changes in crushing strength with aging as an indication to 
predict change in drug activity. Burlinson & Pickering (1950), 
Bergman & Bandelin (1965) used the disintegration time to predict 
changes in drug properties with aging, as they noticed an increase 
in disintegration time with aging. But Horhota 6t al. (1976) found that 
neither crushing strength nor thickness and diameter bear any 
relationship to changes in dissolution rate, and he found that there 
was a substantial change in dissolution efficiency occurring without 
any change in hardness or tablet size. This finding was confirmed by 
Lausier et al. (1977). Alam & Parrott (1971) found that aging 
increases the disintegration time, and crushing strength, and 
dissolution time of tablets granulated with acacia, whilst tablets 
granulated with polyyinylpyrrolidone (PVPj were stable at room 
temperature and only very slight increases in disintegration time 
were observed after one year. Mattok et al. (1971) found that dissolution 
I 
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time increased with aging of acetaminophen and the blood level 
resulting from administration of old tablets was lower than for the 
freshly prepared tablets. Ondari et al. (1984) studied the 
dissolution rate of four types of compressed tablets, the dissolution 
time increasing with age for all four types. 
The effect of aging on solid dispersions has also been examined. 
El Banna. et al. (1974) found the dissolution rate of fused pheno- 
barbitone-urea decreased with age and they attributed this to the 
coarsening of the eutectic mixture. Other workers such as Ford & 
Rubinstein (1979), Chiou & Niazi (1971) found a decrease in 
dissolution time with aging of the solid dispersion of sulphathiazole- 
urea which related to the conversion of metastable polymorphic form 
II of sulphathiazole to the stable form I, whilst Chiou & Riegelman 
(1969) could not find any change in dissolution time for griseofulvin- 
polyethyleneglycol 600 systems when stored at room temperature for 
six months. Even the diluent used in tablet manufacture such as spray 
dried lactose and dextrosetends to harden with age causing increase 
in disintegration times. This effect was greater for lactose than 
dextrose and dissolution rate was also decreased with both additive. s 
ouvall et al. 1965). 
The effect of aging on phenylbutazone tablets has been studied 
by several workers' groups including Barrett & Fell (1975), Matsui 
et al. (1978) and Naggaret al. (1980). These workers studied the 
effect of aging on phenylbutazone tablet alone or with additives and 
the results showed decreasing dissolution rate with aging. 
The degradation of phenylbutazone alone has been examined by 
several workers including Awang et al. (1973),, Kata (1974), Deckstead 
et M. (1968) & Awang et al. (1976). However the method used to detect 
-185- 
and trace the degradation point was different between groups. Most of the 
workers (Awang et al. 1973,1976, Kata 1974) used a thin layer chromatography 
(TLC) technique reported by Beckstead et al. (1968). This technique is 
useful in separating the degradation products for further analysis, 
such as NMR, but the risk of oxidation on the plate can be 
accelerated by the presence of iron in the silica coating. An 
alternative method reported by Watson et al. (1973) was to use gas 
liquid chromatography (GLQ. This method was thought to be more 
accurate and faster. However the limitation for this method is that 
the inj ection point was kept at 2300C which might cause further 
degradation after injecting the samples or break down the degradation 
to be assessed. 
Fabre et al. (1982) recently reported the use of high pressure liquid v 
chromatography (HPLC) which was claimed to be more reliable in 
assessing phenylbutazone degradation due to the absence of risk of 
oxidation and no heat required. Also the technique was fast, so in 
this study HPLC was chosen. 
The objective of this study was to apply an accelerated test 
using elevated temperatures to assess the effect of the presence of 
the additive and the change of the crystallographic nature of 
phenylbutazone on the stability of phenylbutazone. 
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6.2 Experimental 
6.2.1 Materials 
A high pressure liquid chromatograph with a variable wavelength 
U. V. detector, a 20311 loop injection, and reversed phase column were 
used. Phenylbutazone, the pure druq and six degradation products, 
I-VI, and supplied by Ciba-Gei-ay (see Table 6.11 were all used as 
received. Salicylic acid (a6alar grade) was used as the internal 
standard. Solvents used were methanol HPLC grade and double 
distilled water prepared from an all-glass still. The samples PHR4, 
PHS4, PPR3 and PPS3 were used. 
6.2.2 Method 
6.2.2.1 Stability testing for phenylbutazone with additives 
The stability testing was carried out for the samples of phenyl- 
butazone PHS4, PHR4, PPS3 and PPR3. The test was carried out by 
placing 3 gm of the powder of each sample in 20 ml glass bottles 
with rubber lined metal screw lids, four bottles for each sample. 
The sealed bottles were kept at 200C. 370C and 500C. Another bottle 
was kept at 200C and left open and exposed to a relative humidity of 
45%±5% RH. The samples were tested initially and at three and six 
months, to check any change in D. S. C. thermograms and H. P. L. C. 
profiles. 
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6.3 Results and discussion 
Fabre et-pj. (1976), using an HPLC technique, mentioned three 
degradation compounds (Nos. 1 11 andIII see Table 6-1) and used 
a degassed 60: 40 mixture of 0.1 M trimethamine citrate buffer 
(pH 5.25)-acetonitrile as mobile phase. An attempt to follow the 
same system was not successful, as blockage of the chromatographic 
column occurred. One possible cause of blockage is that the 
citric acid used adjusting the buffer pH tends to crystallise. 
An alternative mobile phase was examined in which two systems 
are required to resolve and identify Phenylbutazone and the break- 
down products (Table 6.1). The first system consisted of a degassed 
mixture of 58/42 methanol HPLC grade, with double distilled water, 
and the second system is a degassed mixture of 42/58 methanol/water, 
using salicylic acid analar grade as internal standard in both 
systems (see Figs. 6.1 & 6.2). 
6.3.1 Calibration curve 
Five decomposition products were analysed using HPLC and four 
concentrations of each were injected into the column. Degradation 
product No. I was found to be very unstable during analysis* 
gradually changing to No. IJI after dissolving in the solvent. Thus 
No. I was excluded from further experiments. For breakdown product 
No. Ir, one tenth of the concentration of the other samples, was used 
to bring it within the scale reading. Calibration curves were linear 
passing through the origin. 
6.3.2 Stability testing of phenylbutazone-pol-ymeric 
additive samples 
As illustrated in Fig. 6.3(Awang 1973), oxidation of phenyl- 
butazone at the tertiary C4 results in 4-hydroxyphenylbutazone (No. I) 
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Table 6.1 List of phenylbutazone degradation products 
Degradation Name Number Structure 
4-hydroxyphenylbutazone I 
Q6 
C6H %H 6 *, % w- ýr 
-d4- 7 
a-carboxy-a-hydroxy-N-caproyl- 
hydrazobenzene 
a-carboxy-N-caproylhydrazobenzene 
a-hydroxy-N-caproylhydrazobenzene 
N-caproyl-hydrazobenzene 
N-(a-ketocaproyl)-hydrazobenzene 
ii 
III 
IV 
V 
vi 
c 0ý C6H6 
0i 
N-N 
COOH 
HO nC4 H. 
0 
C6"6 C6H6 
N-N 
COOH 
H nC4H9 
^U 
, 61-6 , OoPd46 
N-N \ iH 
0 %%, 
* NH 
H0 
XnC09 
cr, H ra C H6 
/6 
N 
H 
ýnC4H9 
C6H6 C6 H6 
N 
0 
0 
n C09 
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Pbz 
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No., 
No. 1-1 
No. 111 
No; V, 
No; iv 
inj. 
Fi g. 
Solvent system one (58/42 ethanol/water) for HPLC analysis to 
separate phenylbutazone and degradation products 111, IVV and VI 
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Fig. 6.2 Solvent system two (42/58) methanol/water for HPLC 
to separate phenylbutazone degradation No. 11 
-191- 
Fig. 6.3 Degradation sequence of phenylbutazone 
C Hr, Cr 
NN 
, 
HE 
H" 'nC4H9 
Phenylbutazone 
+02 
+H20 
C H6 6H6 
N 
01 
COOH 
.. 
Y, 
H* nC4Hq 
NO. III 
C6H6 
.I- 
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C6H6 
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/ 
H 02 
0 
nC4Hg 
NO. V 
C06 C6H6 
N-N 
1 
-101 
H9 Hi 00 nC4 
I 
C H6 ' CA 
N-N 
04 
n C4H9 
NO. VI 
*Scheme 1 
C6H6 C6H6 
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0 
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0 
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-4- 
C6H6 C6H6 
N-N 
+OH 
oj 0 
x 
0n C4H9 
*Scheme 2 
C6Hr, C6H6 
N-N 
HO--' NnC4H9 
C 4ýr', 
Ik 
'IC6 
H6 
0 
jN -N 
-"*ý OOH 
.. -AC Ho hC4Hq 
NO. I 
-H20 
I J! 
H20 
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0H 
H 
Hq HO n C4 
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C\6 H6 CrH6 
01NN 
NII-0 
//I'- 
n C4H9 
* From Awang et al. 1973 
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which was found to be unstable converting to a-carpoxy-a-hydroxy-N- 
caproyl-hydrazobenzene (No. II), just after dissolving it in mobile 
phase. The detected amount of II increased with successive 
injections of I. This agrees with the sequence in the degradation 
scheme as product II is the result of bydr6lysis of I. The reaction 
occurs so fast that product I can be regarded as very unstable. 
Awang et al. (1973) were in fact unable to isolate I and this 
observation has also been reported byVeibel et al. (10958). Product 
I however was obtained by Awe & Kierner C1963) and was made available 
for this study by Ciba-Geigy. 
Powelezyk & Wachowlok (1969) reported that I was the major 
degradation product in phenylbutazone suppositories. Awang et al. 
(1973) related this to the hydrophobic nature of the bases with which 
phenylbutazone was compounded in the formulations studies. Hydrolysis 
product I results in cleavage of the C-N amide bond and yields the 
degradation product a-carpoxy-a-hydroxy-N-caproyl-hydrazobenzene (II), 
while hydrolysis of phenylbutazone resultsin degradation product - 
carpoxy-N-cabroylhydrazobenzene (III) which was reported by Matsui 
et al. (1978) to be the major degradation product in phenylbutazone- 
antacid formulations. Schmid (1970) also reported that product III is 
the major degradation product of phenylbutazone in aqueous solution. 
The observation in this study that product III was the only degradation 
product found in the stability tesiing of phenylbutazone with polymeric 
additives is consistent with these reports. 
'The presence of an electron withdrawing group will facilitate 
decarboxilation and loss of carbon dioxide (Hine 1962), so the loss of 
carbon dioxide from degradation products II and III will lead to further 
degradation resulting in product a-hydroxy-N-caproyl-hydrazobenzene (IV), 
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and N-caproyl-hydrazobenzene (V) successively. When IV and V are 
further oxidised degradation product N(a-ketocaproyl )-hydrazobenzene 
(VI) is obtained. 
6.3.2.1 H. P. L. C. 
The stored samples were tested for the presence of any 
degradation product in the samples when exposed to the adverse 
conditions. The retention times of the peaks were examined to 
determine the type of the degradation and the size of the peak to 
calculate the concentration of the degradation product. 
The result of analysing the samples after three and six months 
indicated that the pure phenylbutazone tested as received without 
any further purification or additives, was stable during the testing 
period at all the temperatures studied (see Table 6.3). This agrees 
with Matsui et al C1978) who reported that unformulated drug was 
stable at 600C. 
Results also indicated that there was one degradation product 
a-carboxy-N-caProyl-hydrazobenzene (III) (see Fig. 6.. 4& Table 6.2). 
This is consistent with the report of Matsui et al. (1978) that a- 
carboxy-N-caproyl-hydrazobenzene was the major degradation product 
in the phenylbutazone-antacid tablets. Also Powelezyk & Wachowiak 
(1% 9), who studied the aqueous injection solution of sodium salts 
of phenylbutazone, found this compound to be the major degradation 
product. 
All the samples were stable at 200C after threemonths when kept 
in both closed and open containers, although traces of product III 
were present in open samples presumably due to access of some 
moisture. The degradation product started to appear clearly for 
samples stored at 370C and was more pronounced for samples stored at 
-194- 
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500C (see Fig. 6.5). 
When analysing the samples after storage for six months, 
increased amounts of III were noticed, but no additional 
decomposition product was detected. For samples stored at 200C, the 
presence of degradation product III was detected with reduced amounts 
for samples in sealed containers. 
The moisture levels are likely to differ slightly between 
samples due to both the sample preparation conditions, conventional 
crystallisation or spray drying involving different temperatures and 
and 
rates of crystallisationtalso the different affinity of the polymer 
additive for water molecules dausing samples to release moisture 
during elevated-temperature storage. which will facilitate hydrolysis 
of phenylbutazone. 
6.3.2.2 Differential scanning calorimetry 
The effect of age and storing the sample at different temperatures 
influenced the thermal behaviour of some of the samples. For phenyl- 
butazone pure drug, no change has been observed in its melting 
endothem during the testing period for all storage conditions. The 
same was observed with crystallised samples containing poloxamer 188. 
For samples prepared by spray drying, changes were observed in 
the endotherm at 950C, the effect depending on the additive. For the 
samples spray dried with poloxamer 188 the peak at 950C tompletely 
disappeared for samples stored at all the storage temperatures, this 
effect being noticed after storage f6r three months (see Fig. 6.6). 
The peak at 950C is'attributed to the a-polymorph which is a metastable 
form, so with time and elevated temperature eeversion to the stable'6 
form could occur. For samples spray dried with*H.. P. M. C. there was a 
-197- 
-0 PHS 4 
PHR 4 
A--- - PPS 3 
PPR 3 
60 
M 
2 
12. 
20 
10 
Time (months) 
Fi g. 6.5 
Graphical representation of the percentage of degradation 
product III with time for tested materials, stored at 50*c: 
III 
036 
-198- 
reduction in size of the peak at 950C and the reduction increased 
with increasing storage temperature and with time. After three 
months the 950C endotherm was present for all the samples, but after 
six months it completely disappeared for sample stored at 500C, with 
samples exhibiting a single endotherm at 1070C. 
The difference in rate of solid-solid transition and decreasing 
the peak size at 950C between samples spray dried with ooloxamer 188 
and H. P. M. C. can be explained by the fact that for poloxamer 
188 no reaction or complexation appeared to occur between the drug 
and polymer. The presence of polymer is therefore unlikely to 
interfere with the rate of conversion of metastable polymorph to the 
stable form which is initiated with elevated temperature. However, 
for samples spray dried with H. P. M. C., previous discussion (see 
Chapter 4) suggested that H. P. M. C. formed a complex with the drug 
and it is suggested that this complexation retards the solid-solid 
transition. 
For samples crystallised with H. P. M. C. the samples at time (zero) 
exhibited a single endothermic peak at 970C, but with increased time 
and temperature the 6-peak at 1070C started to appear. As it 
increased the peak at 970C decreased, although after six months the 
970C endotherm was not completely absent. This effect could be 
explained by the high energy complex between the drug and H. P. M. C. 
starting to breakdown and liberate phenylbutazone alone. Elevated 
temperature appears to have accelerated this breakdown. 
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6.4 Conclusion 
1. From the study it was found that HPLC was a reliable, useful 
and fast technique for examinin-a and detecting the degradation 
product of phenylbutazone. The stability study showed that 
phenylbutazone was stable during the period of study even when 
stored at 50 OC. 
2. A degradation product appeared when samples of phenylbutazone 
containing either H. P. M. C. -or poloxamer 183 were stored. 
The product was found to be a-carpoXY-N-caproylhydrazobenzene 
(degradation product No. III) which was present due to the 
hydrolysis of phenylbutazone. 
3. The study revealed that the type of additive and the way of 
preparing the samples played a major role in initiating the 
degradation process. This was seen for samples having the same 
additive but prepared by different processes. Samples prepared by 
conventional crystallisation showed higher concentration of 
degradation product than those prepared by spray drying, whilst 
samples containing poloxamer 188 showed higher concentration of 
decomposition product than those containing H. P. M. C. 
4. The D. S. C. thermograms showed that solid-solid transition 
occurred in the samples on storage and the presence of H. P. M. C. 
tended to slow down this transition. 
5. Elevated temperature appeared to cause the proposed complex 
between H. P. M. C. and phenylbutazone to be broken. 
CHAPTER 7 
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CHAPTER 7 Tableting of spray-dried and crystallised 
phenylbutazone samples containing H. P. M. C. 
7.1 Introduction 
Previous chapters of this thesis have considered the physico- 
chemical and crystallographic of modified phenylbutazone samples. 
It is also of relevant interest to consider the processing 
characteristics of the phenylbutazone: polymer samples. This 
chapter considers aspects of the tableting behaviours of prepared 
samples of phenylbutazone, PS, PHS2, PHS39 PHS4, PHS5, PHR2, PHR3, PHR4 
and PHR5. 
Tableting is a widely used process in the pharmaceutical industry 
and has been used in this work to represent a relevant aspect of 
pharmaceutical processing. 
Powder compaction data have been analysed according'to the Heckel 
pressures vnlume relationship (Heckel, 1961). 
In addition, force transmission through the bed of powder was 
measured to assess changes in frictional effects during compression 
and to monitor a property of the prepared compact, dependent upon both 
material and processing conditions, tablet tensile strength was 
determined. 
-202- 
7.2 Experimental 
7.2.1 Materials 
The materials used were phenylbutazone as supplied (PbZ), Ps, PHS2, 
PHS3, PHS4, PHS5-, ýPHR2, PHR3, PHR4 and PHR5. 
7.2.2 Method 
The samples were prepared using techniques described in Chapter 
2. Tableting and analysis of data were carried out using techniques 
described in Chapter 2. 
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7.3 Results and discussion 
7.3.1 Heckel plot analysis 
Data from the ejected compressed tablets which are listed in 
Appendix 4 Tablesi-lo, plotted according to the Heckel equation gave 
curves which exhibited two distinct sections. The first curved 
section is attributed to initial packing and rearrangement of the 
powder particles under low pressure. The second part of the curve 
gave straight lines where the reciprocal of the slope can be taken to 
equal the mean yield pressure K, (see Figs. 7.1 & 7.2). 
Table 7.1 lists values of mean yield pressure for the various 
samples studied. For the spray-dried materials, it can be seen that 
the estimated values of yield pressure for all samples containing 
H. P. M. C. gave similar figures (mean 93.5 MPa ) suggesting that major 
changes in the yield pressure of the a form prepared did not occur 
when up to 5% w/w H. P. M. C. was included into phenylbutazone. There 
is however a downward displacement of the curves with increasing 
H. P. M. C. concentration. Further analysis of the Heckel relationship 
enables density changes occurring during the rearrangement stages to 
be estimated (see Fig. 7.3 ). 
Table 7.1 lists calculated values of packing fractionrF,, packing 
fraction(FB and it can be seen that as the amount of H. P. M. C. 
present in the phenylbutazone sample increasess the density change 
I 
due to particle rearrangement and repacking decreases. Since only 
minor differences in particle size and shape occur between samples, 
the principle causative factor is attributed to increased cohesion 
between particles due to the presence of the polymer in the samples. 
-204- 
Table 7.1 Values of Ki, the mean yield pressure; 
CFA, 
densification due to die filling and particle 
slippage and rearrangement; (7FO, initial powder 
packing fraction; (FB, densification due to 
particle slippage and rearrangement. 
Crystallised samples Spray dried samples 
Sampl e K, 
ýFO 
(MPa) 
PbZ 142.28 0.090 
PHR2 143.71 0.092 
PHR3 145.10 0.095 
PHR4 147.40 0.131 
PHR5 156.61 0.134 
ýFA 
0.980 
0.886 
0.860 
0.800 
0.660 
CFB 
0.890 PS 
0.788 PHS2 
0.765 PHS3 
0.669 PHS4 
0.526 PHS5 
K, ýF 0 
(MPa) 
89.81 0.128 
92.12 0.130 
92.12 0.132 
94.42 0.143 
94.03 0.145 
GA 
0.860 
0.840 
0.720 
0.581 
0.480 
ýF 
B 
0.732 
0.710 
0.588 
0.435 
0.335 
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A similar family of curves was obtained for the samples prepared 
by conventional crystallisation. The linear portions are again 
similar in slope, although there is a trend of increasing value of 
mean yield pressure as the concentration of H. P. M. C. in the sample 
increases (see Table 7-1). Also as the concentration of H. P. M. C. in 
the sample increases, the curves are displaced downwards. This 
again suggests that the presence of H. P. M. C. increases the cohesive- 
ness of the powder samples. 
Table 7.1 also shows that the mean yield pressure for the 
crystallised material without H. P. M. C. was greater than that obtained 
for the spray-dried phenylbutazone without H. P. M. C., which follows 
the observation of Fell & Newton (1971) for lactose samples, who 
reported that the yield pressure for spray-dried lactose was lower 
than that for the crystalline lactose. In the case of spray-dried 
phenylbutazone the yield pressure and onset of linear section occurred 
at a higher pressure than for the material prepared by conventional 
crystallisation. 
The bulk density and linear onset effects can be attributed to 
differences in the shape, morphology and crystallographic character 
of the materials. In the case of the crystallised phenylbutazone, 
the stable s polymorphic form is present and the particles were 
needles, which will need comparatively higher pressures for packing 
and rearrangement to overcome interparticle friction forces compared 
with the more spherical spray-dried particles. The higher yield 
pressure for the crystallised sample can partly be attributed to the 
fact that samples exist in the stable 6 form whilst the spray-dried 
phenylbutazone is in the 5-metastable formt and partly due to other 
crystallographic and morphological differences between samples. 
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7.3.2 Force transmission 
FL The force transmission F-u is defined in this study as the 
ratio of maximum force transmitted to the lower punch (FL), to the 
maximum force applied to the upper punch (Fu). The lower the ratio, 
the greater the force loss due to friction, primarily between 
Darticles and die wall but also interparticulate friction particle 
rearrangement, heat gain and bonding. Data from the instrumented tablet 
of maximum upper and lower-force are listed in Appendix 4 Tables 1-10. 
' FL Fig. 7.4' & 7.5 show plots of-F-u versus final tablet porosity for 
crystallised and spray-dried samples. The curves show that the 
amount. of force loss at equivalent porosity for the two series of 
materials were very similar. Fig. 7.6" shows that the force loss 
decreased steadily with increasing amounts of H. P. M. C. up to 2% w/w 
concentration then at 5% wjw H. P. M. C. concentration, a much improved 
transmission of applied forces took place. It thus app ears that 
whilst the presence of higher concentrations of H. P. M. C. increases 
interparticle cohesion die wall friction is reduced, and the nature, 
morphology and crystal form of the phenylbutazone does not seem to 
be important in this change in frictional character. 
7.3.3 Tablet tensile strength 
From the Heckel plot discussed earlier it was concluded that the 
spray-dried materials were more plastic (i. e. had lower mean yield 
pressure value), compared with the crystallised materials. Also the 
addition of polymer reduced the extent of particle packing, 
rearrangement and generally particles with polymer were thought to 
be more cohesive making it easier for the particles to form bonds on 
compression.. The tensile strengt Ih data for the sample examined are 
listed in Appendix 4, Table 1-10. - Using-these data (Fig. 7.7 -, 7., B 
-210- .. 
Fig. 7.4 Force transmission ratio versus final tablet porosity 
for samples of spray dried phenylbutazone alone and 
spray dried samples containing different concentrations 
of H. P. M. C. 
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Fig. 7.5 Force transmission ratio against final 
tablet porosity for phenylbutazone as supplied 
and samples cyývstallised Irom solutions containing 
-different concentrations of 
H. P. M. C. 
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demonstrated differences between the spray-dried and the 
conventional crystallised materials. Whilst both groups exhibit 
increases in tensile strength with increasing concentration of 
H. P. M. C. added, for similar porosity values the tensile strength of 
compacts from conventional crystallisation procedures are 
significantly higher. 
The form of the curves is different between the spray dried and 
crystallised materials, with the former showing an exponential 
increase in tensile strength as the porosity decreases compared with 
an apparent linear function for the crystallised materials. It is 
possible that the spray-dried spherical-like particles fracture and/or 
breakdown extensively at higher pressures to achieve low porosities 
and which creates new, clean surfaces in close proximity which would 
lead to increased bonding. 
Fig. 7. ET* shows the change in tablet tensile strength of a fixed 
porosity of 0.2, chosen to minimise extrapolation of data, and to 
approximate to conventional tablet porosity figures. The graph 
confirms that the tablets-prepared from phenylbutazone samples 
containing H. P. M. C. prepared by conventional crystallisation have 
values of tensile strength approximately three times larger than 
equivalent spray-dried samples. Whilst the spray dried materials 
contain the a polymorph of phenylbutazone, they also have different 
shape and morphology, all factors which could contribute to this 
effect. An additional factor could be the nature of the distribution 
pattern of the H. P. M. C. wi. thin the spray-dried and crystalline 
materials. A surface'natrii of H. P. M. C. would facilitate polymer, 
polymer contact and since H. P. M. C. is plastic in nature, deformation 
could readily occur leading to bonding between particles. However, 
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the primary causative feature has not been isolated, but such a 
study would be worthy of further investigations. 
-218- 
7.4 Conclusion 
1. The compressional behaviour of crystallised and spray-dried 
phenylbutazone alone and phenylbutazone containing known 
concentration of H. P. M. C. have been studied using Heckel equation 
analysis, force transmission and tablet tensile strength data. 
2. The yield pressure for crystallised samples with different 
concentrations of H. P. M. C. were similar (mean 147.02MPa) 
Spray-dried samples with different levels of H. P. M. C. gave 
similar yield pressures but exhibited a lower mean value (mean 93.5MPa) 
than crystallised samples. The difference in mean values is thought 
primarily to be due to polymorphic and particulate differences 
between spray dried and crystallised samples. 
3. Force transmission was similar for both spray-dried and 
FL 
crystallised materials. Ratios of F-u rose from 0.65 to 0.81 at a 
fixed porosity % with increasing H. P. M. C. concentration indicating 
that the presence of H. P. M. C. reduced die-wall friction. 
4. Data for tablet tensile strength at fixed porosity showed that 
compacts prepared from crystallised samples were generally 3 times 
higher than for tablets prepared from spray-dried materials. The 
primary cause of this effect has not been isolated but can be 
attributed to a number of factors including crystallographic, shape, 
morphology and polymer distribution differences between the 
material s. 
CHAPTER 8 
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CHAPTER 81 General Discussion 
Drug bioavailability is controlled to a greater or lesser extent 
by the dissolution rate of the drug. For example, for those drugs 
where the dissolution rate is the rate determining step in absorption, 
bioavailability can be improved by increasing dissolution rate. 
Techniques for increasing the dissolution rate include changing the 
crystal shape, size and structure, or lowering the powder interfacial 
tension by the incorporation of hydrophilic materials or surface active 
agents. In this work an attempt to increase the dissolution rate of a 
model sparingly soluble drug, phenylbutazone by changing the crystalline 
state as well as incorporating hydrophilic polymer and surfactant by - 
conventional crystallisation and spray drying is reported. The effects 
of incorporation on the physicochemical properties and stability of the 
drug as well as the powder behaviour when tableted have been examined. 
The study of the polymorphism of phenylbutazone in this work 
revealed three polymorphic forms. The stable a form (after Muller 
(1978) nomination) which is the commercially available phenylbutazone 
powder, exhibited a single endothermic peak at 107 0C on D. S. C. analysis 
which is in general agreement with the literature figures (Matsuda 
1976; Ibrahim 1977; Muller 1978; Tuladhar 1983). The second polymorphic 
form isolated was the 6 metastable polymorph which could be obtained by 
recrystallising from n-heptane. The D. S. C. thermogram showed an 
endothem at 950C, an exothemic peak on recrystallisation at 97 ocs 
followed by a secondmelting endotherm at 1070C. The third identified 
polymorph, the a-forM which was obtained by recrystallising from 
i; ave 0 2-propanol, lan endotherm at 93 C. then recrystallises prior to 
remelting at 1070C. 
-220- 
The transition energy, obtained using the Kissenger equation 
(1957), of the B-polymorph to the stable 6 form was found to be 
796.3 Kj/mol. This is similar to the figure reported by Muller (1978) 
of 850 YTjmol. The value is approximately five times higher than that 
calculated for sulphathiazole form I by Shami et al. (1972). This 
indicates that the a-polymorph of phenylbutazone was stable enough to 
perform the physicochemical studies. 
The powder X-ray diffraction pattern of the original stable 6 form 
exhibited three strong peaks at the regions of 29 at 6.95,8.1 and 
20.90 which agrees closely with the figures reported by Muller (1978). 
For s polymorph movement of these peaks to values of 2. e of 8.6,20.4 
and 70 was associated with increase intensity (see Table3-6). 
However, the third polymorph assigned a form was very unstable and 
could not be isolated for examination by X-ray diffraction. 
The powder X-ray diffraction data were found to be useful in 
differentiating between the polymorphs, supporting the conclusions of 
Muller (1978). In contrast Ibrahim (1977) and Tuladhar (1983) used 
differences between I. 'r. spectra to identify polymorphs rather than 
X-ray diffraction data. In this work, only minor differences in I. r. 
traces are evidenced between samples. It is essential to use a 
combination of techniques, including X-ray diffraction, I. r. analysis. 
and D. S. C., together with information from hot stage microscopy, 
dissolution and solubility experiments when identifying polymorphs. 
Another useful indicator of the presence of polymorphism of a 
material can be the peaking effect in dynamic solubility studies for 
metastable forms. The peaking is attributed to the higher solubility 
leyels of the metastable polymorph which, when in solution form can 
only exist in the stable form. Thus the solution is supersaturated with 
-221- 
respect to the solubility level of the stable polymorph and the 
solution re-equilibrates to a new lower solubility figure as a 
portion of the solute crystallises, out of solution. Whilst several 
workers in this field have concentrated solely on equilibrium 
solubility data (-Muller 1978, Ibrahim 1977) this study has shown the 
peaking solubility effect for the B-phenylbutazone polymorph (see 
Fi g . 3-8) 
The intrinsic dissolution rate of the a and'a polymorphs was 
measured using constant surface area compressed discs. It was thought 
that during compression, a polymorphic transition might take place 
(Ibrahim 1977, Muller 1978). No transition of S form to a form during 
compression was found and examination of a compressed tablet prepared 
from a polymorph sample (see Table 8.1& Fig. 8.1) showed only minimal 
transition occurred during compression. At the upper surface of the 
tablet adjacent to the punch the transition to 6 form was maximal 
(53 %) whilst at the surface exposed to the dissolution medium wasonly 
5.3% . This observation is in agreement with 
that of Chan & Doelker(1984)- 
The dissolution rate for the a form showed a2 fold increase 
compared with the s form and this finding is consistent with the 
increases reported by other workers (Muller 1978; Ibrahim 1977; 
Matsuda 1983; Tuladhar 1983). 
Whilst many workers have examined the effect of changing solvent 
on the polymorphism of phenylbutazone, attention should also be given 
to the crystallisation rate. This study has shown that the rate of 
crystallisation achieYed by Yarying the spray drying conditions 
influences the number of polymorphs present in the samples. It has 
been found that the slower the crystallisation rate the more favourable 
the conditions for forming polymorphs, and the higher the number of 
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Fig. 8.1 D. S. C. endotherms for transition of phenylbutazone ý polymorph 
after compression, at upBer, middle and lower sections of the 
compact Cheating rate 10 Umin, sample size 5-9 mg and under 
nitrogen flow) 
4J 
(o 
Qj 
0 
-0 
Table 8.1 The % of a polymorph of phenylbutazone transferred to 
6 form after compression measured by integrating the 
left $-peak and related to the uncompressed peak 
AH of the remaining 
Sample % transferred poTymorph 
endotherm Kj/hr 
inner face 52.7% 4.42 
middle 36.2% 5.86 
outer face 5.3% 7.78 
uncompressed powder - 4.27 
00 100 110 120 
Temperature oc 
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polymorphs formed. The D. S. C. thermograms for spray-dried samples 
of phenylbutazone showed that for the fastest crystallisation rate 
samples exhibited a single endothermic peak at 1070C which 
corresponds to the stable 6 form thermogram, and showing that no 
metastable polymorph has been formed. As the crystallisation rate 
was reduced a small shoulder appeared on the 1070C endotherm, 
indicating the presence of an additional polymorph. Reducing the 
crystallisation rate further produced an additional endothermic peak 
at 950C, corresponding to the 6 polymorph. When the rate of 
crystallisation was reduced further two extra peaks appeared at 95 0C 
and 990C in addition to the original peak at 1070C. The peak at 990C 
may correspond to one of the additional polymorphic forms reported by 
Tuladhar. et al,. (1983). 
Powder X-ray diffraction traces for these samples showedthat for 
samples exhibiting a single endothermic peak, the trace was similar to 
that of stable 6 form, whilst for samples with two endothermic peaks 
at 950C and 1070C. the X-ray diffraction pattern was very similar to 
that obtained for the a polymorph. The X-ray traces for samples 
exhibiting three endothermic peaks at 950C, 990C and 1070C. were 
different from those obtained for 0 and 6 polymorphs with extra peaks 
present. 
Solubility testing revealed that the spray-dried samples gave 
peaking values prior to an equilibrium solubility value, a feature of 
polymorphic materials. The peaking value of solubility for the 
different samples increased with increasing number of endothermic peaks 
in the D. S. C. thermogram and increased with decreasing crystallisation 
rate. This finding supports the hypothesis that the number of 
polymorphs increases with decreasing crystallisation rate. The intrinsic 
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dissolution rate of the spray-dried samples increased in the same 
sequence, providing further support for the hypothesis. Thus this 
study has shown that crystallisation rate is a critically important 
factor in the formation of polymorphic forms. 
Another technique which can be used to increase the dissolution 
rate of aqueous sparingly soluble drugs is to incorporate a hydro- 
philic polymer into the drug crystals. The way of introducing the 
polymer and the nature of the polymer is thought likely to produce 
different effects on both the crystallographic and physicochemical 
properties of the parent molecule. In this study two types of 
polymer, H. P. M. C. and poloxamers were introduced by conventional 
crystallisation and spray drying. 
The D. S. C. thermograms of samples prepared by crystallisation to 
contain H. P. M. C. showed that the presence of H. P. M. C. produced an 
extra endotherm at 970C. The area under the curve of this new peak 
increased with increasing H. P. M. C. concentration. The increase in the 
endothermic peak at 970C was accompanied by a decrease in the original 
peak at 1070C, until at a limiting H. P. M. C. concentration of 2% w/w 
the original peak was completely absent. This finding raised the 
possibility that phenylbutazone forms a high energy complex with 
H. P. M. C. The high energy complex term was first used by Simonelli et al. 
(1976) to describe drug: polymer complexes which have lower melting 
point than the parent drug, and were not thought to be polymorphic forms. 
Further evidence for complex formation rather than a polymorphic 
form is provided by the absence of an exothermic peak on the D. S. C. 
trace between the two endothermic*peaks at 970C and 1070C even when 
scanned at low heating rate i. e. 20 Cjmin, and also the absence of 
endotherm at 1070C at 2% w/w H. P. M. C. concentration and above. If a 
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polymorphic form had been produced, an exotherm between the two 
endotherms, particularly at low heating rates might be expected, and 
the endotherm at 1070C should be present as the metastable polymorph 
converts to the stable form after melting. In addition no peaking 
effect was observed on solubility testing, a feature of metastable 
polymorph solubility. 
For samples containing the same concentration of H. P. M. C. prepared 
by spray drying under conditions which previously produced s polymorph, 
two endothermic peaks were observed - the first at 950C, due to a 
polymorph and the second at 1070C corresponding to the stable form of 
phenylbutazone. An additional endothermic peak appeared at 990C which 
increased in area with increasing H. P. M. C. concentration. This 
endothermic peak at 99 0C is thought to be due to the presence of a 
complex formed between phenylbutazone and H. P. M. C. The shift in the 
position of the melting endotherm of the complex compared with the 
complex formed after conventional crystallisation might be due to 
differences in the preparation technique, crystallisation rate and 
time allowed for the complex to form. 
The powder X-ray diffraction data showed that for all the samples 
containing H. P. M. C. and prepared by conventional crystallisation and 
spray drying were crystalline in character and not amorphous. The 
appearance of a new peak at 26 of 180 was thought to be due to the 
complex formed between phenylbutazone and H. P. M. C. From the X-ray 
diffraction studies it was also concluded that the presence of 
H. P. M. C. in the crystallisation medium tend to inhibit the formation 
of metastable polymorphs. As the concentration of H. P. M. C. in spray- 
dried samples increased the area of the endotherm at 950C which is 
due to the presence of o polymorph, was reduced. 
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The equilibrium solubility was slightly increased for samples 
prepared by conventional crystallisation and spray drying with 
optimal increase obtained for sample containing 2% w1w H. P. M. C. - 
For samples prepared by crystallisation, no peaking solubility 
effect was noticed which, as mentioned previously, supports the 
conclusion that polymorphism in these samples is absent and that 
the peak at 970C was not due to the presence of a metastable 
polymorph. Whilst the samples prepared by spray drying showed a 
peaking effect, a feature which was expected since the samples 
contained a polymorph, the peaking value decreased with increasing 
amounts of H. P. M. C. added. This further supports the conclusion 
drawn from the D. S. C. studies that the presence of H. P. M. C. inhibited 
the formation of metastable polymorphs. 
For both crystallised and spray-dried samples the dissolution 
rate increased with increasing amounts of H. P. M. C. added until the 
optimal concentration of 2% w/w H. P. M. C. level was reached. At 5% 
w1w H. P. M. C. concentration the dissolution decreased. The increase 
in dissolution rate is attributed to the formation of complexes 
between phenylbutazone and H. P. M. C. which exist at higher energy 
levels than the unchanged drug molecules. In addition the presence 
of hydrophilic polymer eased the wetting of phenylbutazone which may 
contribute in achieving higher dissolution rates. However at a 
certain level the effect was reversed. It is thought that above this 
concentration the H. P. M. C. altered significantly the viscosity in the 
diffusion layer and decreased the diffusion coefficient of the drug 
therefore reducing the dissolution rate (Florence et al.. 1973, 
Braun & Parrott 1971). 
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The second polymer material introduced into the phenylbutazone 
crystals was the surfactant poloxamer 188. Similar procedures to 
those used to introduce H. P. M. C. were employed. All the samples 
prepared by conventional crystallisation exhibited a single endo- 
thermic peak at 1070C on the D. S. C. thermogram which is due to the 
stable 6 form of phenylbutazone. A slight decrease in melting point 
with increasing the amount of poloxamer added, accompanied by a 
widening of the endothermic peak and decrease in the heat of fusion, 
was observed. These observations indicate that when added to the 
crystallisation medium poloxamer 188 did not initiate the formation 
of other polymorphic forms or any type of complexation with phenyl- 
butazone. It is possible that the poloxamer 188 was either adsorbed 
physically to the surface of the phenylbutazone crystals and/or acted 
as impurities 
.( Blain' 
19 8.2 forming a solid solution. 
The incorporated polymeric materials might also lead to additional 
crystal imperfection and defect. 
For samples prepared by spray drying under conditions which 
previously gave a polymorph, two endothermic peaks at 950C and 1070C 
were obtained on D. S. C. thermograms. The size of the end0thermic 
peak at 950C did not change with increased amounts of poloxamer 
added. This finding suggests that when poloxamer is added to the 
crystallisation medium polymorphic formation is neither induced or 
inhibited. 
The powder X-ray diffraction data showed that all the samples 
prepared by-crystallisation exhibited Yery similar X-ray patternst 
similar to the original phenylbutazone pattern, apart from two 
additional peaks at the region of 23 at 16.4 and 21.2. These peaks 
can be attributed to the presence of poloxamer, since the X-ray 
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diffraction of poloxamer 188 flakes alone gave two peaks at these 
positions. The samples prepared by spray drying showed similarities 
in the powder X-ray diffraction patterns, to the pattern exhibited 
by phenylbutazone spray dried alone (a-polymorphic form), apart from 
the appearance of one extra peak at the 20 region at 16.4 due to the 
poloxamer 188. The second poloxamer peak at the region of 29 at 
21.20 is thought to be masked and overlapped with the a peak in the 
same region of spectrum. The similarity in the X-ray pattern for 
samples containing poloxamer and those without poloxamer further 
supports the hypothesis that when added to the crystallisation medium 
poloxamer did not initiate or inhibit the formation of polymorphs, or 
complex with phenylbutazone. 
There was no major change in the maximal solubility of the sample 
containing poloxamer. The solubility increased with increasing amounts 
of poloxamer added until a limiting effect was observed at 1% w/w 
level. This suggests that the increase in solubility was not due to 
micellisation, whilst other factors involved with increasing 
solubility such as improved solid surface wetting were thought likely 
to occur. The small increase in solubility, 1.3 folds, was similar 
for samples prepared by crystallisation and spray drying. The only 
difference between samples was a peaking solubility effect for spray 
dried materials. This was expected and attributed to the presence of 
0 polymorph in spray-dried samples. However, it is interesting to 
note that the peaking value was the same for all the samples containing 
different amounts of poloxamer, an observation which confi rms the 
suggestion that poloxamers do not inhibit the formation of polymorphs. 
A marked increase in intrinsic dissolution rate of more than 3 fold 
for samples prepared by crystallisation and spray drying was observed 
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with maximal increase obtained at 1% w1w poloxamer level. The 
increase in dissolution rate was attributed to lowering of inter- 
facial tension at the solid-liquid interface and facilitated wetting 
of the powder. The limiting effect at 1% w1w poloxamer can be 
explained by the adsorption of poloxamer to phenylbutazone surfaces 
and addition of further poloxamer did not lead to further major 
effects on wetting and interfacial tension. 
An attempt was made in Chapter 6 of this work to examine the 
chemical stability of selected samples. Phenylbutazone alone and 
samples containing H. P. M. C. and poloxamer 188 prepared both by 
crystallisation and spray drying were subjected to HPLC and D. S. C. 
testing using elevated temperatures. Phenylbutazone was found to be 
stable at all the testing temperatures during the period of testing. 
The stability of phenylbutazone was affected by the type of 
polymer additive as well as the process of incorporating the polymer. 
Hydrolysis degradation occurred and degradation product a-carboxy-N- 
cabroyl-hydrazobenzene was spotted. Samples containing H. P. M. C. 
were more stable than samples containing poloxamer. This might be 
due to the nature of the drug and additive combination. For phenyl- 
butazone: H. P. M. C. systems a complex was thought to form, possibly 
linked through hydrogen bonding and/or Van der Wal forces. On the 
other hand poloxamer appeared to also physically adsorb to the 
surface. Possibly the difference in type of associate between drug 
and polymer, reactivity of the polymer itself as well as the 
sensitivity of the drug: polymer system to water vapour may all be 
contributing factors causing observed difference in stability profiles 
between the products. 
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The chemical stability testing showed that phenylbutazone alone 
was stable during the testing period at all the temperatures 
examined (up to 500C). In the presence of polymeric additive a 
chemical breakdown occurred. One degradation product, a-carboxy-N- 
cabroylhydrazobenzene, was detected and this product resulted from 
hydrolysing of phenylbutazone (see Fig. 6.4). Pawlelzyk & Wachowiak 
(1969) found a similar hydrolysis of phenylbutazone for stored 
aqueous injection solutions. The samples were stable at 200C in 
closed containers for three months. However, for open-stored samples 
at RH 40±5% traces of degradation were noticed, which increased in 
concentration with increasing temperature and time of incubation. No 
other breakdown products were detected. 
The type of additive and way of preparing the samples affected the 
stability of the product as samples containing H. P. M. C. possessed 
smaller amounts of breakdown than samples containing poloxamer 188. 
One possible explanation is that poloxamer may have a higher affinity 
for water than H. P. M. C. which could lead to increased hydrolysis. 
The samples prepared by conventional crystallisation showed less 
stability than samples prepared by spray drying for both H. P. M. C. and 
poloxamer containing samples. Differences in preparation conditions 
thus affect stability and may be attributed either to the $ 
polymorphic form present in the spray-dried samples being 
inherently more stable to hydrolysis than the 6 form in the 
conventionally crystallised samples, which seems unlikely, or that 
the conyentionally prepared crystals, unlike the spray-dried samples, 
retain trace amounts of water which initiate a hydrolysis reaction. 
The Heckel plot forcompressed samples of phenylbutazone containing 
H. P. M. C. prepared by spray drying and crystallisation showed that the sample! 
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prepared by the same technique and containing up to 5% w/w H. P. M. C. 
showed similarity in their yield pressure, indicating that adding 
H. P. M. C. up to this level has not affected the yield pressure 
material constant. There is however a downward displacement of the 
curves with increasing H. P. M. C. concentration. This displacement is 
attributed to increasing cohesiveness of the powder as only minor 
differences in particle size and shape existed between the samples. 
The crystallographic nature and preparation conditions of the 
powder affected the yield pressure with the conventionally 
crystallised phenylbutazone exhibiting higher yield pressure than 
the spray-dried samples. This effect was attributed primaril y to the 
fact that spray-dried samples were $-metastable form of phenylbutazone 
which because of their higher energy level would be expected to 
deform plastically at lower pressure than the stable 6 form as 
obtained during conventional crystallisation. In addition the 
difference in crystal shape and size between samples series as the 
spherical spray-dried material would require lower pressureto cause 
particle rearrangement to fill the interparticulate spaces while the 
crystallised samples were needle-like and thereby likely to exhibit 
larger frictional forces between particles with higher bed voidage, and 
so higher pressure would be required to cause rearrangement and 
subsequent particle deformation. 
The force transmission to the lower punch during compression 
increased with increasing H. P. M. C. concentration in sample due to 
decreased die-wall and interparticle friction. Crystallographic 
nature did not seem to affect force transmission as the spray-dried 
and crystallised samples gave similar results. 
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The increase in tablet tensile strength with increasing H. P. M. C. 
concentration for samples prepared by conventional crystallisation 
and spray drying was attributed to increasing particle cohesiveness 
and the increasing amounts of a plastically deforming polymeric 
material. The approximately three-fold increase in tensile strength 
generally observed for samples prepared by crystallisation compared 
with tablets prepared from spray-dried samples, was attributed to 
the difference in crystallographic nature of the samples. The 
crystallised samples consisted of the stable 6 form and/or complex, 
while the spray-dried samples consisted mainly of the $-metastable 
polymorphic form. The tensile strength of compact of any material 
is a function of. the area of contact between the particles, and the 
strength of the bond produced between them (Summers 1977), and as the 
metastable polymorphic form possess higher potential energy and 
weaker bonding (Burger 1951), the strength of particle-particle bond 
will be less for the metastable polymorphic form than the stable form. 
Also difference in the distribution pattern of H. P. M. C. within the 
spray-dried and crystallised materials may play a role. 
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8.2 Conclusions 
1. The polymorphism of phenylbutazone was examined and a, B and 6 
forms (after Muller (1978) nomination) were identified using a 
combination of analytical techniques. 
2. A study on the effect of the operating variables of the Biochi 
mini-spray dryer showed that all the four variables examined 
contribute to the efficiency of performance and the particle size 
of product. 
3. Analysis of spray-dried phenylbutazone products revealed that 
the slower the crystallisation rate, the higher the number of 
polymorphs formed indicating that slower crystallisation rates 
favour polymorphic formation. 
4. For samples of phenylbutazone containing up to 5% w/w H. P. M. C. 
incorporated by conventional crystallisation, a higher energy 
complex was formed which melted 100 lower than the parent drug. 
The complex containing 2% w/w H. P. M. C. exhibited a 2-fold increase 
in intrinsic dissolution rates compared with phenylbutazone. 
5. When H. P. M. C. was incorporated into phenylbutazone by spray 
drying a similar level of increase in intrinsic dissolution rate 
for samples containing 2% w/w H. P. M. C. was observed. The presence 
of H. P. M. C. appeared to inhibit the formation of $ polymorph. 
6. Incorporating poloxamer 188 into 'phenylbutazone increased the 
intrinsic dissolution rate. This increase was thought to be due to 
facilitated powder surface wetting due to lowering interfacial 
tension and not due to micellisation as the increase in solubility 
was not found to be continuous with increasing poloxamer content. 
Unlike H. P. M. C. the poloxamer does not form any complex with 
phenylbutazone. 
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7. Addition of poloxamer 188 by spray drying using the same 
conditions gave similar increases in intrinsic dissolution rate 
compared with crystallised samples. The presence of surfactant 
did not interfere with polymorphic formation during spray drying. 
8. Stability testing of selected products containing polymeric 
additives showed that phenylbutazone alone was stable during the 
period of testing at all temperatures up to 50 0 C. The hydrolysis 
product No. II (a-carboxy-n-caproyl-hydrazobenzene) was detected 
in several samples and the degree of decomposition was found to be 
affected by the type of additive and the technique of incorporation. 
9. The yield pressure-of materials, determined from Heckel plot analysis, 
exhibited only minor changes when up to 5% w/w HPMC was incorporated into 
phenylbutazone, for either conventionally crystallised or spray-dried 
samples, although the value for spray-dried samples (93.5 Mpa ) was 
lower than that for conventionally crystallised product (147.02 MPa)' 
10. The force transmission ratio on compression was similar for 
both crystallised and spray-dried phenylbutazone samples containing 
H. P. M. C. The ratio increased with increasing H. P. M. C. concentrations. 
11. The tensile strength of tablets obtained from samples prepared 
by conventional crystallisation was found in general to be three times 
larger than for tablets prepared from spray-dried products. 
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8.3. Suggestions for future work 
The work in this thesis has dealt with the physicochemical 
properties of the drug phenylbutazone after changing its crystalline 
state and also after adding hydrophilic polymers. Increases in 
in vitro dissolution rate were observed. An in vivo study to 
establish whether the. in vitro increases were observed biologically 
would give an opportunity of establishing possible in vitro/in vivo 
correlations and developing predictive relationships for the in vivo 
performance of these and similar systems. 
Since there is a general interest in retarding dissolution to 
achieve controlled release preparations, using the same principle 
developed in this work, a study of the effect of adding hydrophobic 
polymer to hydrophilic drugs would be worthy of examination. 
The degree of disruption occurring in crystals resulting from 
the incorporation of low level additives has recently been described 
by a dimensionless parameter - the disruption index (York & Grant 
1985) obtained from entropy data. Initial analysis of latent heat 
of fusion data for phenylbutazone:. Doloxamer 188 system prepared by 
conventional crystallisation has revealed that the surfactant acts 
as a major disrupter of the crystals (Al Meshal et al. 1985). 
Further work examining the disruptive effects of different materials 
including other polymers together with a study of the sites of 
location of the additives would provide useful information 
concerning their thermodynamic and solid-state character and may 
provide ainsight into potential series of batch variation in these 
materials. 
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This study which might involve additional analytical 
techniquesisuch as solid-state WIR, would enable the nature of the 
interaction between host and additive molecules to be explored 
further. 
Whilst interesting differences between the compressional 
behaviour of prepared samples have been demonstrated in this work, 
a more vigorous examination of the effect of additive on the 
elasticity, plasticity and other aspects of tableting of the 
material and product performance using more elaborate instrumented 
tableting equipment is required. 
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Symbols and AbbreviaticLns 
A The area of the solvated tablet 
Al Frequency factor 
B. P. British Pharmacopeia 
Cs Maximal solubility 
CO The concentration of drug in solution at time t 
CMC Critical micell concentration 
D Tablet diameter 
D. S. C Differential scanning calorimetry 
dm Rate of increase in amount of material in solution 
dt 
Ep, Activation energy 
Ea Activation energy of degradation 
FD Die wall reaction as wall friction force 
FL Force transmitted to the lower punch 
FR Radical force 
FU Force applied by upper punch 
GLC Gas liquid chromatography 
HPLC High pressure liquid chromatography 
HPMC Hydroxypropyl methyleellulose 
hrs Hours 
allf EnthalPy of fusion 
AHS EnthalPy of solution 
I. R. Infra-rdd 
K Solubility product 
K The rate constant of intrinsic dissolution 
le Degradation rate 
Ki Yield pressure 
-251- 
KN Kilo Newton 
Lh-l Litre/hour 
M Amount of material in solution 
m meter 
mins Minutes 
mv Milli volt 
nl, n2 Number of mole., 
p Load applied 
PbZ Phenylbutazone 
PS Phenylbutazone 
PHR1 Phenylbutazone 
PHR2 Phenylbutazone 
PHR3 Phenylbutazqne 
PHR4 Phenylbutazone 
PHR5 Phenylbutazone 
PHS1 Phenylbutazone 
PHS2 Phenylbutazone 
PHS3 Phenylbutazone 
PHS4 Phenylbutazone 
PHS5 Phenylbutazone 
PPR1 Phenylbutazone 
PPR2 Phenylbutazone 
PPR3 Phenylbutazone 
PPR4 Phenylbutazone 
PPR5 Phenylbutazone 
PPS1 Phenylbutazone 
PPS2 Phenylbutazone 
PPS3 Phenylbutazone 
PPS4 Phenylbutazone 
PPS5 Phenylbutazone 
3 of the constituents 1 and 2 
as supplied 
spray dried alone 
crystallised with 0.01% w/v HPMC 
crystallised with 0.1% w/v HPMC 
crystallised with 1% w/v HPMC 
crystallised with 12% w/v HPMC 
crystallised with 5% w/v HPMC 
spray dried with 0.01% w/w HPMC 
spray dried with 0.1% w/w HPMC 
spray dried with 1% w/w HPMC 
spray dried with, 2% w/w HPMC 
spray dried with 5% w/w HPMC 
crystallised with 0.01% w/v poloxamer 188 
crystallised with 0.1% w/v poloxamer 188 
crystallised with 1% w/v poloxamer 188 
crystallised with 2% w/v poloxamer 188 
crystallised with 5% w/v poloxamer 188 
spray dried with 0.01% w/w poloxamer 188 
spray dried with 0.1% w/w poloxamer 188 
spray dried with 1% w/w poloxamer 188 
spray dried with 2% w/w poloxamer 188 
spray dried with 5% w/w poloxamer 188 
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PM Mean compaction pressure 
R Universal gas constant 
RH Relative humidity 
SEM Scanning electron microscope 
T Absolute temperature 
TLC Thin layer chromatography 
t Time 
t Tablet thickness 
Tr Tablet tensile strength 
V Volume 
USP United States Pharmacopeia 
UV Ultra violet 
X1. ) X2 Mole fraction of constituents 
1 and 2 
Heating rate 
ýFo Initial powder packing fraction 
CFA Total powder packing 
CFB 
Packing fraction due to particle slippage 
APPENDIX 1. 
Appendix 1 Table J. 
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Dissolution data for phenylbutazone as supplied without any treatment (Pbz) at 370C. 
Experiment A Experiment B Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) 
I 
(mg/600ml) i 
30 0.04 0.00006 0.04 0.00007 4.0 
60 0.07 0.00011 0.07 0.00011 7.0 
90 0.12 0.00017 0.12 0.00017 10.0 
120 0.14 0.00022 0.14 0.00022 13.0 
150 0.18 0.00027 0.18 0.00027 16.0 
180 0.20 0.00030 0.21 0.00032 18.0 
210 0.25 0.00036 0.25 0.00036 21.5 
Appendix 1 Table 2 
Dissolution data for a-polymorph of Phenylbutazone prepared by Crystallisation 
at 37*C. 
Experiment A Experiment B Average 
total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600ml). 
30 0.07 0.00011. 0.07 0.00010 6.6 
60 0.14 0.00021 0.14 0.00021 12.6 
90 0.20 0.00030 0.20 0.00030 18.0 
120 0.28 0.00042 0.28 0.00042 25.2 
150 0.33 0.00050 0.33 0.00050 30.0 
180 0.39 0.00060 0.39 0.00060 36.0 
210 0.44 0.00068 0.44 0.00068 40.8 
Appendix 1 Table 3 -254- 
Particle size analysis data of phenylbutazone spray dried under 
different spray drying conditions 
Particle size in ýLm 
Run 1-9.9 10-14 141- 20- 28.3- 40- 66.6- < N 
Arith- 
metic 
< 
<nd3 
No gm 19.9 28.2 39.9 66.5 80 
< 
mean(pm) 
&d' 
(4m) 
1 24 35 50 90 95 78 10 382 30.59 45.99 
2 18 45 65 120 110 40 15 413 31.76 44.06 
3 20 42 68 126 102 34 18 410 20.18 44.86 
4 54 76 68 58 40 26 28 350 24.38 52.99 
5 36 28 36 26 10 6 2 144 17.78 38.44 
6 21 40 42 48 58 38 12 259 28.32 47.96 
7 36 48 36 24 14 - - 158 15.33 23.86 
8 48 62 42 28 22 6 2 210 17.08 35.68 
9 68 78 71 44 30 26 27. 344 23.04 53.92 
10 69 43 56 35 62 26 15 306 23.84 48.52 
11 21 11 20 22 12 15 9 110 27.04 54.04 
12 28 25 14 29 26 28 4 154 26.28 47.06 
13 37 23 55 28 21 9 8 181 21.28 46.78 
14 38 49 23 52 43 25 13 243 25.4 48.94 
15 21 19 24 20 45 43 27 199 35.30 56.70 
16 40. 35 49 50 47 32 43 296 30.8 55.88 
17 59 73 58 47 41 19 6 303 20.25 41.80 
is 91 105 142 128 42 16 - 524 18.12 29.80 
19 21 30 53 85 93 75 - 357 29.63 42.31 
20 is 36 51 111 30 7 - 253 21.58 29.49 
Appendix 1 Table 3 continued 
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Particle size in 4m 
Run 1-9.9 10-14 14.1- 20- 28 , 3- 40- 66.6- <N 
Arith- 
<3 
<nd 
No 19.9 28.2 39.9 66.5 
1 
80 < metic &d' 
mean(pm) O. Lm) 
21 37 31 40 52 36 25 29 250 28.69 55.77 
22 62 71 88 67 19 10 60 323 18.24 38.59 
23 49 73 108 92 25 3 - 350 17.67 25.35 
24 63 91 108 92 24 4 - 382 16.99 25.54 
25 53 61 42 105 31 - - 292 18.14 25.30 
26 62 121 175 40 3 - 401 14.46 18.24 
27 145 252 279 20 - - - 696 12.88 15.93 
28 84 151 152 55 15 2 - 459 14.72 21.86 
29 61 100 119 82 58 is - 439 19.26 32.02 
30 227 240 114 6 - 587 10.37 14.19 
31 65 113 93 35 - - - 306 13.41 17.74 
32 81 98 102 97 27 4 - 409 16.60 25.67 
33 67 106 143 91 10 - - 417 15.75 20.89 
34 70 6ý 105 116 8 - - 365 16.42 20.9 
35 75 100 156 110 10 - - 451 16.00 21.08 
36 26 42 76 41 6 - - 191 16.32 21.21 
37 71 76 74 50 6 2 - 279 14.47 23.01 
38 40 51 86 112 15 - - 304 18.04 23.15 
39 48 74 92 68 12 4 - 298 16.60 25.36 
40 66 85 166 134 2 - - 453 16.48 20.60 
41 18 21 38 35 21 6 - 139 20.62 32.20 
42 25 27 36 52 20 2 - 162 19.15 27.68 
43 27 18 38 58 28 8 - 177 21.32 32.48 
44 35 55 so 51 19 - - 240 16.46 23.44 
45 49 37 63 85 11 - 245 17.06 23.08 
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Appendix 1 Table 4 
Dissolution data for sample PS1 at 370C. 
Experiment A Experiment B Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.05 0.00007 0.05 0.00007 4.6 
60 0.08 0.00011 0.08 0.00011 6.7 
90 0.11 0.00016 0.11 0.00016 9.8 
120 0.13 0.00019 0.13 0.00019 11.7 
150 0.16 0.00024 0.16 0.00024 14.9 
180 0.18 0.00027 0.18 0.00027 16.9 
210 0.23 0.00034 0.23 0.00034 21.8 
Appendix 1 Table 5 
Dissolution data for sample PS2 at 370C. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600ml). 
30 0.08 0.00012 0.08 0.00012 6.0 
60 0.10 0.00014 0.10 0.00014 9.5 
90 0.13 0.00014 0.13 0.00019 13.6 
120 0.16 0.00025 0.16 0.00025 16.8 
150 0.20 0.00030 0.20 0.00030 20.0 
180 0.23 0.00035 0.23 0.00035 22.1 
210 0.28 0.00043 0.28 0.00043 24.6 
-257- 
Appendix I Table 6 
Dissolution data for sample PS3 at 370C. 
Experiment A Experiment B Average 
total amount: 
of drug 
Time Absorbence Concentration Absorbencd Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600mi) 
30 0.07 0.00010 0.08 0.00011 6.0 
60 0.12 0.00018 0.13 0.00019 11.1 
90 0.17 0.00025 0.17 0.00025 15.0 
120 0.21 0.00031 0.22 0.00032 19.2 
150 0.25 0.00038 0.25 0.00038 22.8 
180 0.29 0.00045 0.29 0.00045 26.4 
210 0.33 0.00050 0.33 0.00050 30.2 
Appendix I Table 7 
Dissolution data for sample PS4 at 370C. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm. (mg/ml) at 264 nm' (mg/ml) (mg/600mll 
30 0.07 0.0001 0.07 0.00010 6.0 
60 0.13 0.00020 0.13 0.00020 12.0 
90 0.17 0.00025 0.16 0.00024 14.8 
120 0.22 0.00033 0.23 0.00035 20.4 
150 0.26 0.00040 0.36 0.00040 24.0 
180 0.31 0.00047 0.32 0.00048 28.5 
210 0.37 0.00056 0.38 0.00058 34.2 
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Appendix 1 Table 10 
Calibration of dial reading for aspiration rate of the 
Buchi Spray drier 
Rate of 200 L/hr 400 L/hr 600 L/hr 
Flow 
Dial Meter Total Meter Total Meter Total 
Reading reading volume of reading volume of reading volume of 
air air air 
AB (m-/sec) AB W/sec) AB W/sec) 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
9.3 9.3 
9.7 97 
10 10 
10.3 10.3 0.008232 
10.5 10.5 - 
11 11 
11.3 11.3 0.00903 
11.6 11.6 - 
12 12 - 
12.3 12.3 - 
12.6 12.6 - 
13 13 - 
13.3 13.3 0.0106 
13.7 13.7 - 
14.3 14.3 
14.7 14.7 
15 15 
Above mej er limits 
9.3 9.3 
9.7 9.7 
10 10 
10.3 10.3 0.008232 
10.5 10.5 - 
11 11 
11.3 11.3 0.00903 
11.6 11.6 - 
12 12 - 
12.3 12.3 - 
12.6 12.6 - 
13 13 - 
13.2 13.3 0.0106 
13.7 13.7 - 
14.3 14.3 - 
14.7 14.7 - 
15 15 - 
9.3 9.3 
9.7 9.7 
10 10 
10.3 10.3 0.008232 
10.5 10.5 - 
11 11 
11.3 11.3 0.00903 
11.6 11.6 - 
12 12 - 
12.3 12.3 - 
12.6 12.6 - 
13 13 - 
13.3 13.3 0.0106 
13.7 13.7 - 
14.3 14.3 - 
14.7 14.7 - 
15 is - 
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Appendix 2 Table 1 
Dissolution data for sample PHR1 at 3711C. 
Experiment A Experiment B 
Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.09 0.00007 0.05 0.00006 4.0 
60 0.10 0.00011 0.10 0.00011 7.0 
90 0.11 0.00016 0.11 0.00016 10.0 
120 0.18 0.00028 0.19 0.00029 16.8 
150 0.22 0.00030 0.22 0.00030 18.0 
180 0.25 0.00040 0.26 0.00041 24.6 
210 0.32 0.00048 0.32 0.00048 28.0 
Appendix 2 Table 2 
Dissolution data for sample PHR2 at 370C. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600ml). 
30 0.06 0.00007 0.06 0.00007 4.2 
60 0.10 0.00013 0.10 0.00013 7.8 
90 0.15 0.00021 0.14 0.00019 11.76 
120 0.18 0.00028 0.18 0.00028 16.6 
150 0.22 0.00031 0.22 0.00031 18.6 
ISO 0.26 0.00041 0.26 0.00041 24.15 
210 0.32 0.00050 0.32 0.00050 30.0 
Appenix 2 Table 3 -262- 
Dissolution data for sample PHR3 at 370C. 
Experiment A Experiment B 
Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.05 0.00006 0.06 0.00009 4.5 
60 0.11 0.00016 0.11 0.00015 9.3 
90 0.17 0.00025 0.16 0.00022 14.4 
120 0.20 0.00030 0.21 0.00031 18.3 
150 0.26 0.00038 0.26 0.00039 23.4 
180 0.30 0.00046 0.31 0.00047 27.9 
210 0.35 0.00053 0.36 0.00054 32.4 
Appendix 2 Table 4 
Dissolution data for sample PHR4 at 370C. 
Experiment A Experiment B 
Average 
total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600ml). 
30 0.09 0.00013 0.09 0.00013 7.6 
60 0.16 0.00025 0.14 0.00021 13.8 
90 0.23 0.00035 0.21 0.00031 18.6 
120 0.29 0.00045 0.29 0.00045 26.4 
150 0.35 0.00054 0.35 
. 
0.00054 32.6 
180 0.41 0.00062 0.42 0.00064 37.5 
210 0.50 0.00077 0.49 0.00075 45.6 
Appendix 2 Table 5 -263- 
Dissolution data for sample PHR5 at 370C. 
Experiment A Experiment B 
Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.09 0.00013 0.05 0.00007 6.0 
60 0.15 0.00023 0.12 0.00018 12.0 
90 0.23 0.00035 0.16 0.00023 13.8 
120 0.27 0.00041 0.23 0.00035 22.8 
150 0.32 0.00049 0.30 0.00045 28.2 
180 0.41 0.00061 0.35 0.00053 34.2 
210 0.45 0.00068 0.40 0.00061 38.7 
Appendix 2 Table 6 
Dissolution data for sample PHS1 at 37"C. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml). 
30 0.06 0.00009 0.07 0.00008 5.0 
60 0.10 0.00015 0.10 0.00015 9.0 
90 0.20 0.00025 0.19 0.00024 14.6 
120 0.21 0.00031 0.20 0.00030 18.0 
150 0.26 0.00037 0.25 0.00036 22.0 
180 0.32 0.00045 0.30 0.00045 27.0 
21*0 0.34 0.00052 0.35 0.00052 31.0 
Appendix 2 Table 7 -264- 
Dissolution data for sample PHS2 at 37"C. 
Experiment A Experiment B Average 
total amountl: 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/60Cml) 
30 0.07 0.0001 0.070 0.00010 6.0 
60 0.12 0.00017 0.12 0.00017 9.6 
90 0.17 0.00025 0.180 0.00027 15.0 
120 0.22 0.00033 0.23 0.00033 19.0 
150 0.26 0.00040 0.28 0.00039 23.8 
180 0.31 0.00046 0.31 0.00046 28.0 
210 0.36 0.00053 0.36 0.00053 32.0 
Appendix 2 Table 8 
Dissolution data for sample PHS3 at 3711C. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
ofdrug 
released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml). 
30 0.06 0.00018 0.06 0.00008' 5.4 
60 0.11 0.00014 0.08 0.00011 10.0 
90 0.18 0.00027 0.15 0.00022 15.9 
120 0.21 0.00030 0.20 0.00029 21.0 
150 0.25 0.00038 0.23 0.00035 24.5 
180 0.30 0.00045 0.28 0.00042 30.1 
21-0 0.35 0.00054 0.33 0.00051 35.0 
Appendix 2 Table 9 -265- 
Dissolution data for sample'? 'HSI at 37"C. 
Experiment A Experiment B Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.08 0.00012 0.07 0.00010 6.6 
60 0.13 0.00020 0.12 0.00017 12.3 
90 0.18 0.00028 0.18 0.00028 16.8 
120 0.25 0.00037 0.26 0.00039 28.0 
150 0.34 0.00051 0.33 0.00050 38.0 
180 0.40 0.00061 0.37 0.00054 34.8 
210 0.43 0.00066 0.42 0.00065 40.0 
Appendix 2 Table 10 
Dissolution data for sample PIiS5at 37*C. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600ml). 
30 0.06 0.00009 0.07 0.0001 6.0 
60 0.15 0.00021 0.15 0.00021 12.0 
90 0.18 0.00028 0.18 0.00027 16.5 
120 0.24 0.00036 0.24 0.00036 22.0 
150 0.31 0.00045 0.30 0.00045 27.0 
180 0.36 0.00055 0.36 0.00055 33.0 
210 
L 
0.41 
I 
0.00061 
I- 
0.41 
I 
0.00061 
I 
37.5 
II 
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Appendix 2 Table 11 
Results of solubility experiment for samples of PHR1, PHR2, PHR3, 
PHR4, PHR 5 containing different concentration of H. P. M. C. at 370C. 
Time 
(hrs) 
PHR1 
Ryn Rýn Avge 
(mg/looml) 
Ryn 
(m 
PHR2 
Rýn Avge 
g/looml) 
Ryn 
(mg 
PHR 3 
R? n Avge 
/looml) 
PHR4 ' 
Ryn R? n Avge 
(Mqllooml) 
PHR4 
Ryn R? n Avge 
(Mqllooml) 
1 300 300 300 315 306 310 310 310 310 310 330 310 360 340 350 
2 318 322 320 350 350 350 330 320 325 330 340 335 340 360 350 
3 340 340 340 379 380 380 354 346 350 350 350 350 370 390 380 
4 36 380 370 380 400 390 390 400 395 380 380 380 390 410 400 
24 390 394 392 400 400 400 410 410 410 420 430 425 420 420 420 
48 396 405 400 418 412 410 427 435 431 450 450 450 440 440 440 
Appendix 2 Table 12 
Results of solubility experiment for samples PHS1, PHS21 P5S31 P5S41 
and P5S5 concentrations at 370C. 
Time 
(hrs) 
I 
PHSJ 
Run Run Avge 
12 
(mg/looml) 
PHS2 
Run Run Avge 
12 
(mg/looml) 
PHS3 
Run Run Avge 
12 
(mg/looml) 
PHS4 
Run Run Avge 
12 
(mg/looml) 
PHS. 5 
Run Run Avge 
12 
(mg/looml) 
1 390 400 395 400 400 400 370 480 390 375 375 375 360 380 370 
2 500 500 500 490 480 485 465 495 480 480 480 480 445 455 450 
4 535 525 530 520 520 520 520 520 510 510 500 505 480 490 485 
8 560 560 560 550 550 550 530 550 540 525 515 520 500 500 500 
24 520 520 520 520 390 500 495 505 500 480 480 480 460 460 460 
48 405 395 400 410 410 410 415 415 415 460 420 440 435 435 435 
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Appendix 3 Table 1 
Dissolution data for sample PPR1 at 370C. 
Experiment A Experiment B Average total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.09 0.00013 0.08 0.00012 7.5 
60 0.14 0.00022 0.14 0.00022 12.9 
90 0.19 0.00029 0.20 0.00030 17.7 
120 0.25 0.00038 0.26 0.00040 23.4 
150 0.31 0.00047 0.33 0.00048 28.4 
180 0.37 0.00057 0.39 0.00059 34.8 
210 0.42 0.00064 0.45 0.00068 40.0 
Appendix 3 Table 2 
Dissolution data for sample PPR2 at 37*C. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600ml). 
30 0.09 0.00013 0.10 0.00014 8.1 
60 0.17 0.00025 0.17 0.00025 15.0 
90 0.25 0.00038 0.26 0.00039 23.1 
120 0.33 0.00051 0.34 0.00051 30.6 
150 0.41 0.00062 0.42 0.00064 37.8 
180 0.50 0.00076 0.50 0.00076 45.0 
210 0.58 0.00089 0.58 0.00084 53.4 
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Appendix 3 Table 3 
Dissolution data for sample PPR3 at 370C. 
Experiment A Experiment B 
Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.11 0.00015 0.11 0.00015 9.0 
60 0.2 0.00030 0.20 0.00030 18.0 
90 0.30 0.00045 0.30 0.00045 27.0 
120 0.38 0.00058 0.39 0.00059 35.1 
150 0.48 0.00073 0.48 0.00073 43.8 
180 0.56 0.00087 0.57 0.00088 52.5 
210 0.65. 0.00105 0.65 0.00105 64.0 
Appendix 3 Table 4 
Dissolution data for sample PPR4 at 370C. 
Experiment A Experiment B 
Average 
total amount 
d 
Time Absorbence Concentration Absorbence Concentration 
rug of 
released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600ml). 
30 0.11 0.00015 0.11 0.00015 9.0 
60 0.20 0.0003 0.22 0.00032 18.0 
90 0.30 0.00045 0.30 0.00045 27.0 
120 0.38 0.00058 0.39 0.00059 35.1 
150 0.48 0.00073 0.49 0.00074 44.1 
180 0.57 0.00088 0.57 0.00088 52.8 
210 0.65 0.00103 0.66 0.00107 64.0 
-270- 
Appendix 3 Table 5 
Dissolution data for sample PPR5 
Experiment A Experiment B 
Average 
total amount 
of dr-; z 
Time Absorbence Concentration Absorbence Concentration release= 
(min) at 264 nm (mg/ml) at 264 nm (mg/mil, (mg/600-m--', 
30 0.11 0.00015 0.11 0.00015 9.0 
60 0.20 0.0003 0.21 0.00030 18.6 
90 0.30 0.00045 0.30 0.00045 27.0 
120 0.39 0.0006 0.38 0.00058 35.2 
150 0.48 0.00074 0.48 0.00074 44.2 
180 0.58 0.00089 0.57 0.00087 52.8 
210 0.66 0.0011 0.64 0.00100 64.2 
AppendIX 3 Table 7 -271- 
Dissolution data for sample PIPS2 at 37*C. 
Experiment A Experiment B 
Average 
total anvount; 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600MI) 
30 U. 1U 0.00014 0.09 0.00013 8.1 
60 0.18 0.00028 0.19 0.00028 16.8 
90 0.28 0.00042 0.28 0.00042 25.2 
120 0.37 0.00055 0.36 0.00055 33.0 
ISO 0.46 0.0007 0.46 0.0007 42.0 
ISO 0.54 0.00083 0.55 0.00084 50.1 
210 0.63 0.00096 0.62 0.00965 57.9 
Appendix 3 Table 6 
Dissolution data for sample PPSI at 370C. 
Experiment A Experiment B 
Time Absorbence lConcentration Absorbence lConcentration 
(min) 
lat264 
nm I (mg/ml) 
lat 
264 nm l(mg/ml) 
Average 
total amount 
of drug 
released 
(mg/600ml). 
30 0.08 0.00012 0.08 0.00012 6.9 
60 0.16 0.00 024 0.16 0.00024 14.4 
90 0.25 0.00038 0.25 0.00038 22.5 
120 0.32 0.00049 0.33 0.00048 29.1 
150 0.39 0.00060 '0.4 0.00061 36.6 
ISO 0.47 0.00071 0.48 0.00071 43.2 
210 0.54 0.00082 0.58 0.00089 51.3 
Appendix 3 Table 8 -272- 
Dissolution data for sample PPS1 at 370c. 
Experiment A Experiment B 
Average 
total amcu. -r-i 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/000ml) 
30 0.09 0.00012 0.1 0-00015 8.1 
60 0.18 0.00027 0.19 0.00028 16.5 
90 0.28 0.00042 0.28 0.00042 25.2 
120 0.37 0.00056 0.36 0.00055 33.3 
150 0.46 0.0007 0.48 0.00073 42.9 
180 0.56 0.00085 0.56 0.00085 51.0 
210 0.64 0.00103 0.63 0.00105 63.5 
Appendix 3 Table 9 
Dissolution data for sample PPS4. at 370C. 
a 
Experiment A Experiment B Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm' (mg/ml) (mg/600mll 
30 0.10 0.00014 0.09 * 0.00012 1 8.2 
60 0.20 0.00030 0.20 0.00030 18.0 
90 0.30 0.00045 0.30 0.00045 27.0 
120 0.38 0.00058 0.38 0.00058 34.8 
ISO 0.48 0.00071 0.49 i 0.00075 43.8 
180 0.58 0.00089 0.57 0.00087 52.8 
210 0.65 0.00105 0.65 0.00105 64 
-273- 
Appendix 3 Table 10 
Dissolution data for sample PPS5 at 370C. 
Experiment A Experiment B Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min at 264 nm. (mg/ml) at 264 nm. (mg/ml) (mg/600ml) 
30 0.10 0.00015 0.10 0.00015 9.0 
60 0.19 0.00028 0.19 0.00028 17 .8 
90 0.30 0.00045 0.30 0.00045 27.0 
120 0.38 0.00058 0.38 0.00058 35.0 
150 0.48 0.00073 0.48 0.00073 43.1 
180 0.58 0.00084 0.57 0.00087 52.5 
210 0.64 0.00104 0.65 0.00105 64.0 
Appendix 3 Table 11 
-274- 
Dissolution data of phenylbutazone crystallised from 2% pOjGxa,,.,. er 181 
solution at 370C. 
Experiment A Experiment B 
Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.10 0.00015 0.12 0.00015 8.0 
60 0.20 0.00030 0.21 0.00031 14.0 
90 0.29 0.00044 0.31 0.00046 25.2 
120 0.37 0.00056 0.37 0.00056 32.6 
150 0.43 0.00065 0.46 0.00070 40.0 
180 0.51 0.00078 0.52 0.00079 47.4 
210 0.56 
1. 
0.000ý5 
I 
0.58 
I 
0.00088 
I 
54.6 
II 
Appendix 3 Table 12 
Dissolution data of phenylbutazone crystallised from 2% pol oxamer 184 
solution at 37*c. 
Experiment A Experiment B Average total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm* (mg/ml) (mg/600mll 
30 0.10 0.00015. 0.11 0.00015 9 
60 0.19 0.00028 0.18 0.00028 16.8 
90 0.29 0.00044 0.30 0.00045 26.4 
120 0.38 0.00058 0.38 0.00058 34.8 
150 0.47 0.00070 0.47 0.00070 42.6 
180 0.56 0.00085 0.57 0.00086 51.0 
210 0.64 0.00098 0.65 0.00101 60.0 
Appendix 3 Table 13 -275- 
Dissolution of phenylbutazone crystallised with 2% W/V noloxamer 338 
at 37*C. 
Experiment A Experiment B 
Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.13 0.00019 0.13 0.00019 11.7 
60 0.23 0.00035 0.23 0.00035 20.8 
90 0.33 0.00050 0.33 0.00050 30.3 
120 0.46 0.00069 0.45 0.00067 41.0 
150 0.55 0.00085 0.55 0.00085 50.7 
180 0.67 0.00110 0.64 0.00097 62.1 
210 0.76 0.00116 0.75 0.00114 69.0 
Appendix 3 Table 14 
Dissolution data of phehylbutazone Crystallised from 2% poloxamer lol 
solution of 37*C. 
Experiment A Experiment B 
Average 
total amount 
Time Absorbence Concentration Absorbence Concentration 
of drug 
released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml). 
30 0.10 0.00015 0.10 0.00015 8.7 
60 0.19 0.00028 0.18 0.00027 16.5 
90 0.26 0.00039 0.26 0.00039 23.4 
120 0.32 0.00049 0.32 0.00049 29.4 
150 0.39 0.00059 0.41 0.0006 36.3 
180 0.46 0.00070 0.47 0.00070 42.3 
210 0.55 0.00084 0.56 0.00085 51.0 
-276- 
Appendix 3 Table 15 
Dissolution data of phenylbutazone Crystallised from 2% poloxarier 407 
solution at 37*C. 
Experiment A Experiment B 
Average 
total amount 
of drug 
Time Absorbence Concentration Absorbence Concentration released 
(min) at 264 nm (mg/ml) at 264 nm (mg/ml) (mg/600ml) 
30 0.12 0.00018 0.13 0.00185 10.0 
60 0.21 0.00032 0.21 0.00032 18.6 
90 0.31 0.00046 0.32 0.00047 28.0 
120 0.39 0.00060 0.40 0.00061. 36.0 
150 0.49 0.00075 0.50 0.00076 45.0 
180 0.60 0.00091 0.60 0.00091 54.6 
210 0.70 
1 
0.00105 
1 
0.70 
1 
0.00105 
1- 
63.0 
II 
Appendix 3 Table 16 -07- 
Results of solubility, experiment for samples of PPR1, PPR2 , PPR 
PPR4, and PPR 5 containing different concentrations of 
188.5 at 37*C. 
Time 
(hrs) 
PPR1 
Run Run Avge 
12 
(mg/looml) 
PPR2 
Run Run Avge 
12 
(mg/lOOMI) 
PPR3 
Run Run Avge 
12 
(mg/looml) 
PPR4 
Run Run Avge 
12 
(mg/looml) 
PPR 
Run Run Avge 
12 
(mg/looml) 
1 390 390 390 390 390 390 405 395 400 400 400 400 410 400 405 
2 390 400 395 400 400 400 410 410 410 420 420 420 420 410 410 
4 398 400 398 400 410 405 425 435 430 425 445 440 425 415 420 
8 400 400 400 420 420 420 440 440 440 450 450 450 435 435 435 
24 400 400 400 430 440 435 460 460 460 460 460 460 455 456 455 
48 400 410 405 435 435 435 460 460 460 460 456 458 465 455 460 
72 400 400 400 435 435 435 460 460 460 460 460 -460 460 460 460 
Appendix 3 Table 17 
Results of solubility experiments for samples of PPSj, PPS21 PPSP 
PPS4, and PPS5 at 370C. 
Time 
(hrs) 
I 
PPSJ 
Run Run Avge 
12 
(mg/looml) 
PPS2 
Run Run Avge 
12 
(mg/looml) 
PPS3 
Run Run Avge 
12 
(mg/looml) 
PPS4 
Run Run Avge 
12 
(mg/looml) 
PPS. 5 
Run Run Avge 
12 
(mg/looml) 
1 450 470 460 470 470 470 450 470 465 480 480 480 480 480 480 
2 510 530 520 540 420 535 530 550 540 550 550 550 550 430 540 
4 580 580 580 576 572 574 580 576 578 570 590 580 580 576 578 
8 490 490 490 500 500 500 515 505 510 500 500 500 520 520 520 
24 560 440 450 440 550 445 460 460 460 460 460 460 470 460 465 
48 440 440 440 445 435 440 460 460 460 460 452 456 460 460 460 
72 440 440 440 440 440 440 460 460 460 460 460 460 460 460 460 
Appendix 4 Table 3 -276- 
Calibration curve for Lower Punch Load Washer. 
AV. force 
(KN) 
n= 5) 
S. D. 
x 10' 
% C. V. AV. voltage 
(n=5) 
S. D. 
x 101 
% C. V. 
1.760 2.22 0.183 0.989 10.23 1.034 
3.161 7.86 0.249 1.968 26.87 1.365 
4.550 4.63 0.102 2.919 10.80 0.370 
5.953 5.38 0.090 3.852 17.22 0.447 
7.345 4.56 0.062 4.755 16.45 0.346 
8.740 7.76 0.089 5.663 21.25 0.375 
10.140 16.38 0.162 6.566 27.08 0.412 
11.547 24.37 0.211 7.456 29.32 0.393 
12.921 13.03 0.101 8.315 6.35 0.076 
14.327 16.35 0.114 9.164 37.90 0.414 
r=0.999 5 
-279- 
Appendix 4 Table 1 
Calibration Curve for 903A Load Washer 
Calibrated against Universal Testing Machine, T42, Devison - 
calibrated to grade A standard. 
Force (KN) Average 
Voltage (V) 
(. n= 5) 
S. D. 
No 3 
% C. V. 
2.224 1.6277 1.90 1.190 
4.448 9.0468 7.33 0.240 
6.672 4.5896 9.50 0.207 
8.896 6.1404 7.67 0.125 
11.120 7.6602 15.47 0.202 
13.344 9.1896 8.204 0.089 
Appendix 4 Table 2 
Calibration Curve for Upper Punch load washer. 
Force (KN) 
n= 4) 
S. D. 
x 10-' 
C. V. Average 
Voltage(V) 
(n = 4) 
S. D. 
X 10_3 
C. V. 
1.426 9.44 0.662 0.814 11.11 1.366 
2.834 4.04 0.142 1.682 14.15 0.841 
4.256 2.03 0.048 2.615 15.99 0.611 
5.673 9.15 0.161 3.592 19.05 0.530 
7.095 8.19 0.115 4.598 22.24 0.484 
8.498 2.09 0.025 5.593 19.41 0.347 
9.939 31.63 0.318 6.628 15.43 0.233 
11.338 10.20 0.090 7.685 13.34 0.174 
12.756 10.97 0.086 8.762 10.66 0.122 
14.167 14.30 0.101 9.874 16.30 0.165 
r=0.9991 7 
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